Methods of identifying HIV patients sensitive to therapy with gp120 v3 glycan-directed antibodies
Patent Information
- Application Number
- HK42026125492
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-05-21
- Filing Date
- 2022-03-15
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202610131591.9 (22) Application Date 2020.05.18 (30) Priority Data 62 / 850,994 2019.05.21 US (62) Divisional Application Data 202080037770.7 2020.05.18 (71) Applicant Gilead Sciences, Inc. Address California, USA (72) Inventors B. Moldett C.S. Pace (74) Patent Agency King & Wood Mallesons, Beijing 11256 Patent Attorneys Chen Wenping Yuan Quan (51) Int.Cl. A61K 39 / 42 (2006.01) C07K 16 / 114 (2026.01) C12Q 1 / 70 (2006.01) C12Q 1 / 6869 (2018.01) G01N 33 / 569 (2006.01) A61K 31 / 4745 (2006.01) A61K 31 / 519 (2006.01) A61K 39 / 21 (2006.01) A61K 45 / 06 (2006.01) A61P 31 / 18 (2006.01) C12R 1 / 93 (2006.01) (54) Invention Title Method for Identifying HIV Patients Sensitive to Therapies Using GP120 V3 Glycan-Directed Antibodies (57) Abstract This invention provides a method for identifying a population of patients infected with HIV that can be targeted by antibodies that bind to the HIV 120 V3 glycan region. Claims (5 pages), Description (81 pages), Sequence Listing (electronic publication), Drawings (3 pages), CN 122005785 A, 2026.05.12, CN 1 22 00 57 85 A 1. Use of a reagent and antibody or an antigen-binding fragment thereof in the preparation of a kit for performing a method of treating or preventing HIV-1 clade B in a human subject in need, wherein the reagent identifies HIV-1 clade B species having the following viral genotypes gp120: N332 glycan, D325, and L179, wherein the amino acid positions refer to SEQ ID NO: 4, the method comprising: a) using the reagent to identify a human subject infected with HIV-1 clade B or HIV-1 clade B population having the viral genotype gp120 in a biological sample from the human subject; and b) administering to the human subject an effective amount of the antibody or an antigen-binding fragment thereof, comprising the amino acid sequences of the VH and VL regions respectively as shown below: i. SEQ ID NO: ii. SEQ ID NO: 400 and 401; oriii. SEQ ID NO: 405 and 406. 2. The use according to claim 1, wherein the method comprises using the reagent to identify human subjects infected with HIV-1 clade B or HIV-1 clade B population having gp120 of the following viral genotypes: i. N332 glycan, D325, T63, and L179; ii. N332 glycan, D325, L179, and T320; iii. N332 glycan, D325, L179, and H330; iv. N332 glycan, D325, T63, L179, and T320; v. N332 glycan, D325, T63, L179, and H330; vi. N332 glycan, D325, L179, T320, and H330; or vii. N332 glycan, D325, T63, L179, T320, and H330. 3. The use according to claim 1, wherein the method comprises using the reagent to identify human subjects infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes gp120: i. N332 glycan, D325, T63, and L179; ii. N332 glycan, D325, L179, and T320; or iii. N332 glycan, D325, L179, and H330. 4. The use according to claim 1, wherein the method comprises using the reagent to identify human subjects infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes gp120: i. N332 glycan, D325, T63, L179, and T320; or ii. N332 glycan, D325, T63, L179, and H330. 5. The use according to claim 1, wherein the method comprises using the reagent to identify a human subject infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: i. N332 glycan, D325, L179, T320, and H330; or ii. N332 glycan, D325, T63, L179, T320, and H330. 6. The use according to claim 1, wherein 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the HIV-1 clade B population comprises the viral genotype. 7. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region containing the following amino acids at designated positions according to EU index numbers: i. tyrosine at position 252, threonine at position 254, and glutamic acid at position 256; or claim 1 / 5 page 2 CN 122005785 A ii.8. Leucine at position 428 and serine at position 434. 9. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region containing the following amino acids at designated positions according to EU index numbers: aspartic acid at position 239 and glutamic acid at position 332. 10. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region containing the following amino acids at designated positions according to EU index numbers: aspartic acid at position 239, glutamic acid at position 332, and leucine at position 330. 11. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region containing the following amino acids at designated positions according to EU index numbers: aspartic acid at position 239, glutamic acid at position 332, alanine at position 236, and leucine at position 330. 12. The use according to any one of claims 1 to 6, wherein the method comprises administering an antigen-binding fragment. 13. The use according to claim 12, wherein the antigen-binding fragment is selected from: scFv, Fab, Fab', F(ab')2, and Fv. 14. The use according to claim 12, wherein the antigen-binding fragment is a bivalent antibody. 15. The use according to any one of claims 1 to 6, wherein the antibody is a multispecific antibody. 16. The use according to any one of claims 1 to 6, wherein the human subject is acutely infected with HIV-1 clade B. 17. The use according to claim 16, wherein the antibody is administered to a human subject with Fiebig stage IV or earlier HIV-1 clade B infection. 18. The use according to claim 16, wherein the antibody is administered to a human subject who has not undergone seroconversion. 19. The use according to any one of claims 1 to 6, wherein the antibody is administered to a human subject infected with HIV-1 clade B at Fiebig stage V or Fiebig stage VI. 20. The use according to any one of claims 1 to 6, wherein the human subject is chronically infected with HIV-1 clade B. 21. The use according to any one of claims 1 to 6, further comprising administering to the human subject one or more additional therapeutic agents for treating HIV infection. 22. The use according to any one of claims 1 to 6, wherein the human subject has not received antiretroviral therapy or has discontinued antiretroviral therapy prior to administration of the antibody.23. The use according to any one of claims 1 to 6, wherein antiretroviral therapy is discontinued after one or more administrations of the antibody or its antigen-binding fragment. 24. The use according to any one of claims 1 to 6, wherein the method further comprises administering one or more antiretroviral therapeutic agents to the human subject. 25. The use according to any one of claims 1 to 6, wherein the method further comprises administering a second antibody or its antigen-binding fragment to the human subject, the second antibody or its antigen-binding fragment binding to an epitope or region of gp120, said epitope or region being selected from: i. a second variable loop and / or the apex of an Env trimer; ii. a CD4 binding site; iii. a gp120 / gp41 interface; or iv. a gp120 silencing surface. 26. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 at the apex of the second variable ring and / or Env trimer, and comprises a VH region and a VL region of an antibody selected from the group consisting of: PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CH01, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E, and VRC38.01. 27. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to the epitope or region of gp120 in the CD4 binding site and comprises a VH region and a VL region of an antibody selected from: b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01, VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103, 44-VRC13.01, 1NC9, 12A12, N6, N6LS, N49-P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25. 28. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 at the gp120 / gp41 interface and comprises a VH region and a VL region from an antibody selected from:PGT-151, CAP248-2B, 35O22, 8ANC195, ACS202, VRC34, and VRC34.01. 29. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of the gp120 silencing surface and comprises a VH region and a VL region from antibody VRC-PG05. 30. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp41 in the proximal region of the membrane and comprises a VH region and a VL region from an antibody selected from: 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01. 31. The use of claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of the gp41 fusion peptide and comprises a VH region and a VL region of an antibody selected from VRC34 and ACS202. 32. The use of any one of claims 1 to 6, wherein the method further comprises administering a TLR agonist to the human subject. 33. The use of claim 32, wherein the TLR agonist is a TLR2 agonist, a TLR3 agonist, a TLR7 agonist, a TLR8 agonist, or a TLR9 agonist. 34. The use of claim 33, wherein the TLR7 agonist is selected from vesamimod, imiquimod, and requimod. 35. The use of any one of claims 1 to 6, wherein the method comprises administering the antibody or its antigen-binding fragment multiple times at predetermined intervals. 36. The use of claim 35, wherein the antibody or its antigen-binding fragment is administered together with a TLR agonist. 37. The use according to any one of claims 1 to 6, wherein, following one or more administrations of the antibody or its antigen-binding fragment, in the absence of antiretroviral therapy, the subject does not exhibit symptoms of HIV or AIDS for 6 months, 1 year, 2 years, or 3 years. 38. The use according to any one of claims 1 to 6, wherein, following one or more administrations of the antibody, in the absence of antiretroviral therapy, the subject has a viral load of less than 500, less than 400, less than 300, less than 200, less than 100, or less than 50 copies / ml of blood for 6 months, 1 year, 2 years, or 3 years. Claims 3 / 5 Page 4 CN 122005785 A 39. The use according to any one of claims 1 to 6, wherein the viral genotype of said gp120 is identified in one or more gp120 polypeptide sequences expressed in HIV-1 clade B or HIV-1 clade B population isolated from said human subject.40. The use according to any one of claims 1 to 6, wherein the viral genotype of said gp120 is identified in one or more gp120 polynucleotide sequences isolated from said human subject clade B or HIV-1 clade B population. 41. The use according to claim 40, wherein said method comprises next-generation sequencing of a polynucleotide sequence encoding gp120 from HIV-1 clade B population. 42. Use of the reagent in the preparation of a kit for performing a method for identifying a human subject infected with HIV-1 clade B or HIV-1 clade B population sensitive to an antibody or antigen-binding fragment thereof, wherein the reagent identifies HIV-1 clade B species having the following viral genotypes gp120: N332 glycan, D325, and L179, wherein the amino acid positions are referenced to SEQ ID NO: 4, the method comprising using the reagent to identify HIV-1 clade B or HIV-1 clade B population having the viral genotype gp120 in a biological sample from the human subject, wherein the antibody or antigen-binding fragment thereof comprises the VH and VL amino acid sequences shown below, respectively: i. SEQ ID NO: 400 and 401; ii. SEQ ID NO: 402 and 404; or iii. SEQ ID NO: 405 and 406. 43. The use according to claim 42, wherein the human subject is infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes gp120: i. N332 glycan, D325, T63, and L179; ii. N332 glycan, D325, L179, and T320; iii. N332 glycan, D325, L179, and H330; iv. N332 glycan, D325, T63, L179, and T320; v. N332 glycan, D325, T63, L179, and H330; vi. N332 glycan, D325, L179, T320, and H330; or vii. N332 glycan, D325, T63, L179, T320, and H330. 44. The use according to claim 42, wherein the human subject is infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes of gp120: i. N332 glycan, D325, T63, and L179; ii. N332 glycan, D325, L179, and T320; or iii. N332 glycan, D325, L179, and H330. 45. The use according to claim 42, wherein the human subject is infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes of gp120: i.ii. N332 glycan, D325, T63, L179, and T320; or ii. N332 glycan, D325, T63, L179, and H330. 46. The use according to claim 42, wherein the human subject is infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes of gp120: i. N332 glycan, D325, L179, T320, and H330; or ii. N332 glycan, D325, T63, L179, T320, and H330. Claims 4 / 5 Page 5 CN 122005785 A 47. The use according to claim 42, wherein 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the HIV-1 clade B population comprises the viral genotype. 48. The use according to any one of claims 42 to 47, wherein the human subject is acutely infected with HIV-1 clade B. 49. The use according to claim 48, wherein the antibody is administered to a human subject with Fiebig stage IV or earlier HIV-1 clade B infection. 50. The use according to claim 49, wherein the antibody is administered to a human subject who has not undergone seroconversion. 51. The use according to any one of claims 42 to 47, wherein the antibody is administered to a human subject with Fiebig stage V or Fiebig stage VI HIV-1 clade B infection. 52. The use according to any one of claims 42 to 47, wherein the human subject is chronically infected with HIV-1 clade B. 53. The use according to any one of claims 42 to 47, wherein the viral genotype of said gp120 is identified in one or more gp120 polypeptide sequences expressed in HIV-1 clade B or HIV-1 clade B population isolated from said human subject. 54. The use according to any one of claims 42 to 47, wherein the viral genotype of said gp120 is identified in one or more gp120 polynucleotide sequences in HIV-1 clade B or HIV-1 clade B population isolated from said human subject. 55. The use according to claim 54, wherein the method comprises next-generation sequencing of a polynucleotide sequence encoding gp120 from an HIV-1 clade B population. 56. The use according to any one of claims 1 to 6 or 42 to 47, wherein the gp120 amino acid is identified in one or more biological samples from the subject, wherein the one or more biological samples are obtained from blood, peripheral blood mononuclear cells, serum, plasma, semen, or lymph nodes. 57.58. The method according to any one of claims 1 to 6 or 42 to 47, wherein the method comprises identifying an HIV-1 clade B RNA population in a serum or plasma sample. 59. The method according to any one of claims 1 to 6 or 42 to 47, further comprising the step of obtaining one or more biological samples from the subject. 60. The method according to claim 59, wherein the two or more biological samples are obtained from the same tissue or fluid at two or more different time points. 61. The method according to claim 59, wherein the two or more biological samples are obtained from different tissues or fluids or from different anatomical locations. Claims 5 / 5 Page 6 CN 122005785 A Method for identifying HIV patients sensitive to therapy using GP120 V3 glycan-guided antibodies
[0001] This application is a divisional application of patent application No. 202080037770.7, filed May 18, 2020, entitled “Method for identifying HIV patients sensitive to therapy using GP120 V3 glycan-guided antibodies”. Cross-Reference to Related Applications
[0002] This patent application claims the benefit of U.S. Provisional Application 62 / 850,994, filed May 21, 2019, pursuant to 35 U.S.C., § 119(e), which is incorporated herein by reference in its entirety for all purposes.
[0003] Sequence List This patent application contains a sequence list submitted electronically in ASCII format, which is incorporated herein by reference in its entirety. The ASCII copy was created on April 27, 2020, named 1289PF_SL.txt, and has a size of 199,543 bytes. Background Art
[0004] Human immunodeficiency virus (HIV) infection and related diseases are a major public health problem worldwide. Most currently approved HIV infection therapies target viral reverse transcriptase, protease, and integrase, but HIV resistance to these existing drugs, long-term toxicity, and lack of patient adherence to daily dosing regimens have proven to be problems associated with these therapies. Therefore, the discovery and development of new HIV drugs is of great importance.
[0005] WO 2009 / 066702, WO 2012 / 030904, WO 2014 / 063059, WO 2016 / 149698, WO 2017 / 106346; WO 2018 / 075564 and WO 2018 / 125813, McCoy, Retrovirology, 2018, Volume 15, Page 70; Sok and Burton, Nat Immunol, 2018, Vol. 19, No. 11, pp. 1179-1188; Possas et al., Expert Opinion Ther Pat., July 2018, Vol. 28, No. 7, pp. 551-560; and Stephenson and Barouch, Curr HIV / AIDS Rep., 2016, Vol. 13, pp. 31-37, describe human anti-HIV antibodies derived from memory B cells of HIV-infected donors that target the V3 glycan region of gp120 and are capable of inhibiting infection from multiple HIV-1 species from various clades. The therapeutic use of antibodies may be limited because it requires identifying patients infected with HIV-1 species that can be targeted by antibodies targeting the V3 glycan region of HIV gp120. Summary of the Invention
[0006] The present invention provides a method for identifying patients most likely to benefit from therapy using antibodies targeting the V3 glycan region of HIV gp120.
[0007] Therefore, in one aspect, the present invention provides a method for treating or preventing HIV in a human subject in need of such treatment, the method comprising: a) identifying a human subject infected with HIV or a population of HIV expressing gp120 comprising the following amino acid residues: glycosylated asparagine (N332 glycan) at position 332 of amino acid residue, aspartic acid (D325) at position 325 of amino acid residue, and one or more amino acid residues selected from the following amino acid residues: threonine (T63) at position 63 of amino acid residue, leucine (L179) at position 179 of amino acid residue, threonine (T320) at position 320 of amino acid residue, and histidine (H330) at position 330 of amino acid residue, wherein the amino acid positions refer to SEQ ID NO: 4; and b) administering to the subject an effective amount of an antibody or its antigen-binding fragment thereof, which competes for or includes the VH and VL regions, the VH and VL region binding fragment binding to an epitope of gp120 within a third variable ring (V3) and / or a high-mannose patch containing N332 oligomannose glycan. In some embodiments, the method requires identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, and T63; ii. N332 glycan, D325, and L179; iii. N332 glycan, D325, and T320; iv. N332 glycan, D325, and H330; v. N332 glycan, D325, T63, and L179; vi.N332 polysaccharides, D325, T63, and T320; vii. N332 polysaccharides, D325, T63, and H330; viii. N332 polysaccharides, D325, L179, and T320; ix. N332 polysaccharides, D325, L179, and H330; x. N332 polysaccharides, D325, T320, and H330; xi. N332 polysaccharides, D325, T63, T320, and H330; xii. N332 polysaccharides, D325, T63, L179, and T320; xiii. N332 polysaccharides, D325, T63, L179, and H330; xiv. N332 polysaccharides, D325, L179, T320, and H330; or xv. N332 glycan, D325, T63, L179, T320, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4. In some embodiments, the method requires identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, and T63; ii. N332 glycan, D325, and L179; iii. N332 glycan, D325, and T320; or iv. N332 glycan, D325, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4. In some embodiments, the method requires identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, T63, and L179; ii. N332 glycan, D325, T63, and T320; iii. N332 glycan, D325, T63, and H330; iv. N332 glycan, D325, L179, and T320; v. N332 glycan, D325, L179, and H330; or vi. N332 glycan, D325, T320, and H330, wherein the amino acid positions refer to SEQ ID NO: 4. In some embodiments, the method requires identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, L179, T320, and H330; ii. N332 glycan, D325, T63, T320, and H330; iii. N332 glycan, D325, T63, L179, and T320; or iv. N332 glycan, D325, T63, L179, and H330, wherein the amino acid positions refer to SEQ ID NO: 4. In some embodiments, the method requires identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, T63, and H330; ii.iii. N332 polysaccharide, D325, T320 and H330; or iv. N332 polysaccharide, D325, T63, L179, T320 and H330, wherein the amino acid positions are referenced to SEQ ID NO: 4. In some implementations, the subject is infected with HIV or HIV populations expressing gp120 that also contains one or more of the following amino acid residues: glycan at amino acid residue 301 (glycan 301); lysine at amino acid residue 677 (K677); amino acid residues other than tryptophan at position 17 (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y) (not_W17); amino acid residues other than arginine at position 747 (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y) (not_R747); insertion_321.01 (e.g., at position G321). The insertion of any amino acid between and K322 (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y)); glutamic acid at position 429 (E429); glutamine at position 442 (Q442); arginine at position 335 (R335); isoleucine at position 165 (I165); serine at position 393 (S393); isoleucine at position 307 (I307); polysaccharide at position 295 (295 polysaccharide); and / or asparagine at position 300 (N300), wherein the amino acid positions refer to SEQ ID NO: 4. In some implementations, at least 90%, for example, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the HIV species in the population contain the amino acid residues. In some embodiments, the applied antibody or its antigen-binding fragment competes for or includes the VH and VL regions of an antibody selected from the following: GS-9722 (epavivirumab), GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139. (Instructions for Use, Page 2 / 81, CN 122005785 A)10-1074, 10-1074-J, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03. In some embodiments, the antibody or its antigen-binding fragment competes for or includes the VH and VL regions of an antibody selected from the following: GS-9722, GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-124, PGT-134, GS-2872, 10-1074, 10-1074-J, PGT-122, and PGT-123. In some embodiments, these methods include administering an antibody containing an Fc region comprising one or more amino acid substitutions that extend serum half-life. In some embodiments, these methods include administering an antibody containing an Fc region comprising the following amino acids at designated positions (EU index numbers): i. tyrosine at position 252, threonine at position 254, and glutamic acid (YTE) at position 256; or ii. leucine at position 428 and serine (LS) at position 434. In some embodiments, these methods include administering an antibody containing an Fc region comprising the following amino acids at designated positions (EU index number): i. aspartic acid at position 239 and glutamic acid at position 332 (DE); ii. aspartic acid at position 239, glutamic acid at position 332, and leucine at position 330 (DEL); iii. aspartic acid at position 239, glutamic acid at position 332, and alanine at position 236 (DEA); or iv. aspartic acid at position 239, glutamic acid at position 332, alanine at position 236, and leucine at position 330 (DEAL). In some embodiments, these methods include administering an antigen-binding fragment. In some embodiments, the antigen-binding fragment is selected from scFv, Fab, Fab2, Fab', F(ab')2, Fv, and bivalent antibodies. In some embodiments, the antibody is one or more arms of a multispecific antibody (e.g., a bispecific antibody). In some embodiments, the human subject is acutely infected with HIV. In some embodiments, the antibody is administered to a subject with HIV infection at or earlier, such as Fiebig stage IV, Fiebig stage III, Fiebig stage II, or Fiebig stage I. In some embodiments, the antibody is administered to a subject who has not undergone seroconversion.Human subjects are subject to HIV infection. In some embodiments, the human subject has recently been infected with HIV, for example, within 1, 2, 3, or 4 weeks, or before detection, seroconversion, or symptom presentation. In some embodiments, antibodies are administered to human subjects with HIV infection in Fiebig stage V or Fiebig stage VI. In some embodiments, the human subject has a chronic HIV infection. In some embodiments, the human subject is infected with HIV clade B virus. In some embodiments, the human subject is infected with HIV clade B virus, and these methods require identification of subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, T63, and H330; ii. N332 glycan, D325, L179, T320, and H330; or iii. N332 glycan, D325, T63, L179, T320, and H330. In some embodiments, the human subject is infected with HIV clade A virus. In some embodiments, the human subject is infected with HIV clade C virus. In some embodiments, these methods also include administering one or more additional therapeutic agents to the subject for treating HIV infection. In some embodiments, the subject has not received antiretroviral therapy (ART) or has discontinued ART before antibody administration. In some embodiments, ART is discontinued after one or more administrations of the antibody or its antigen-binding fragment. In some embodiments, these methods also include administering one or more antiretroviral therapy (ART) agents to the subject. In some embodiments, these methods also include administering a second antibody or its antigen-binding fragment to the subject, the second antibody or its antigen-binding fragment binding to an epitope or region of gp120 selected from: a second variable loop (V2) and / or the Env trimer apex; a CD4 binding site (CD4bs); the gp120 / gp41 interface; or the gp120 silencing surface. In some embodiments, the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 in the second variable loop (V2) and / or the apex of the Env trimer, and competes for or includes the VH and VL regions of antibodies selected from the following: PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CH01, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E, and VRC38.01. In some embodiments, the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 in the CD4 binding site (CD4bs), and competes for or includes the VH and VL regions of antibodies selected from the following:Page 3 / 81, 9 CN 122005785 A Antibodies whose VH and VL regions compete with or contain these VH and VL regions: b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01, VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103, 44-VRC13.01, 1NC9, 12A12, N6, N6LS (VRC-HIVMAB091-00-AB), N49- P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25. In some embodiments, the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 at the gp120 / gp41 interface and competes for or includes the VH and VL regions of antibodies selected from: PGT-151, CAP248-2B, 35O22, 8ANC195, ACS202, VRC34 and VRC34.01. In some embodiments, the second antibody or its antigen-binding fragment binds to an epitope or region of the gp120 silencing surface and competes for or includes the VH and VL regions of antibody VRC-PG05. In some embodiments, the second antibody or its antigen-binding fragment binds to an epitope or region of gp41 in the proximal membrane region (MPER) and competes for or includes the VH and VL regions of an antibody selected from the following: 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01. In some embodiments, the second antibody or its antigen-binding fragment binds to an epitope or region of the gp41 fusion peptide and competes for or includes the VH and VL regions of an antibody selected from the following: VRC34 and ACS202. In some embodiments, these methods further include administering a TLR agonist to the subject. In some embodiments, the TLR agonist is a TLR2 agonist, a TLR3 agonist, a TLR7 agonist, a TLR8 agonist, or a TLR9 agonist. In some embodiments, the TLR7 agonist is selected from vesamimod, imiquimod, and requimod. In some embodiments, these methods include administering the antibody or its antigen-binding fragment multiple times at predetermined intervals, optionally in conjunction with the TLR agonist. In some embodiments, following one or more administrations of the antibody or its antigen-binding fragment, in the absence of antiretroviral therapy (ART), the subject remains in the body for at least 6 hours.The subject has not exhibited symptoms of HIV or AIDS for at least 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, or longer. In some embodiments, after one or more administrations of the antibody, in the absence of antiretroviral therapy (ART), the subject has an HIV viral load of less than 500, for example less than 400, 300, 200, 100, or 50 copies / ml of blood for at least 6 months, 1 year, 2 years, 3 years, or longer.
[0008] In another aspect, the present invention provides a method for identifying human subjects infected with HIV or HIV populations who are sensitive to antibodies or antigen-binding fragments thereof, the antibodies or antigen-binding fragments thereof competing for or containing VH and VL regions that bind to epitopes of gp120 within a third variable ring (V3) and / or a high-mannose patch containing N332 oligomannan. In some embodiments, these methods include identifying gp120 in a biological sample from a human subject containing the following amino acid residues: glycosylated asparagine (N332 glycan) at position 332 of amino acid residue, aspartic acid (D325) at position 325 of amino acid residue, and one or more amino acid residues selected from the following amino acid residues: threonine (T63) at position 63 of amino acid residue, leucine (L179) at position 179 of amino acid residue, threonine (T320) at position 320 of amino acid residue, and histidine (H330) at position 330 of amino acid residue, wherein the amino acid positions are referenced in SEQ ID NO: 4. In some implementations, the method requires identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, and T63; ii. N332 glycan, D325, and L179; iii. N332 glycan, D325, and T320; iv. N332 glycan, D325, and H330; v. N332 glycan, D325, T63, and L179; vi. N332 glycan, D325, T63, and T320; vii. N332 glycan, D325, T63, and H330; viiii. N332 glycan, D325, L179, and T320; ix. N332 glycan, D325, L179, and H330; x. N332 polysaccharides, D325, T320, and H330; xi. N332 polysaccharides, D325, T63, T320, and H330; xii. N332 polysaccharides, D325, T63, L179, and T320; xiii. N332 polysaccharides, D325, T63, L179, and H330; xiv.N332 glycan, D325, L179, T320, and H330; or xv. N332 glycan, D325, T63, L179, T320, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4. In some embodiments, the method requires identification of subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, and T63; ii. N332 glycan, D325, and L179; iii. N332 glycan, D325, and T320; or iv. N332 glycan, D325, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4. In some implementations, the method requires identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, T63, and L179; ii. N332 glycan, D325, T63, and T320; iii. N332 glycan, D325, T63, and H330; iv. N332 glycan, D325, L179, and T320; v. N332 glycan, D325, L179, and H330; or vi. N332 glycan, D325, T320, and H330, wherein the amino acid positions refer to SEQ ID NO: 4. In some implementations, the method requires identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, L179, T320, and H330; ii. N332 glycan, D325, T63, T320, and H330; iii. N332 glycan, D325, T63, L179, and T320; or iv. N332 glycan, D325, T63, L179, and H330, wherein the amino acid positions refer to SEQ ID NO: 4. In some embodiments, the method requires identifying a subject infected with HIV or an HIV population expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, T63, and H330; ii. N332 glycan, D325, T320, and H330; iii. N332 glycan, D325, L179, T320, and H330; or iv. N332 glycan, D325, T63, L179, T320, and H330, wherein the amino acid positions refer to SEQ ID NO: 4. In some embodiments, the subject is infected with HIV or an HIV population expressing gp120 that also contains one or more of the following amino acid residues: glycan at amino acid residue 301 (glycan 301); lysine at amino acid residue 677.(K677); amino acid residues other than tryptophan at position 17 (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y) (not_W17); amino acid residues other than arginine at position 747 (e.g., A, C, D, E, F, G, H, I, ... K, L, M, N, P, Q, S, T, V, W, or Y (not_R747); insertion_321.01 (e.g., any amino acid insertion between positions G321 and K322 (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y)); glutamic acid at position 429 (E429); glutamine at position 442 (Q442); arginine at position 335 (R335); isoleucine at position 165 (I165); serine at position 393 (S393); isoleucine at position 307 (I307); polysaccharide at position 295 (295 polysaccharide); and / or asparagine at position 300 (N300), wherein the amino acid positions refer to SEQ ID NO: 4. In some embodiments, the antibody or its antigen-binding fragment competes for or includes the VH and VL regions of an antibody selected from the following: GS-9722, GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, 10-1074, 10-1074-J, VRC24, 2G12. BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03. In some embodiments, the antibody or its antigen-binding fragment competes for or includes the VH and VL regions of an antibody selected from the following: GS-9722, GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-124, PGT-134, GS-2872, 10-1074, 10-1074-J, PGT-122, and PGT-123. In some embodiments, the human subject is acutely infected...HIV. In some embodiments, the antibody is administered to a human subject with Fiebig stage IV or earlier HIV infection. In some embodiments, the antibody is administered to a human subject who has not undergone seroconversion. In some embodiments, the human subject has recently been infected with HIV. In some embodiments, the antibody is administered to a human subject with Fiebig stage V or Fiebig stage VI HIV infection. In some embodiments, the human subject has a chronic HIV infection. In some embodiments, the human subject is infected with HIV clade B virus. In some embodiments, the human subject is infected with HIV clade B virus, and these methods require identification of subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, T63, and H330; ii. N332 glycan, D325, L179, T320, and H330; or iii. N332 glycan, D325, T63, L179, T320, and H330. In some embodiments, the human subject is infected with HIV clade A virus. In some embodiments, as described on page 5 / 81 of CN 122005785 A, the human subject is infected with HIV clade C virus.
[0009] In some embodiments, relative to other embodiments of the methods described herein, gp120 amino acids are identified in one or more gp120 polypeptide sequences expressed from HIV or HIV populations isolated from the subject. In some embodiments, gp120 amino acids are identified in one or more gp120 polynucleotide sequences encoding gp120 polypeptides from HIV or HIV populations isolated from the subject. In various embodiments, these methods require next-generation sequencing (NGS) of the gp120-encoding polynucleotide sequences from the HIV population. In some embodiments, gp120 variants are detected at a frequency level of about 1% of the viral population (e.g., about 0.5% of the frequency level). In some embodiments, gp120 amino acids are identified in one or more biological samples from a subject, wherein the one or more biological samples are obtained from blood, peripheral blood mononuclear cells (PBMCs), serum, plasma, semen, or lymph nodes. In some embodiments, these methods require identification of HIV RNA populations in serum or plasma samples. In some embodiments, these methods further include the step of obtaining one or more biological samples from a subject. In some embodiments, two or more biological samples are obtained from a subject. In some embodiments, two or more biological samples are obtained from the same tissue or fluid at two or more different time points. In some embodiments, two or more biological samples are obtained from different tissues or fluids or from different anatomical locations.
[0010] DefinitionsUnless otherwise specified, the terms “a” and “an” mean one or more (kinds).
[0011] The term “about” means a quantity, level, value, numerical value, frequency, percentage, size, size, quantity, weight, or length that differs from a reference quantity, level, value, numerical value, frequency, percentage, size, quantity, weight, or length by up to 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%. In any embodiment discussed in the context of the numerical value used in conjunction with the term “about,” the omission of the term “about” is particularly considered.
[0012] Unless the context otherwise requires, throughout this specification and claims, the terms “comprising” and their variations such as “including” and “containing” should be interpreted in an open, inclusive sense, i.e., as “including but not limited to.” Where the terms “comprising” or “containing” are used herein, it should be understood that this disclosure also includes embodiments in which these terms are replaced by “consisting of” or “substantially consisting of.”
[0013] The term “consisting of…” means including but not limited to anything following the phrase “consisting of…”. Therefore, the phrase “consisting of…” indicates that the listed elements are necessary or mandatory, and other elements may be absent.
[0014] The term “substantially consisting of…” means including any elements listed following the phrase, and is limited to other elements that do not interfere with or contribute to the activity or function of the listed elements specified in this disclosure. Therefore, the phrase “substantially consisting of…” indicates that the listed elements are necessary or mandatory, but other elements are optional and may or may not be present, depending on whether they affect the activity or function of the listed elements.
[0015] Throughout this specification, the terms “an embodiment” or “an embodiment” refer to a particular feature, structure, or characteristic described in connection with that embodiment, which is included in at least one embodiment described herein. Therefore, the phrases “in one embodiment” or “in an embodiment” appearing in various places throughout this specification do not necessarily refer to the same embodiment. Furthermore, in one or more embodiments, a particular feature, structure, or characteristic may be combined in any suitable manner.
[0016] The “increased” or “enhanced” amount is generally a “statistically significant” amount and may include increases of 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, or 50 times or more (e.g., 100 times, 500 times, 1000 times) (including all integer and decimal points between 1 and greater than 1, e.g., 2.1, 2.2, etc.) of the amount or level described herein.2.3, 2.4, etc.). It may also include an increase of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 500%, or at least 1000% of the amount or level described herein.
[0017] The “reduced” or “less” or “less” amount is generally a “statistically significant” amount and may include a reduction of about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times or 50 times or more (e.g., 100 times, 500 times, 1000 times) (including all integer points and decimal points between 1 and greater than 1, e.g., 1.5, 1.6, 1.7, 1.8, etc.). It may also include a reduction of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, at least 100%, at least 150%, at least 200%, at least 500%, or at least 1000% of the amount or level described herein.
[0018] The “composition” may contain an active agent, such as a contrast agent, and an inert or active carrier, such as a pharmaceutically acceptable carrier, diluent, or excipient. The composition may be a pharmaceutical composition. In certain embodiments, the composition is sterile and substantially free of endotoxins or non-toxic to the recipient at the dose or concentration used.
[0019] "Pharmaceutically acceptable carriers, diluents, or excipients" include, but are not limited to, any adjuvants, carriers, excipients, flow aids, sweeteners, diluents, preservatives, dyes / colorants, flavor enhancers, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, solvents, or emulsifiers that have been approved by the U.S. Food and Drug Administration for acceptable use in humans or livestock.
[0020] "Biosample" or "sample" means any fluid, cellular, or solid tissue sample from a subject who has or is suspected of having detectable HIV.
[0021] "Subject," "individual," or "patient" means any mammal, including humans and non-human primates. In a particular embodiment, the mammal is a human.
[0022] As used herein, the term "buffer" refers to a pharmaceutically acceptable excipient that stabilizes the pH of a pharmaceutical preparation. Suitable buffers are well known in the art. Suitable pharmaceutically acceptable buffers include, but are not limited to, acetate buffer, histidine buffer, citrate buffer, succinate buffer, tris buffer, and phosphate buffer. In someIn the embodiments, the concentration of the buffer solution is about 0.01 mM to about 1000 mM, about 0.1 mM to about 1000 mM, about 0.1 mM to about 500 mM, about 0.1 mM to about 200 mM, about 0.1 mM to about 100 mM, about 1 mM to about 1000 mM, about 1 mM to about 500 mM, about 1 mM to about 200 mM, about 1 mM to about 100 mM, about 1 mM to about 50 mM, about 2 mM to about 60 mM, about 4 mM to about 60 mM, or about 4 mM to about 40 mM, about 5 mM to about 20 mM, or about 5 mM to about 25 mM.
[0023] "Optional" or "optionally" means that the event described below may or may not occur, and the description includes instances where said event or condition occurs and instances where said event or condition does not occur.
[0024] A “pharmaceutical composition” means a formulation of a compound and a medium commonly accepted in the art for the delivery of a bioactive compound to a mammal (e.g., a human). Such a medium may include any pharmaceutically acceptable carrier, diluent, or excipient.
[0025] An “effective amount” or “therapeutic effective amount” means an amount of an antibody or antigen-binding fragment thereof that, when administered alone or in combination with another therapeutic agent, is sufficient to achieve a therapeutic or beneficial outcome in a subject. The amount constituting an “effective amount” will vary depending on the antibody or antigen-binding fragment thereof and its specific use, as well as any underlying condition and its severity, the manner of administration, and the age of the subject to be treated, but may be determined conventionally by one of ordinary skill in the art with reference to their own knowledge and this disclosure. A therapeutic effective amount also means an amount of an antibody or antigen-binding fragment thereof sufficient to treat, prevent, or improve an infection or disease condition or the progression of an infection or disease, and an amount sufficient to achieve an increased rate of treatment, cure, prevention, or improvement of such condition. When applicable to a single antibody or antigen-binding fragment thereof administered alone, a therapeutic effective amount means the single active ingredient. When applied in combination, the therapeutically effective dose refers to the combined amount of the active ingredient that results in the therapeutic effect, whether applied in combination, continuously, or simultaneously.
[0026] As used herein, “treatment” (“Treat,” “treating,” or “treatment”) covers treating a subject (e.g., a mammal, such as a human) with a disease, injury, or condition of concern, such as HIV-1 infection, and includes: (i) inhibiting the progression of the disease, injury, or condition, i.e., preventing its development; (ii) reducing or alleviating the disease, injury, or condition, i.e. causing the remission of the disease or condition; or (iii) alleviating symptoms caused by the disease, injury, or condition. As used herein, the terms “disease,” “disorder,” and “condition” are used interchangeably. As used herein, “inhibition,” “treatment,” (“treatment,”"treating" and "improvement" are used interchangeably and refer to, for example, stagnation of symptoms, prolonged survival, partial or complete improvement of symptoms, and partial or complete eradication of a condition, disease, or disorder.
[0027] As used herein, "prevention" ("prevent" or "prevention") includes (i) preventing or inhibiting the occurrence of a disease, injury, or condition in a subject, particularly when such subjects are susceptible to the condition but have not yet been diagnosed with it; or (ii) reducing the likelihood of a subject developing a disease, injury, or condition.
[0028] As used herein, the term "antibody" means an isolated or recombinant binder containing the necessary variable region sequence for specifically binding an antigenic epitope. Thus, an antibody is any form of antibody or fragment thereof that exhibits the desired biological activity (e.g., binding to a specific target antigen). Therefore, it is used in the broadest sense and specifically covers monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, nanobodies, bivalent antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, including but not limited to scFv, Fab, and Fab2, provided they exhibit the desired biological activity.
[0029] The term "human antibody" refers to an antibody containing a human-derived sequence other than a possible non-human CDR region, and does not imply the presence of the complete structure of an Ig molecule, only that the antibody has a minimal immunogenic effect in humans.
[0030] An "antibody fragment" contains a portion of a complete antibody, such as the antigen-binding or variable region of a complete antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; bivalent antibodies; linear antibodies (e.g., Zapata et al., Protein Eng., Vol. 8, No. 10, pp. 1057-1062, 1995); single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. Papain digestion of the antibody produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, the name reflecting its ease of crystallization. Pepsin treatment produces an F(ab’)2 fragment with two antigen-binding sites and still capable of cross-linking the antigen.
[0031] “Fv” is the smallest antibody fragment containing complete antigen recognition and binding sites. This region consists of a dimer of a tightly non-covalently associated heavy chain variable domain and a light chain variable domain. In this configuration, the three CDRs of each variable domain typically interact to define the antigen-binding site on the surface of the VH-VL dimer. Generally, the six CDRs collectively confer antibody antigen-binding specificity, but when one or more of the six CDRs are missing or modified, for example, through…Examples exist of maintaining antigen-binding specificity by altering the amino acid sequence of one or more CDRs, for example, through amino acid insertion, deletion, or substitution. Additionally, even a single variable domain (or only half of the Fv of the three CDRs specific to the antigen) has the ability to recognize and bind antigens, but with lower affinity than the entire binding site. Residues other than those present in the CDRs may also be important for or play a role in antigen binding and / or specificity, as shown by closely related somatic variants of PGT121 and those that interact with the gp120 antigen using residues in the light chain framework 3 (Julien et al., Science, Vol. 342, pp. 1477–1483, 2013; Julien et al., PLOS Pathog., Vol. 9, pp. e1003342, (2013)). These residues are partly derived from an unusual three-amino acid insertion that extends the originally short surface loop in PGT121 and associated somatic variants (e.g., PGT122, PGT123, PGT124, PGT133, PGT134, 10-1074) that contacts both the N332 polysaccharide and protein residues on HIV Env, thereby effectively forming an additional (e.g., a fourth) complementarity-determining region (CDR) loop in the PGT121 light chain between LC CDR 2 and LC CDR 3. Specification 8 / 81 pages 14 CN 122005785 A
[0032] The term “hypervariate region” refers to the amino acid residue of the antibody that is normally responsible for antigen binding. Hypervariable regions typically contain amino acid residues from the complementarity-determining region (CDR) or CDR (e.g., approximately residues 24–34 (L1), 50–56 (L2), and 89–97 (L3) in VL when numbered according to the Kabat numbering system, and approximately residues 31–35 (H1), 50–65 (H2), and 95–102 (H3) in VH; Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, Md., 1991); and / or residues from the hypervariable ring (e.g., residues 24–34 in VL when numbered according to the Chothia numbering system). (L1), 50-56 (L2) and 89-97 (L3), and residues 26-32 (H1), 52-56 (H2) and 95-101 (H3) in VH; Chothia and Lesk, J. Mol.Biol., Vol. 196, pp. 901–917, 1987; and / or those residues from the “high-variance ring” VCDR (e.g., residues 27–38 (L1), 56–65 (L2), and 105–120 (L3) in VL when numbered according to the IMGT numbering system, and residues 27–38 (H1), 56–65 (H2), and 105–120 (H3) in VH; Lefranc, MP et al., Nucl. Acids Res., Vol. 27, pp. 209–212, 1999; Ruiz, M. et al., Nucl. Acids Res., Vol. 28, pp. 219–221, 2000). Optionally, when numbered according to AHo, the antibody has symmetrical insertions at one or more of the following points 28, 36 (L1), 63, 74-75 (L2) and 123 (L3) in VL and at the following points 28, 36 (H1), 63, 74-75 (H2) and 123 (H3) in VH; Honneger, A and Plunkthun, A., J., Mol. Biol., Vol. 309, pp. 657-670, 2001).
[0033] The “Fab” fragment is the region on the antibody that binds to the antigen. It consists of a constant domain and a variable domain in each of the heavy and light chains. These domains shape the complementary site (antigen binding site) at the amino terminus of the monomer. The two variable domains bind to the epitope on their specific antigen. The Fab fragment differs from the Fab' fragment in that some residues are added to the carboxyl terminus of the CH1 domain of the heavy chain, including one or more cysteine residues from the antibody hinge region. Fab'-SH is the name for Fab' in this document, where the cysteine residues of the constant domain have a free thiol group. The F(ab')2 antibody fragments are initially produced as Fab' fragment pairs with a hinge cysteine residue between them. Other chemical conjugations of antibody fragments are also known.
[0034] The "light chain" of an antibody (immunoglobulin) from any vertebrate species can be designated as one of two distinct types (called κ and λ) based on the amino acid sequence of its variable or constant domain. Immunoglobulins can be designated as different classes based on the amino acid sequence of the constant domain of their heavy chain. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these immunoglobulins can be further subdivided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.
[0035] The “single-chain Fv”, “scFv”, or “sFv” antibody fragment contains the VH and VL domains of the antibody, wherein these domainsIt exists within a single polypeptide chain. In some embodiments, the Fv polypeptide also includes a polypeptide linker between the VH and VL domains, which enables the sFv to form the desired antigen-binding structure.
[0036] The term "bivalent antibody" refers to a small antibody fragment having two antigen-binding sites, which contains a heavy chain variable domain (VH) linked to a light chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domain is forced to pair with a complementary domain of another chain, resulting in two antigen-binding sites. Bivalent antibodies are described more fully, for example, in EP404,097; WO 93 / 11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 6444-6448, 1993.
[0037] An “isolated” antibody or its antigen-binding fragment is an antibody or its antigen-binding fragment that has been identified and isolated and / or recovered from components of its native environment. Contaminant components of its native environment are materials that will interfere with the diagnostic or therapeutic use of the antibody and may include enzymes, hormones, and other protein- or non-protein-based solutes. In some embodiments, the antibody will be purified (1) to a concentration greater than 95% by weight, e.g., greater than 99% by weight, as determined by the Lowry method, (2) to a degree sufficient to obtain at least 15 N-terminal or internal amino acid sequence residues by using a rotary cup sequencer, or (3) to obtain homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or silver staining. Isolated antibodies include recombinant intracellular in situ antibodies because at least one component of the antibody’s native environment will be absent. However, typically, isolated antibodies will be prepared by at least one purification step.
[0038] An antibody or antigen-binding fragment thereof that is “specifically bound to” or “specific to” a particular polypeptide or an epitope on a particular polypeptide is an antibody or antigen-binding fragment thereof that binds to that particular polypeptide or an epitope on a particular polypeptide and substantially does not bind to any other polypeptide or polypeptide epitope. In some embodiments, the antibodies of this disclosure specifically bind antigens in the form of monoclonal antibodies, scFv, Fab, or other forms of antibodies measured at temperatures of about 4°C, 25°C, 37°C, or 42°C, for example, HIV-1 gp120 polypeptide with a dissociation constant Kd equal to or less than 100 nM, optionally less than 10 nM, optionally less than 1 nM, optionally less than 0.5 nM, optionally less than 0.1 nM, optionally less than 0.01 nM, or optionally less than 0.005 nM. The affinity of the antibody can be readily determined using conventional techniques, such as those described by Scatchard et al. (Ann. NY, Acad. Sci.).USA, Vol. 51, p. 660, 1949, ELISA assay, biolayer interferometer (BLI) assay, and surface plasmon resonance (SPR) assay. The binding properties of antibodies to antigens, cells, or their tissues can generally be determined and evaluated using immunoassay methods, including, for example, immunofluorescence-based assays such as immunohistochemistry (IHC) and / or fluorescence-activated cell sorting (FACS).
[0039] As used herein, an “internalized” antibody is an antibody that is taken up (i.e., enters) by a cell when it binds to an antigen on a mammalian cell (e.g., a cell surface polypeptide or receptor). Of course, internalized antibodies will include antibody fragments, human or chimeric antibodies, and antibody conjugates. For certain therapeutic applications, in vivo internalization is envisioned. The number of internalized antibody molecules will be sufficient or adequate to kill cells or inhibit their growth, especially infected cells. Depending on the potency of the antibody or antibody conjugate, in some cases, the uptake of a single antibody molecule by a cell is sufficient to kill the target cell to which the antibody binds. For example, some toxins are highly effective in killing, such that the internalization of a single molecule of the toxin conjugated to an antibody is sufficient to kill infected cells.
[0040] The term "antagonist antibody" is used in the broadest sense and includes antibodies that partially or completely block, inhibit, or neutralize the biological activity of epitopes, peptides, or cells to which they specifically bind. Methods for identifying antagonist antibodies may include contacting a peptide or cell specifically bound by a candidate antagonist antibody with the candidate antagonist antibody and measuring detectable changes in one or more biological activities typically associated with the peptide or cell.
[0041] An "antibody that inhibits the growth of infected cells" or a "growth-inhibiting antibody" is an antibody that binds to infected cells that express or are capable of expressing HIV1 epitopes bound by the antibody and causes measurable growth inhibition of those cells. Compared to a suitable control (which is typically infected cells not treated with the antibody being tested), the preferred growth-inhibiting antibody inhibited the growth of infected cells by more than 20%, preferably from about 20% to about 50%, and even more preferably more than 50% (e.g., from about 50% to about 100%). Growth inhibition can be measured in cell cultures at antibody concentrations of about 0.1 µg / ml to about 30 µg / ml or about 0.5 nM to about 200 nM, wherein growth inhibition is determined 1 to 10 days after the infected cells are exposed to the antibody. Growth inhibition of infected cells in vivo can be determined in various ways known in the art. If administration of the antibody at about 1 µg / kg to about 100 mg / kg body weight results in a reduction in the percentage or total number of infected cells within about 5 days to 3 months, preferably within about 5 days to 30 days, after the first administration of the antibody, the antibody is considered growth-inhibiting in vivo.
[0042] Antibodies that “induce apoptosis” do so through binding to annexin V, DNA breakage, cell contraction, and endoplasmic reticulum expansion.Antibodies that induce programmed cell death, as determined by the formation of cell fragmentation, cell breakage, and / or membrane vesicles (called apoptotic bodies). Preferably, the cell is an infected cell. Various methods are available for evaluating cellular events associated with apoptosis. For example, phosphatidylserine (PS) translocation can be measured by annexin binding; DNA breakage can be evaluated by DNA gradient; and nuclear / chromatin condensation along with DNA breakage can be evaluated by any increase in hypoploid cells. Preferably, the antibody that induces apoptosis (see page 16 of CN 122005785 A, specification 10 / 81) is an antibody that induces annexin binding about 2 to 50 times, preferably about 5 to 50 times, and most preferably about 10 to 50 times relative to untreated cells in an annexin binding assay.
[0043] Antibody “effective function” refers to those biological activities attributable to the Fc region of the antibody (natural sequence Fc region or amino acid sequence variant Fc region) and varies with antibody isotype. Examples of antibody effector functions include: Clq binding and complement-dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis (e.g., antibody-dependent cell-mediated phagocytosis (ADCP)); downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation.
[0044] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted or exogenously applied Ig binds to Fc receptors (FcRs) on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages), enabling these cytotoxic effector cells to specifically bind to target cells carrying antigens and subsequently kill the target cells with cytotoxins. Antibodies "arm" cytotoxic cells and are required for this type of killing. Primary NK cells used to mediate ACC express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. The expression of FcR on hematopoietic cells is summarized in Table 4 of Ravetch and Kinet, Annu. Rev. Immunol, Vol. 9, pp. 457–492, 1991, p. 464. To assess the ADCC activity of the molecule of interest, in vitro ADCC assays, such as those described in U.S. Patent 5,500,362 or U.S. Patent 5,821,337, can be performed. Effector cells that can be used for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively or additionally, the ADCC activity of an antibody or its antigen-binding fragment can be assessed in vivo, for example, in animal models, such as those disclosed in Clynes et al., Proc. Natl. Acad. Sci. (USA), Vol. 95, pp. 652–656, 1998.
[0045] The term "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. In some embodiments, the FcR is a naturally occurring human FcR. Furthermore, preferred FcRs are FcRs that bind to IgG antibodies (γ receptors) and include receptors of the FcγRI, FcγRII, and FcγRIIII subclasses, including allelic variants and alternative splice forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences that differ primarily in their cytoplasmic domains, and FcγRIIC, which includes the FcγRIIB extracellular domain fused to the activating cytoplasmic region. The activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain (see review M. in Daeron, Annu. Rev. Immunol., Vol. 15, pp. 203–234, 1997). FcRs are reviewed in Ravept and Kinet, Annu. Rev. Immunol., Vol. 9, pp. 457–492, 1991; Capel et al., Immunomethods, Vol. 4, pp. 25–34, 1994; and de Haas et al., J. Lab. Clin. Med., Vol. 126, pp. 330–341, 1995. The term “FcR” in this article encompasses other FcRs, including those to be identified in the future. The term also includes neonatal receptors FcRn, which are responsible for transferring maternal IgG to the fetus (Guyer et al., J. Immunol., Vol. 117, p. 587, 1976; and Kim et al., J. Immunol., Vol. 24, p. 249, 1994), and for rescuing IgG from lysosomal degradation via FcRn-dependent recycling after endocytosis. FcRn binding following endothelial cell endocytosis has been shown to be important for maintaining the prolonged pharmacokinetic half-life of antibodies. In vitro assessments of pH-dependent human FcRn binding of antibodies can be performed to provide predictions of favorable clinical pharmacokinetic potential (Datta-Mannan and Wroblewski, Drug Metab. Dispos., Vol. 42, pp. 1867–1872, 2014).
[0046] “Human effector cells” are leukocytes that express one or more FcRs and perform effector functions. Preferably, the cells express at least FcγRIII and perform ADCC effector functions. Examples of human leukocytes mediating ADCC include PBMCs, NK cells, and mononuclear cells.Nucleated cells, cytotoxic T cells, and neutrophils; among which PBMCs and NK cells are preferred. Effector cells may be isolated from natural sources, for example, from blood. Specification 11 / 81 pages 17 CN 122005785 A
[0047] "Complement-dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to an antibody (appropriate subclass) bound to its homologous antigen. To assess complement activation, a CDC assay may be performed, for example, as described in Gazzano-Santoro et al., J. Immunol. Methods, Vol. 202, p. 163, 1996.
[0048] "Neutralizing antibody" is an antibody that can neutralize the ability of the pathogen to initiate and / or maintain infection in host and / or target cells in vitro. This article describes neutralizing monoclonal human antibodies and their antigen-binding fragments, wherein the antibody recognizes antigens from HIV, such as the gp120 peptide. In some embodiments, the “neutralizing antibody” can inhibit the entry of HIV-1 virus, for example, SF162 and / or JR-CSF with a neutralization index >1.5 or >2.0 (Kostrikis LG et al., / Virol., 1996, Vol. 70, No. 1, pp. 445-458). The term “broadly neutralizing antibody” means an antibody that neutralizes more than one species of HIV-1 virus (from different clades and different strains within clades) in a neutralization assay. Broadly neutralizing antibodies can neutralize at least 2, 3, 4, 5, 6, 7, 8, 9 or more different strains of HIV-1 belonging to the same or different clades. In certain embodiments, broadly neutralizing antibodies can neutralize multiple HIV-1 species belonging to at least 2, 3, 4, 5, or 6 different clades. In some embodiments, the inhibitory concentration of the monoclonal antibody can be less than about 0.0001 µg / ml, less than about 0.001 µg / ml, less than about 0.01 µg / ml, less than about 0.1 µg / ml, less than about 0.5 µg / ml, less than about 1.0 µg / ml, less than about 5 µg / ml, less than about 10 µg / ml, less than about 25 µg / ml, less than about 50 µg / ml, or less than about 100 µg / ml to neutralize about 50% of the introduced virus in a neutralization assay.
[0049] HIV is divided into specific groups M, N, O, and P, with M being the “major” group and responsible for the majority of HIV / AIDS worldwide. Based on their genetic sequences, group M is further subdivided into subtypes (also called clades) with prevalence in different geographic locations.
[0050] Group M "subtypes" or "clades" are subtypes of HIV-1 group M defined by gene sequence data. Examples of group M subtypes.This includes subtypes A-K. Some subtypes are known to be more virulent or resistant to different drugs. There are also "circular recombination forms," or CRFs derived from recombinations between different subtypes, each with its own designation. For example, CRF12_BF is a recombination between subtypes B and F. Subtype A is common in West Africa. Subtype B is the dominant form in Europe, the Americas, Japan, Thailand, and Australia. Subtype C is the dominant form in parts of South Africa, East Africa, India, Nepal, and China. Subtype D is generally found only in East and Central Africa. Subtype E has never been identified as a non-recombinant form, only recombinating with subtype A to form CRF01_AE. Subtype F has been found in Central Africa, South America, and Eastern Europe. Subtype G (and CRF02_AG) has been found in Africa and Central Europe. Subtype H is limited to Central Africa. Subtype I was originally used to describe the strain now considered to be CRF04_cpx, where cpx is used for "complex" recombinations between several subtypes. Subtype J is mainly found in North Africa, Central Africa, and West Africa, while Caribbean subtype K is limited to the Democratic Republic of Congo and Cameroon. These subtypes are sometimes further divided into subtypes, such as A1 and A2 or F1 and F2. In 2015, strain CRF19 was found to be a recombinant of subtypes A, D, and G, with its subtype D protease closely associated with the rapid development of AIDS in Cuba.
[0051] "HIV tropism" refers to the specificity of HIV virus for a particular host cell, which is determined in part by the interaction between viral surface structures and receptors present on the surface of host cells. HIV tropism of a patient's virus can be measured, for example, by sequencing analysis or by the TROFILE® assay (monogrambio.com). (See, for example, Lee et al., AIDS Res Hum Retroviruses., 2013, Vol. 29, No. 6, pp. 979-984).
[0052] HIV can infect a variety of cells, such as CD4+ helper T cells and macrophages, which express CD4 molecules on their surface. HIV-1 entry into macrophages and T helper cells is mediated not only by the interaction of viral envelope glycoproteins (e.g., gp120) with CD4 molecules on target cells, but also by the interaction of its chemokine co-receptor. HIV-1 macrophage (M-tropic) strains or non-syncytial inducible (NSI) strains enter using the β-chemokine receptor CCR5 and are therefore able to replicate in macrophages and CD4+ T cells. These strains are called R5 viruses. This CCR5 co-receptor is used by almost all primary HIV-1 isolates, regardless of viral genetic subtype. T-tropic isolates or syncytial inducible (SI) strains replicate in primary CD4+ T cells and macrophages and enter using the α-chemokine receptor CSCR4. These strains are called X4 viruses.Viruses that use only the CCR5 receptor are called R5, those that use only the CXCR4 receptor are called X4, and those that use both are called X4R5 or dual / mixed tropism. However, the use of a co-receptor alone does not explain viral tropism, as not all R5 viruses are able to use CCR5 on macrophages for productive infection.
[0053] This document also describes “non-neutralizing antibodies,” which in some embodiments are antibodies that bind to one or more viral strains but do not neutralize the virus. However, in terms of Fc-mediated killing, non-neutralizing antibodies can still eliminate cells expressing viral antigens that bind to the antibody but are not neutralized by the antibody. Thus, in some embodiments, antibodies can bind to viral antigens and eliminate virus-infected cells without neutralizing the virus.
[0054] The term “nucleic acid molecule” refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, and genomic DNA, as well as synthetic forms and mixed polymers described above. In a particular embodiment, a nucleotide refers to a modified form of ribonucleotides, deoxyribonucleotides, or any type of nucleotide, and combinations thereof. The term also includes, but is not limited to, single-stranded and double-stranded forms of DNA. Additionally, polynucleotides such as cDNA or mRNA may include one or both of naturally occurring and modified nucleotides linked together by naturally occurring and / or non-naturally occurring nucleotide bonds. As will be readily understood by those skilled in the art, nucleic acid molecules may be chemically or biochemically modified, or may contain non-natural or derived nucleotide bases. Such modifications include, for example, labeling, methylation, substitution of one or more naturally occurring nucleotides with analogs, internucleotide modifications such as uncharged bonds (e.g., methyl phosphonate, triphosphate, aminophosphate, carbamate, etc.), charged bonds (e.g., thiophosphate, dithiophosphate, etc.), side chain portions (e.g., polypeptides), intercalating agents (e.g., acridine, psoralen, etc.), chelating agents, alkylates, and modified bonds (e.g., α-anomeric nucleic acids, etc.). The foregoing terms are also intended to include any topological conformation, including single-stranded, double-stranded, partially double-stranded, triple-stranded, hairpin, cyclic, and padlock conformations. Unless otherwise specified, references to nucleic acid sequences encompass their complementary sequences. Therefore, references to nucleic acid molecules having a specific sequence should be understood to encompass their complementary strand and its complementary sequence. The term also includes codon-optimized nucleic acids.
[0055] The term “operably linked” refers to two or more nucleic acid sequence elements that are generally physically linked and functionally related to each other. For example, if a promoter is capable of initiating or regulating transcription or expression of a coding sequence, then the promoter is operably linked to the coding sequence, in which case the coding sequence should be understood as “under the control of the promoter.”
[0056] As used herein, “substitution” means that one or more amino acids or nucleotides are substituted by different amino acids or nucleotides, respectively.
[0057] "Isolated" nucleic acid refers to a nucleic acid molecule that has been isolated from components of its natural environment. Isolated nucleic acids include nucleic acid molecules contained in cells that typically contain nucleic acid molecules, but which are present outside the chromosome or at a chromosomal location different from their natural chromosomal location.
[0058] "Isolated nucleic acid encoding an antibody or a fragment thereof" refers to one or more nucleic acid molecules encoding the heavy and light chains (or fragments thereof) of an antibody, including such nucleic acid molecules in a single vector or in a single vector, and such nucleic acid molecules present at one or more locations in a host cell.
[0059] As used herein, the term "vector" refers to a nucleic acid molecule capable of proliferating another nucleic acid to which it is linked. This term includes vectors as self-replicating nucleic acid structures as well as vectors integrated into the genome of a host cell to which the vector has been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are effectively linked. Such vectors are referred to as, as used herein, by the term polynucleotide "variant," which is a polynucleotide that is generally different from the polynucleotide specifically disclosed herein in one or more substitutions, deletions, additions, and / or insertions. Such variants may be naturally occurring or synthesized, for example, by modifying one or more of the polynucleotide sequences described herein and evaluating one or more biological activities of the polypeptide encoded as described herein and / or using any of a variety of techniques well known in the art.
[0060] As used herein, the term polypeptide “variant” is a polypeptide that is generally different from the polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and / or insertions. Such variants may be naturally occurring or synthesized, for example, by modifying one or more of the polypeptide sequences of the present invention described above and evaluating one or more biological activities of the polypeptide as described herein and / or using any of a variety of techniques well known in the art.
[0061] The term “variant” may also refer to any naturally occurring or engineered molecule containing one or more nucleotide or amino acid mutations. In one embodiment, the molecule is an antibody. For example, somatic variants may cover all relevant naturally occurring antibodies that are part of or derived from the same B cell lineage. Engineered variants may cover all single or combined mutations made to the antibody.
[0062] Modifications can be made to the structure of the polynucleotides and polypeptides of the present invention, and functional molecules encoding variants or derived polypeptides having the desired properties are still obtained. When it is desired to change the amino acid sequence of a polypeptide to produce an equivalent or even improved variant or portion of the polypeptide of the present invention, those skilled in the art will typically change one or more of the codons encoding the DNA sequence.
[0063] For example, certain amino acids can replace other amino acids in the protein structure without significantly losing their ability to bind other polypeptides (e.g., antigens) or cells. Since it is the binding ability and properties of a protein that define its bioavailability...The functional activity of the protein can be obtained by making certain amino acid sequence substitutions in the protein sequence, and of course, certain amino acid sequence substitutions in its basic DNA coding sequence, while still obtaining a protein with similar properties. Therefore, it is conceivable that various changes can be made to the polypeptide sequence of the disclosed antibody and its antigen-binding fragment or the corresponding DNA sequence encoding the polypeptide without significantly losing their biological efficacy or activity.
[0064] In many cases, the polypeptide variant will contain one or more conserved substitutions. A “conserved substitution” is a substitution in which an amino acid has similar properties to another amino acid, such that a person skilled in the art of peptide chemistry would expect the secondary structure and hydrophilicity of the polypeptide to remain substantially unchanged.
[0065] When comparing polynucleotide and polypeptide sequences, if the sequences of nucleotides or amino acids in the two sequences are identical when the maximum correspondence is aligned, the two sequences are considered “identical”, as described below. Comparisons between two sequences are usually performed by comparing sequences on a comparison window to identify and compare local regions of sequence similarity. As used herein, a “comparison window” refers to a segment of at least about 20 consecutive positions (typically 30 to about 75, 40 to about 50), which, after optimal alignment of two sequences, can be compared with a reference sequence having the same number of consecutive positions.
[0066] Sequence alignment for comparison can be performed using the Megalign procedure in the Lasergene bioinformatics software package (DNASTAR, Inc., Madison, WI) with default parameters. This procedure incorporates several alignment schemes described in the following references: Dayhoff, M.O., 1978, A model of evolutionary change in proteins – Matrices for detecting distant relationships, Dayhoff, M.O. (ed.), Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC, Vol. 5, Supplement 3, pp. 345–358; Hein J., 1990, Unified Approach to Alignment and Phylogenes, pp. 626–645, Methods in Enzymology, Vol. 183, Academic Press, Inc., San Diego, CA; Higgins, DG. and Sharp, PM, 1989, CABIOS, Vol. 5, pp. 151–153; Myers,EW. and Muller W., 1988, CABIOS, Vol. 4, pp. 11–17; Robinson, ED., 1971, Comb. Theor., Vol. 77, p. 105; Santou, N. Nes, M., 1987, Mol. Biol. Evol., Vol. 4, pp. 406–425; Sneath, PHA and Sokal, RR., 1973, Numerical Taxonomy Manual, 14 / 81 pages, 20 CN 122005785 A – the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA; Wilbur, WJ and Lipman, DJ., 1983, Proc. Natl. Acad., Sci. USA, Vol. 80, pp. 726–730.
[0067] Alternatively, sequence alignment for comparison may be performed by Smith and Waterman’s local identity algorithm (1981, Add. APL. Math, Vol. 2, p. 482), by Needleman and Wunsch’s identity alignment algorithm (1970, J. Mol. Biol., Vol. 48, p. 443), by Pearson and Lipman’s similarity search method (1988, Proc. Natl. Acad. Sci. USA, Vol. 85, p. 2444), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.
[0068] An example of an algorithm suitable for determining the percentage of sequence identity and sequence similarity is the BLAST and BLAST 2.0 algorithms, described respectively in Altschul et al., 1977, Nucl. Acids Res., Vol. 25, pp. 3389-3402 and Altschul et al., 1990, J. Mol. Biol., Vol. 215, pp. 403-410. BLAST and BLAST 2.0 can be used, for example, with the parameters described herein to determine the percentage of sequence identity of the polynucleotides and peptides described herein. Software for performing BLAST analysis is publicly available from the National Center for Biotechnology Information.
[0069] In an exemplary example, for nucleotide sequences, the parameter M (a reward score for a pair of matching residues) can be used.The cumulative score is calculated using (always > 0) and N (penalty score for mismatched residues; always < 0). Word hits in each direction cease when the cumulative alignment score decreases by an amount X from its maximum realized value; the cumulative score becomes zero or lower due to the accumulation of one or more negative score residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) defaults to using a word length (W) of 11 and an expected value (E) of 10, along with the BLOSUM62 scoring matrix (see Henikoff and Henikoff, 1989, Proc. Natl. Acad. Sci. USA, Vol. 89, p. 10915) for alignment, where (B) is 50, expected value (E) is 10, M=5, N=-4, and two strands are compared.
[0070] For amino acid sequences, the cumulative score can be calculated using the scoring matrix. The extension of word hits in each direction stops when: the cumulative alignment score decreases by an amount X from its maximum realized value; the cumulative score becomes zero or lower due to the accumulation of one or more negative score residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
[0071] In one method, a “sequence identity percentage” is determined by comparing two best-aligned sequences over a comparison window of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may contain 20% or less, typically 5% to 15%, or 10% to 12% of additions or deletions (i.e., vacancies) compared to a reference sequence (excluding additions or deletions) used to align the two sequences. The percentage is calculated by determining the number of positions where the same nucleic acid base or amino acid residue appears in the two sequences to generate a number of matching positions, dividing the number of matching positions by the total number of positions in the reference sequence (i.e., the window size), and multiplying the result by 100 to generate the sequence identity percentage.
[0072] "Homology" refers to the percentage of residues in a polynucleotide or polypeptide sequence variant that are identical to those in a non-variant sequence after sequence alignment and the introduction of vacancies (if necessary) to achieve the maximum percentage of homology.
[0073] "Binding affinity" may refer to the binding dissociation constant (Kd) or the apparent affinity (e.g., EC50) value. Figure Description
[0074] Figure 1 shows the number of screened subjects from the Zurich Primary HIV Infection Cohort Study whose genotypes predicted sensitivity to GS-9722 (epavirinzab). Plasma samples from 92 individuals prior to ART instruction manual page 15 / 81 21 CN 122005785 A were analyzed in the GenoSure HIV envelope RNA assay. "None" indicates that no specific amino acid was selected in the HIV envelope gene in all screened individuals. Amino acid positions indicated for each category.
[0075] Figure 2 shows the number of subjects from the Zurich Primary HIV Infection Cohort Study who were screened for clade B, and their genotype predictions for GS-9722. Plasma samples from 59 clade B infected individuals were analyzed in the GenoSure HIV envelope RNA assay before ART. “None” indicates that no specific amino acid was selected in the HIV envelope gene in all screened individuals. Amino acid positions indicated for each category.
[0076] Figure 3 shows the susceptibility of swarm virus from pre-ART plasma samples from the Zurich Primary HIV Infection Cohort Study to GS-9722. Viruses from 29 samples with a positive predictive value of 80.7% or higher were analyzed in the PHENOSENSE® HIV Entry Assay (Monogram Biosciences). Amino acid positions indicated for each category.
[0077] Figure 4 shows the susceptibility of subclones of swarm virus from pre-ART plasma samples from the Zurich Primary HIV Infection Cohort Study to GS-9722. Twenty individual viruses from four pre-ART plasma samples were analyzed in the PHENOSENSE® HIV Entry Assay (Monogram Biosciences), where susceptibility to the ensemble virus was predicted by genotyping and susceptibility was tested by phenotyping. The solid line represents the IC50 of the ensemble virus. Detailed Description
[0078] 1. Introduction The method of the present invention is based in part on the unexpected discovery of a population of HIV-infected patients who responded to administration of an anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment, and who did not receive additional anti-HIV antibodies co-administered against other HIV antigens (e.g., gp41) or non-overlapping epitopes of the same HIV antigen (e.g., gp120 in the CD4 binding site region or V2 apex region). These patients were infected with a species of HIV containing the gp120 protein, which is bound by a V3 glycan-directed antibody or its antigen-binding fragment.
[0079] Typically, these methods require identification of human subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: glycosylated asparagine (N332 glycan) at position 332, aspartic acid (D325) at position 325, and one or more amino acid residues selected from: threonine (T63) at position 63, leucine (L179) at position 179, threonine (T320) at position 320, and histidine (H330) at position 330, wherein the amino acid positions are referenced in SEQ ID NO: 4.(i.e., residues 1-511 of NCBI reference sequence number NP_057856.1). In various embodiments, the glycan is oligomannose.
[0080] 2. Identification of subjects who respond to treatment with an antibody directed against HIV gp120 V3 glycan or an antigen-binding fragment thereof.
[0081] In some embodiments, the patient is identified by receiving a report of the HIV species of an infected patient that identifies HIV gp120 amino acid residues present at a specified amino acid position of interest, for example, positions 332 and 325, and one or more amino acid positions selected from the following amino acid positions: 63, 179, 320, and 330, wherein the amino acid positions refer to SEQ ID NO: 4. In some embodiments, the patient is identified by performing one or more assays (e.g., polynucleotide or peptide sequencing) to determine the amino acid sequence of gp120 or amino acid residues present at a specified amino acid position of interest in the gp120 protein of the HIV species of an infected patient. Identification of the full-length or partial sequence of the gp120 protein obtained from the subject can be determined at the polynucleotide or peptide level. In some embodiments, amino acids present at the sites of gp120 residues of interest are determined at the peptide level.
[0082] In various embodiments, these methods require identification of subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, and T63, wherein the amino acid positions refer to SEQ ID NO: 4.
[0083] In various embodiments, these methods require identification of subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, and L179, wherein the amino acid positions refer to SEQ ID NO: 4.
[0084] In various embodiments, these methods require identification of subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, and T320, wherein the amino acid positions refer to SEQ ID NO: 4.
[0085] In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4.
[0086] In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, T63, and L179, wherein the amino acid positions are referenced in SEQ ID NO: 4.
[0087] In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, T63, and T320, wherein the amino acid positions are referenced in SEQ ID NO: 4.
[0088] In some embodiments, the subject is infected with HIV clade B virus. In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, T63, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4. In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, T63, L179, T320, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4.
[0089] In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, T320, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4.
[0090] In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, L179, T320, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4. In some embodiments, the subject is infected with HIV clade A and / or HIV clade C virus. In some embodiments, the subject is infected with HIV clade A, clade B, and / or HIV clade C virus.
[0091] In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, T63, L179, and T320, wherein the amino acid positions are referenced in SEQ ID NO: 4.
[0092] In various embodiments, these methods require identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: N332 glycan, D325, T63, L179, and H330, wherein the amino acid positions are referenced in SEQ ID NO: 4.
[0093] In some embodiments, the subject is infected with HIV or an HIV population expressing gp120 that also contains one or more of the following amino acid residues: a glycan at amino acid residue 301 (glycan 301); a lysine at amino acid residue 677 (K677); amino acid residues other than tryptophan (Trp, W) (e.g., alanine (Ala, A); cysteine (Cys, C); acetaminophen (Cys ...Aspartic acid or aspartic acid (Asp, D); glutamic acid or glutamic acid (Glu, E); phenylalanine (Phe, F); glycine (Gly, g); histidine (His, H); isoleucine (Ile, I); lysine (Lys, K); leucine (Leu, L); methionine (Met, M); asparagine (Asn, N); proline (Pro, P); glutamine (Gln, Q); arginine (Arg, R); serine (Ser, S); threonine (Thr, T); valine (Val, V) or tyrosine (Tyr, Y) at position 17 (not_W17); amino acid residues other than arginine at position 747 (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y) (not_R747); Specification 17 / 81 pages 23 CN 122005785 A insertion_321.01 (e.g., any amino acid insertion between positions G321 and K322 (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y)); glutamic acid at position 429 (E429); glutamine at position 442 (Q442); arginine at position 335 (R335); isoleucine at position 165 (I165); serine at position 393 (S393); isoleucine at position 307 (I307); polysaccharide at position 295 (295 polysaccharide); and / or asparagine at position 300 (N300), wherein the amino acid positions refer to SEQ ID NO: 4.
[0094] gp120 The envelope glycoprotein gp120 (or gp120) is a 120 kDa glycoprotein that is part of the HIV outer layer. It exists as a viral membrane spike and consists of three linked gp120 molecules, anchored to the membrane by the gp41 protein. Gp120 is essential for viral infection because it facilitates HIV entry into host cells through its interaction with cell surface receptors. These receptors include DC-SIGN, heparan sulfate proteoglycan, and the CD4 receptor. Binding to CD4 on helper T cells initiates a cascade of conformational changes in gp120 and gp41, which leads to viral fusion with the host cell membrane.
[0095] Gp120 is encoded by the HIVenv gene. The env gene encodes a gene product of approximately 850 amino acids. The main env product is protein gp160, which is cleaved in the endoplasmic reticulum by the cellular protease furin protease into gp120 (approximately 480 amino acids) and gp41 (approximately 345 amino acids).
[0096] The V3 glycan site on gp120 is partly formed by a portion of the CCR5 co-receptor site and partly by the peritoneum.The formation of dummy glycans (so-called “high-mannose patches”) around the site (Sok et al., Immunity, 2016, Vol. 45, pp. 31–45). Broadly neutralizing antibodies (bnAbs) at the V3 glycan site are the most common of all antibodies found in HIV infection (Walker et al., PLoS Pathog., 2010, Vol. 6, p. e1001028, 2010; Landais et al., PLoS Pathog., 2016, Vol. 12, p. e1005369; Georgiev et al., Science, 2013, Vol. 340, pp. 751–756). The shared sequence of the V3 region of gp120 (Milich et al., J Virol., Vol. 67, No. 9, pp. 5623-5634, 1993) is provided as follows: CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC (SEQ ID NO: 1).
[0097] The amino acid sequence of the exemplary gp160 peptide of the HIV clone WITO is provided below (V3 hypervariable loop is bolded, and potential N-linked glycosylation sites at N332 are bolded and underlined): MKVMGTKKNYQHLWRWGIMLLGMLMMSSAAEQLWVTVYYGVPVWREANTTLFCASDAKAYDTEVHNVW ATHACVPTDPNPQEVVMGNVTEDFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNVTISSTNGSTAN VTMREEMKNCSFNTTTVIRDKIQKEYALFYKLDIVPIEGKNTNTSYRLINCNTSVITQACPKVSFEPIPIHYCAPA GFAILKCNNKTFNGKGPCRNVSTVQCTHGIKPVVSTQLLLNGSLAEEDIIIRSENFTNNGKNIIVQLKEPVKINCT RPGNNTRRSINIGPGRAFYATGAIIGDIRKAHCNISTEQWNNTLTQIVDKLREQFGNKTIIFNQSSGGDPEVVMHT FNCGGEFFYCNSTQLFNSTWFNNGTSTWNSTADNITLPCRIKQVINMWQEVGKAMYAPPIRGQIDCSSNITGLILT RDGGSNSSQNETFRPGGGNMKDNWRSELYKYKVVKIEPLGIAPTRAKRRVVQREKRAVTLGAVFLGFLGAAGSTMGAASLTLTVQARLLLSGIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQARVLAIERYLKDQQLLGIWGCSGKLICTTT VPWNTSWSNKSYDYIWNNMTWMQWEREIDNYTGFIYTLIEESQNQQEKNELELLELDKWASLWNWFNITNWLWYIK LFIMIIGGLVGLRIVCAVLSIVNRVRQGYSPLSFQTRLPNPRGPDRPEETEGEGGERDRDRSARLVNGLFLAIIWDD LRSLCLFSYHRLRDLLLIVARVVEILGRRGWEILKYWWNLLKYWSQELKNSAVSLLNVTAIAVAEGTDRVIEIVQR AVRAILHIPTRIRQGFERALL (SEQ ID NO: 2) The amino acid sequence of an exemplary gp160 peptide of an HIV clone identified in NCBI reference sequence number NP_057856.1 is provided below (V3 hypervariable ring is bolded, and potential N-linked glycosylation sites at N332 are bolded and underlined): MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNV (Instructions 18 / 81 pages 24 CN 122005785 A WATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSS GRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAP) AGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINC TRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIV THSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSN ITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSG KLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT NWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGS LALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDR VIEVVQGACRAIRHIPRRIRQGLERILL (SEQ ID NO: 3) Amino acid sequence of an exemplary gp120 peptide of HXB2B subtype HIV-1 isolate (GenBank accession number K0345; Residues 1-511 corresponding to NCBI reference sequence number NP_057856.1- are provided as follows (V3 hypervariable loop is bolded, and potential N-linked glycosylation sites of N332 are bolded and underlined; signal peptide is underlined): MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNV WATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSS GRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAP AGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINC TRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIV THSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR (SEQ ID NO: 4) The amino acid sequence of an exemplary gp120 polypeptide is provided below: AEQLWVTVYYGVPVWREANTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVMGNVTEDFNMWKN NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNVTISSTNGSTANVTMREEMKNCSFNTTTVIRDKIQKEYALF YKLDIVPIEGKNTNTSYRLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGKGPCRNVSTVQCTHG IKPVVSTQLLLNGSLAEEDIIIRSENFTNNGKNIIVQLKEPVKINCTRPGNNTRRSINIGPGRAFYATGAIIGDIR KAHCNISTEQWNNTLTQIVDKLREQFGNKTIIFNQSSGGDPEVVMHTFNCGGEFFYCNSTQLFNSTWFNNGTSTWN STADNITLPCRIKQVINMWQEVGKAMYAPPIRGQIDCSSNITGLILTRDGGSNSSQNETFRPGGGNMKDNWRSELY KYKVVKIEPLGIAPTRAKRRVVQREKR (SEQ ID NO: 5).
[0098] The amino acid sequence of another exemplary gp120 polypeptide (see, bioafrica.net / proteomics / ENV‑ GP120prot.html) is provided below: TEKLWVTVYY GVPVWKEATT TLFCASDAKA YDTEVHNVWA THACVPTDPN PQEVVLVNVT ENFNMWKNDM VEQMHEDIIS LWDQSLKPCV KLTPLCVSLK CTDLKNDTNT NSSSGRMIME KGEIKNCSFN ISTSIRGKVQ KEYAFFYKLD IIPIDNDTTS YKLTSCNTSV ITQACPKVSF EPIPIHYCAP AGFAILKCNN KTFNGTGPCT NVSTVQCTHG IRPVVSTQLL LNGSLAEEEV VIRSVNFTDN AKTIIVQLNT SVEINCTRPN NNTRKRIRIQRGPGRAFVTI GKIGNMRQAH CNISRAKWNN TLKQIASKLR EQFGNNKTII FKQSSGGDPE IVTHSFNCGG EFFYCNSTQL FNSTWFNSTW STEGSNNTEG SDTITLPCRI KQIINMWQKV GKAMYAPPIS GQIRCSSNIT GLLLTRDGGN SNNESEIFRP GGGDMRDNWR SELYKYKVVK IEPLGVAPTK AKRRVVQREK R (SEQ ID NO: 6) Instructions for Use 19 / 81 pages 25 CN 122005785 A Genomic diversity among independent human immunodeficiency virus type 1 (HIV-1) isolates, and to a lesser degree among consecutive isolates from the same patient, and even in isolates from a single patient, is a well-known characteristic of HIV-1. Although this sequence heterogeneity is distributed throughout the genome, most of the heterogeneity is located in the env gene. Comparison of predicted amino acid sequences from several different isolates has shown that sequence heterogeneity clusters in five variable regions (designated V1 to V5) of the surface glycoprotein gp120. Region V3, though only 35 amino acids long, exhibits considerable sequence variability. Interestingly, despite this variability, region V3 contains determinants mediating interactions with CD4+ cells. Increased gp120 variability leads to higher levels of viral replication, suggesting increased viral fitness in individuals infected with different HIV-1 variants. Variability in potential N-linked glycosylation sites (PNGS) also contributes to increased viral fitness. PNGS allows long-chain carbohydrates to bind to highly variable regions of gp120. Therefore, the number of PNGS in the env can influence viral fitness by providing more or less sensitivity to neutralizing antibodies.
[0099] The HIV gp120 amino acid residues of interest in the biosamples are determined by HIV present or suspected to be present in biosamples from subjects. Biosamples may be derived from solid tissues or biological fluids from subjects known or suspected to contain HIV. In various implementations, the biological sample comprises or is derived from blood, peripheral blood mononuclear cells (PBMCs), serum, plasma, semen, or lymph nodes. In some implementations, the biological sample comprises or is derived from bile, blood, plasma, serum, breast milk, feces, pus, saliva, sebum, semen, sweat, tears, urine, or vomit. In patients, for example, whose viral levels are suppressed by antiretroviral (ART) therapy, the biological sample comprises solid tissue or biofluids of subjects known or suspected of having an HIV reservoir, such as solid tissue and / or biofluids containing potentially HIV-infected CD4+ T cells (including memory and non-memory effector CD4+ T cells).Hematopoietic progenitor cells, including CD4+ T cells, γδT cells (including memory and non-memory effector γδT cells), natural killer (NK) cells, bone marrow cells (including monocytes and macrophages), and follicular dendritic cells, are present in the body. Anatomical reservoirs that can carry potentially HIV-infected cells include lymphoid tissues, the brain and central nervous system, the gastrointestinal tract and gut-associated lymphoid tissue (GALT), the reproductive tract, the lungs, and the skin. Tissues and cells found to contain potentially HIV-infected cells and HIV reservoirs are described, for example, in Kuo et al., Curr Opin HIV AIDS., 2018, Vol. 13, No. 2, pp. 137-142; Mzingwane et al., Rev Med Virol., March 2017, Vol. 27, No. 2, doi: 10.1002 / rmv, 1924, (PMID 28128885); Churchill et al., Nat Rev Microbiol., 2016, Vol. 14, No. 1, pp. 55-60; Barton et al., Trends Microbiol., 2016, Vol. 24, No. 5, pp. 345-355, and these references are therefore incorporated herein by reference in their entirety for all purposes.
[0100] In some embodiments, multiple biological samples from a single patient are evaluated. For example, in some embodiments, two or more biological samples from two or more different tissues or two or more different anatomical repositories from a single patient are evaluated.
[0101] Infection Stage In various embodiments, the human individual is an adult, adolescent, or infant. The subject may be symptomatic (e.g., viremia) or asymptomatic (e.g., acute infection or ART suppression). In some embodiments, the human subject has an acute infection or has recently been infected with HIV. In some embodiments, the subject has not undergone seroconversion. In some embodiments, the human subject has a chronic HIV infection. The subject may be receiving or may not be receiving an antiretroviral therapy (ART) regimen.
[0102] Patients may be classified into Fiebig stages I through VI, which is based on a successive gain of positive HIV-1 clinical diagnostic assays (viral RNA measured by PCR, and p24 and p31 viral antigens measured by enzyme-linked immunosorbent assay (ELISA)). The P24 antigen is a core viral protein that appears transiently in the bloodstream during the rising phase, once HIV-1 RNA levels rise above 10,000 copies / mL and before detectable HIV antibodies are produced. In Fiebig Phase I, during the rising phase... (See page 20 / 81 of CN 122005785 A for more information on viral antigens).During toxemia, only HIV-1 RNA is detectable in the blood. Fiebig stage II begins approximately 7 days later, at which point the p24 antigen test is positive. In Fiebig stage III, approximately 5 days after a positive p24 antigen test, IgM anti-HIV-1 antibodies can be detected using a sufficiently sensitive enzyme immunoassay (EIA) (e.g., third-generation EIA). Stage III typically occurs 1 to 2 weeks after the onset of acute retroviral symptoms. Fiebig stage IV represents the development of an indeterminate Western blot test and occurs approximately 3 days after a positive EIA test. The transition to a clearly positive Western blot test, Fiebig stage V, typically occurs 7 days after the initial infection or approximately 1 month later. The Fiebig stage of HIV infection is described, for example, by Fiebig et al., AIDS, 2003, Vol. 17, No. 13, pp. 1871–1879; Cohen et al., J Infect Dis., 2010, Vol. 202, Supplement 2, pp. 270–277; and McMichael et al., Nature Reviews Immunology, 2010, Vol. 10, pp. 11–23, and these references are incorporated herein by reference in their entirety for all purposes. In some embodiments, the biological samples being evaluated are from subjects with HIV infection at Fiebig stage IV or earlier, such as Fiebig stage I, Fiebig stage II, Fiebig stage III, or Fiebig stage IV. In some embodiments, the biological samples being evaluated are from subjects with HIV infection at Fiebig stage V or Fiebig stage VI.
[0103] In some embodiments, these methods further include the step of obtaining biological samples from the subject. In some embodiments, these methods require receiving a report of HIV gp120 amino acid residues present at a designated location of interest, such as 332 and 325, and one or more amino acid positions selected from 63, 179, 320, and 330, wherein the amino acid positions refer to SEQ ID NO: 4.
[0104] Identifying the gp120 amino acid of interest can be done at the polynucleotide or peptide level by identifying amino acid residues of the subject's HIV gp120 sequence at a designated location of interest (e.g., 332 and 325, and one or more amino acid positions selected from 63, 179, 320, and 330), wherein the amino acid positions refer to SEQ ID NO: 4. At the polynucleotide level, HIV RNA or proviral DNA isolated from one or more biological samples can be sequenced using methods known in the art. In some embodiments, HIV RNA or proviral DNA isolated from two or more biological samples of the subject is sequenced.RNA or proviral DNA is sequenced. In some embodiments, the two or more biological samples are obtained from different tissue sources (e.g., blood, peripheral blood mononuclear cells, lymph nodes, and / or semen). In some embodiments, the two or more biological samples are obtained at different time points, e.g., at intervals of 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks, or at intervals of 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.
[0105] Depending on the circumstances, primers that anneal and amplify the HIVenv coding sequence, especially the V3 variable region of gp120, may be used. In some embodiments, nested primer sets may be used. In various embodiments, the RNA is directly sequenced or can be subjected to reverse transcriptase polymerase chain reaction (RT-PCR). In some implementations, Sanger sequencing may be performed, for example, when sequencing is used to determine amino acid residues in the V3 region, or when sequencing samples from patients in the early stages of the disease (e.g., prior to Fiebig stage III, such as Fiebig stage I or II). In various implementations, single-genome amplification (SGA) and sequencing are performed. Methods for single-genome amplification (SGA) and sequencing of plasma HIV viral somatic RNA are described, for example, in Salazar-Gonzalez et al., 2008, J Virol, Vol. 82, pp. 3952–3970; and Keele et al., Proc Natl Acad Sci USA., 2008, Vol. 105, No. 21, pp. 7552–7557. SGA is used to determine amino acid sequence changes in the HIV gp120 sequence and its application in the methods described herein is described, for example, in Bar et al., N Engl J Med., 2016, Vol. 375, No. 21, pp. 2037-2050; and Mendoza et al., Nature, 2018, Vol. 561, No. 7724, pp. 479-484. In various embodiments, high-throughput next-generation sequencing (NGS), massively parallel, or deep sequencing technologies are used to sequence gp120 (including at least the V3 variable region) of a population of HIV species from one or more biological samples from a single patient or subject. In such cases, multiple nucleic acid sequences encoding at least the V3 variable region of gp120 are sequenced and aligned. In some embodiments, the full length of gp120 is sequenced. Exemplary platforms for NGS sequencing that can be used to determine the gp120 sequence of HIV species in one or more biological samples from a patient include Illumina (Solexa) (illumina.com), Ion...Torrents include Proton / PGM sequencing (thermofisher.com), SOLiD (thermofisher.com), and Single Molecule and Real-Time (SMRT) sequencing (Pacific Biosciences, pacb.com). Methods for isolating and sequencing HIV gp120 (including at least the V3 glycan region) from patients and applicable to the methods of this invention are described, for example, in Shioda et al., J Virol., 1997, Vol. 71, No. 7, pp. 4871-4881; Colón et al., J Virol Antivir Res., 2015, Vol. 4, No. 3, pii: 143 (PMID: 27358904); Kafando et al., PLoS One., 2017, Vol. 12, No. 12, p. e0189999; Hebberecht et al., PLoS One., 2018, Vol. 13, No. 4, p. e0195679; Andrews et al., Sci Rep., 2018, Vol. 8, No. 1, p. 5743; and Landais et al., Immunity , 2017, Vol. 47, No. 5, pp. 990-1003. Depending on the circumstances, shorter reads of nucleic acid sequences (“contigs”) may be assembled into longer sequences, including at least the V3 variable region of gp120. Methods for assembling contigs of HIV genome sequences applicable to the methods of this invention are described, for example, Huang et al., Bioinformation, 2018, Vol. 14, No. 8, pp. 449-454; Hiener et al., J Vis Exp., October 16, 2018, Vol. 140, doi: 10.3791 / 58016; and Wymant et al., Virus Evol., May 18, 2018, Vol. 4, No. 1, vey007, doi: 10.1093 / ve / vey007.
[0106] In some embodiments, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the V3 variable region of the sequencing of gp120 from one or more biological samples of a single patient comprises an amino acid sequence comprising: glycosylated asparagine (N332 glycan) at position 332, aspartic acid (D325) at position 325, and threonine (T63) at position 63, and threonine (T63) at position 63, and threonine (D ...The amino acid residues are leucine at position 179 (L179), threonine at position 320 (T320), and histidine at position 330 (H330), with reference to SEQ ID NO: 4. As used herein, when the position of any given polymer component (e.g., amino acid, nucleotide, also collectively referred to as “residue”) is specified by reference to the same or equivalent position in the selected amino acid or nucleic acid polymer (e.g., based on best alignment or common sequence), rather than by the actual numerical position of the component in the given polymer, the number of the given amino acid polymer or nucleic acid polymer “corresponds to,” “is associated with,” or “is relative to” the number of the selected or referenced amino acid polymer or nucleic acid polymer. In some embodiments, the HIV gp120 variant is detected at a frequency level of approximately 1% of the viral population (e.g., 1% mutation or variant frequency). In some embodiments, the HIV gp120 variant is detected at a frequency level of approximately 0.5% of the viral population. Based on experience, reliable detection of variants at a frequency of 1% would require an HIV RNA level of at least 1000 copies / mL. See, for example, Casadellà et al., Virus Research, Vol. 239, 2017, pp. 69–81; Noguera-Julian et al., J Infect Dis., 2017, Vol. 216, Supplement 9, pp. 829–833; and Lee et al., Sci Rep., 2020, Vol. 10, No. 1, p. 1634.
[0107] 3. Administration of anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment thereof In some embodiments, these methods require administration of an anti-HIV antibody or antigen-binding fragment thereof or antigen-binding molecule targeting the V3 glycan-binding region of gp120.
[0108] HIV-1 is the dominant family of HIV and accounts for 95% of all infections worldwide. HIV-2 is mainly found in a few West African countries.
[0109] HIV viruses are divided into specific groups, M, N, O, and P, with M being the "major" group and responsible for the majority of HIV / AIDS cases globally. Based on their genetic sequences, group M is further subdivided into subtypes with prevalence in different geographic locations (also known as clades, see page 22 / 81, CN 122005785 A).
[0110] A group M "subtype" or "clade" is a subtype of HIV-1 group M defined by gene sequence data. Examples of group M subtypes include subtypes A-K. Some subtypes are known to be more virulent or resistant to different drugs. There are also "circular recombination forms," or CRFs derived from recombination between viruses of different subtypes, each with a unique identifier. For example, CRF12_BFThis is a recombination between subtypes B and F. Subtype A is common in West Africa. Subtype B is the dominant form in Europe, the Americas, Japan, Thailand, and Australia. Subtype C is the dominant form in parts of South Africa, East Africa, India, Nepal, and China. Subtype D is generally found only in East and Central Africa. Subtype E has never been identified as a non-recombinant, only recombinating with subtype A to form CRF01_AE. Subtype F is present in Central Africa, South America, and Eastern Europe. Subtype G (and CRF02_AG) has been found in Africa and Central Europe. Subtype H is limited to Central Africa. Subtype I was originally used to describe the strain now considered to be CRF04_cpx, where cpx is used for “complex” recombination of several subtypes. Subtype J is mainly present in North, Central, and West Africa, while Caribbean subtype K is limited to the Democratic Republic of Congo and Cameroon. These subtypes are sometimes further divided into subtypes, such as A1 and A2 or F1 and F2. In 2015, strain CRF19 was found to be a recombinant of subtypes A, D, and G, with its subtype D protease being closely associated with the rapid development of AIDS in Cuba.
[0111] This disclosure particularly provides a method for administering human anti-HIV neutralizing antibodies (e.g., broadly neutralizing antibodies) that target the V3 glycan region of the gp120 polypeptide on the surface of HIV-infected cells. Neutralizing antibodies against viral envelope proteins provide adaptive immune defense against HIV-1 exposure by blocking infection of susceptible cells. Broad neutralization indicates that the antibody can neutralize HIV-1 isolates from different clades. Therefore, the anti-HIV gp120 V3 glycan-directed antibodies or antigen-binding fragments described herein have cross-clade binding activity.
[0112] Antibodies targeting the V3 glycan region of HIV gp120 and their antigen-binding fragments thereof are administered to a subject in some embodiments of the methods described herein, either as antibodies or antigen-binding fragments thereof, or antigen-binding molecules that bind to the HIV gp120 protein within the V3 glycan region, such as the third variable ring (V3) of gp120 and / or epitopes or regions of high-mannose patches containing N332 oligomannose glycans. In some embodiments, the administered antibody or its antigen-binding fragment or antigen-binding molecule binds to HIV-1 antigens expressed on cell surfaces and eliminates or kills infected cells.
[0113] In some embodiments, the administered antibody or its antigen-binding fragment or antigen-binding molecule is or is derived from human neutralizing antibodies (e.g., monoclonal antibodies) targeting HIV-1. A “neutralizing antibody” is an antibody capable of neutralizing the ability of HIV to initiate and / or maintain infection in host and / or target cells in vitro. This disclosure provides neutralizing monoclonal human antibodies, wherein the antibody recognizes an antigen from HIV, such as the gp120 polypeptide. In some implementations, "neutralizing antibodies" can inhibit the entry of HIV-1 virus, for example, SF162 and / or JR-CSF, where the neutralization index is >1.5 or >2.0 (Kostrikis LG et al., J).Virol., Vol. 70, No. 1, pp. 445-458, 1996.
[0114] In some embodiments, the applied antibody or its antigen-binding fragment or antigen-binding molecule is or is derived from a broadly neutralizing antibody (e.g., a monoclonal antibody) targeting HIV-1. A “broadly neutralizing antibody” means an antibody that neutralizes more than one HIV-1 viral species (from different clades and different strains within clades) in a neutralization assay. Broadly neutralizing antibodies can neutralize at least 2, 3, 4, 5, 6, 7, 8, 9 or more different strains of HIV-1 belonging to the same or different clades. In a particular embodiment, a broadly neutralizing antibody can neutralize multiple HIV-1 species belonging to at least 2, 3, 4, 5 or 6 different clades. In some implementations, the inhibitory concentration of the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment may be less than about 0.0001 µg / ml, less than about 0.001 µg / ml, less than about 0.01 µg / ml, less than about 0.1 µg / ml, less than about 0.5 µg / ml, less than about 1.0 µg / ml, less than about 5 µg / ml, less than about 10 µg / ml, less than about 25 µg / ml, less than about 50 µg / ml, or less than about 100 µg / ml, to neutralize about 50% of the imported virus in the assay. Instructions for Use, Page 23 / 81, 29 CN 122005785 A
[0115] gp120 bound to a third variable ring (V3) and / or a high-mannose patch containing N332 oligomannose and can be used in the methods described herein. Exemplary broadly neutralizing antibodies include, but are not limited to, GS-9722 (epavivir), GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, 10-1074, 10-1074-J, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1, and VRC29.03. gp120 binds to a third variable ring (V3) and / or a high-mannose patch containing N332 oligomannan and can be used in the methods described herein as additional broadly neutralizing antibodies, such as those described in WO.2012 / 030904; WO 2014 / 063059; WO 2016 / 149698; WO 2017 / 106346; WO 2018 / 075564, WO 2018 / 125813; WO 2018 / 237148, WO 2019 / 226829, WO 2020 / 023827, WO2020 / 056145, and Kerwin et al., J Pharm Sci, January 2020, Vol. 109, No. 1, pp. 233-246, all of which are incorporated herein by reference in their entirety for all purposes.
[0116] Exemplary sequences of complementarity-determining regions (CDRs) of antibodies or antigen-binding fragments targeting the HIV gp120 V3 glycan region are provided in Tables A1 to A4. Exemplary sequences of VH and VL of antibodies or antigen-binding fragments targeting the HIV gp120 V3 glycan region are provided in Table B. Instruction manual 24 / 81 pages 30 CN 122005785 A
[0117] Instruction manual 25 / 81 pages 31 CN 122005785 A Instruction manual 26 / 81 pages 32 CN 122005785 A Instruction manual 27 / 81 pages 33 CN 122005785 A Instruction manual 28 / 81 pages 34 CN 122005785 A Instruction manual 29 / 81 pages 35 CN 122005785 A Instruction manual 30 / 81 pages 36 CN 122005785 A Instruction manual 31 / 81 pages 37 CN 122005785 A Instruction manual 32 / 81 pages 38 CN 122005785 A Instruction manual 33 / 81 pages 39 CN 122005785 A Instruction manual 34 / 81 pages 40 CN 122005785 A Specification 35 / 81 Page 41 CN 122005785 A Specification 36 / 81 Page 42 CN 122005785 A Specification 37 / 81 Page 43 CN 122005785 A Specification 38 / 81 Page 44 CN 122005785 A Specification 39 / 81 Page 45 CN 122005785 A Specification 40 / 81 Page 46 CN 122005785 A Specification 41 / 81 Page 47 CN 122005785 A Specification 42 / 81 Page 48 CN 122005785 A Specification 43 / 81 Page 49 CN 122005785 A In some embodiments, anti-HIVThe gp120 V3 glycan-directed antibody or its antigen-binding fragment comprises VH containing VH-CDR1, VH-CDR2, and VH-CDR3; and VL containing VL-CDR1, VL-CDR2, and a second VH-CDR3; wherein VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VH-CDR3 comprise the sequences shown below: SEQ ID NO: 7, 8, 9, 10, 11, and 12; SEQ ID NO: 7, 13, 9, 10, 11, and 12; SEQ ID NO: 14, 15, 16, 17, 11, and 18; SEQ ID NO: 14, 19, 20, 17, 11, and 18; SEQ ID NO: SEQ ID NO: 21, 22, 23, 24, 25 and 26; SEQ ID NO: 21, 22, 27, 24, 25 and 26; SEQ ID NO: 28, 29, 30, 31, 32 and 33; SEQ ID NO: 34, 35, 36, 37, 25 and 38; SEQ ID NO: 39, 40, 41, 42, 43 and 44; SEQ ID NO: 45, 46, 47, 48, 49 and 50; SEQ ID NO: 45, 51, 52, 53, 49 and 54; SEQ ID NO: 55, 56, 57, 58, 59 and 44; SEQ ID NO: 61, 46, 63, 58, 49 and 44; SEQ ID NO: 64, 65, 66, 67, 68 and 69; SEQ ID NO: 70, 71, 72, 73, 74 and 75; SEQ ID NO: 76, 77, 78, 79, 80 and 75; SEQ ID NO: 81, 82, 83, 84, 85 and 75; SEQ ID NO: 85, 86, 87, 88, 89 and 90; SEQ ID NO: 85, 91, 92, 93, 94 and 90; SEQ ID NO: 85, 96, 92, 93, 94 and 90; SEQ ID NO: 85, 86, 87, 97, 98 and 90; SEQ ID NO: 85, 99, 100, 101, 102 and 95; SEQ ID NO: 85, 99, 100, 101, 102 and 103; SEQ ID NO: 85, 99, 100, 104, 102 and 90; SEQ ID NO: 85, 105, 92, 93, 94 and 90; SEQ ID NO: 85, 99, 100, 101, 102 and 107; SEQ ID NO: 108, 109, 110, 111, 112 and 113; SEQ ID NO:108, 114, 115, 111, 116 and 117; or SEQ ID NO: 108, 118, 119, 111, 120 and 121 (according to Kabat's CDR).
[0118] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment comprises a VH containing VH-CDR1, VH-CDR2, and VH-CDR3; and a VL containing VL-CDR1, VL-CDR2, and a second VH-CDR3; wherein VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VH-CDR3 comprise the sequences shown below: SEQ ID NO: 123, 124, 9, 10, 11, and 12; SEQ ID NO: 125, 126, 16, 17, 11, and 18; SEQ ID NO: 127, 128, 20, 17, 11, and 18; SEQ ID NO: 129, 130, 23, 24, 25, and 26; SEQ ID NO: SEQ ID NOs: 129, 130, 27, 24, 25, and 26; SEQ ID NOs: 131, 132, 30, 31, 32, and 33; SEQ ID NOs: 133, 134, 36, 37, 25, and 38; SEQ ID NOs: 135, 136, 41, 42, 43, and 44; SEQ ID NOs: 137, 138, 47, 48, 49, and 50; SEQ ID NOs: 137, 138, 52, 53, 49, and 54; SEQ ID NOs: 139, 56, 57, 58, 59, and 44; SEQ ID NOs: 141, 138, 63, 58, 49, and 44; SEQ ID NOs: 142, 143, 66, 67, 68, and 69; SEQ ID NOs: SEQ ID NO: 144, 145, 72, 73, 74 and 75; SEQ ID NO: 146, 147, 78, 79, 80 and 75; SEQ ID NO: 146, 147, 83, 84, 85 and 75; SEQ ID NO: 149, 150, 87, 88, 89 and 90; SEQ ID NO: 151, 150, 87, 88, 89 and 90; SEQ ID NO: 152, 153, 92, 93, 94 and 90; SEQ ID NO: 151, 150, 87, 97, 98 and 90; SEQ ID NO: 152, 153, 100, 101, 102 and 95; SEQ ID NO: 152, 153, 100, 101, 102 and 103; SEQ ID NO: 152, 153, 100, 104, 102 and 90; SEQ ID NO: 152, 153, 100, 101,102 and 107; SEQ ID NO: 154, 155, 110, 111, 116 and 117; SEQ ID NO: 156, 157, 115, 111, 116 and 117; or SEQ ID NO: 158, 159, 119, 111, 120 and 121 (according to Chothia's CDR).
[0119] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment comprises a VH containing VH-CDR1, VH-CDR2, and VH-CDR3; and a VL containing VL-CDR1, VL-CDR2, and a second VH-CDR3; wherein VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VH-CDR3 comprise the sequences shown below: SEQ ID NO: 160, 161, 162, 163, 164, and 12; SEQ ID NO: 165, 166, 167, 168, 164, and 18; SEQ ID NO: 165, 166, 166, 161, 168, 164, and 18; SEQ ID NO: 169, 170, 171, 168, 164, and 18; SEQ ID NO: SEQ ID NO: 172, 173, 174, 175, 164 and 26; SEQ ID NO: 172, 173, 176, 175, 164 and 26; SEQ ID NO: 177, 178, 179, 180, 164 and 38; SEQ ID NO: 181, 182, 183, 184, 185 and 33; SEQ ID NO: 186, 187, 188, 189, 190 and 44; SEQ ID NO: 191, 192, 193, 194, 195 and 50; SEQ ID NO: 191, 196, 197, 198, 195 and 54; SEQ ID NO: 199, 200, 201, 202, 399 and 44; SEQ ID NO: SEQ ID NOs: 203, 204, 205, 202, 195, and 44; SEQ ID NOs: 206, 207, 208, 209, 210, and 69; 211, 212, 213, 214, 215, and 75; SEQ ID NOs: 216, 217, 218, 219, 220, and 75; SEQ ID NOs: 221, 217, 83, 223, 224, and 75; SEQ ID NOs: 225, 226, 87, 227, 228, and page 45 / 81 of the specification, 51 CN 122005785 A 90; SEQ ID NOs: 229, 226, 87, 227, 228, and 90; SEQ ID NOs:SEQ ID NO: 230, 231, 92, 232, 233 and 90; SEQ ID NO: 230, 234, 92, 232, 233 and 90; SEQ ID NO: 229, 226, 87, 235, 398 and 90; SEQ ID NO: 230, 236, 100, 232, 233 and 95; SEQ ID NO: 230, 236, 100, 232, 233 and 103; SEQ ID NO: 230, 236, 100, 237, 233 and 90; SEQ ID NO: 230, 238, 92, 232, 233 and 107; SEQ ID NO: 239, 240, 110, 241, 242 and 113; SEQ ID NO: 243, 244, 115, 241, 245 and 117; or SEQ ID NO: 243, 246, 119, 241, 247 and 121 (according to the CDR of IMGT).
[0120] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment comprises a VH containing VH-CDR1, VH-CDR2, and VH-CDR3; and a VL containing VL-CDR1, VL-CDR2, and a second VH-CDR3; wherein VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VH-CDR3 comprise the sequences shown below: SEQ ID NO: 248, 249, 250, 251, 252, and 253; SEQ ID NO: 248, 254, 250, 251, 252, and 253; SEQ ID NO: 255, 256, 257, 258, 252, and 259; SEQ ID NO: 260, 261, 262, 258, 252, and 259; SEQ SEQ ID NO: 263, 264, 265, 266, 267 and 268; SEQ ID NO: 263, 264, 397, 266, 267 and 268; SEQ ID NO: 269, 270, 271, 272, 273 and 274; SEQ ID NO: 275, 276, 277, 278, 279 and 280; SEQ ID NO: 281, 282, 283, 284, 285 and 286; SEQ ID NO: 287, 288, 289, 290, 291 and 286; SEQ ID NO: 287, 292, 293, 294, 295 and 296; SEQ ID NO: 297, 298, 299, 300, 301 and 286; SEQ ID NO: 302, 288, 303, 300, 295, and 286; SEQ ID NO:SEQ ID NOs: 304, 305, 306, 307, 308, and 309; SEQ ID NOs: 310, 311, 312, 313, 314, and 315; SEQ ID NOs: 316, 316, 318, 319, 320, and 315; SEQ ID NOs: 321, 322, 323, 324, 325, and 315; 326, 327, 328, 329, 330, and 331; SEQ ID NOs: 332, 327, 328, 329, 330, and 331; SEQ ID NOs: 333, 334, 335, 336, 337, and 338; SEQ ID NOs: 333, 339, 335, 336, 337, and 338; SEQ ID NOs: 332, 327, 328, and 340. SEQ ID NO: 341 and 338; SEQ ID NO: 342, 343, 344, 336, 345 and 346; SEQ ID NO: 342, 343, 344, 336, 347 and 348; SEQ ID NO: 342, 343, 344, 349, 350 and 338; SEQ ID NO: 333, 351, 335, 336, 337 and 338; SEQ ID NO: 342, 343, 344, 336, 347 and 352; SEQ ID NO: 353, 354, 355, 356, 357 and 358; SEQ ID NO: 359, 360, 361, 356, 362 and 363; or SEQ ID NO: 359, 364, 365, 356, 366 and 358. (According to Honegger's CDR).
[0121] Exemplary embodiments of CDR sequences of anti-HIV gp120 V3 glycan-directed antibodies or antigen-binding fragments thereof that can be used in the methods described herein are provided in Tables A1 to A4.
[0122] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment comprises VH and VL, the amino acid sequences comprising which have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the illustrated amino acid sequences respectively selected from the following amino acid sequences: SEQ ID NO: 400 and 401; SEQ ID NO: 402 and 403; SEQ ID NO: 402 and 404; SEQ ID NO: 462 and 463; SEQ ID NO: 464 and 465; SEQ ID NO: 405 and 406; SEQ ID NO: 466 and 467; SEQ ID NO: 407 and 408; SEQ ID NO: 408;SEQ ID NO: 409 and 410; SEQ ID NO: 411 and 412; SEQ ID NO: 413 and 414; SEQ ID NO: 415 and 416; SEQ ID NO: 417 and 418; SEQ ID NO: 419 and 420; SEQ ID NO: 421 and 422; SEQ ID NO: 423 and 424; SEQ ID NO: 425 and 426; SEQ ID NO: 427 and 428; SEQ ID NO: 429 and 430; SEQ ID NO: 431 and 432; SEQ ID NO: 433 and 434; SEQ ID NO: 435 and 436; SEQ ID NO: 437 and 438; SEQ ID NO: 439 and 440; SEQ ID NO: 441 and 442; SEQ ID NO: 443 and 444; SEQ ID NO: SEQ ID NOs: 445 and 446; SEQ ID NOs: 447 and 448; SEQ ID NOs: 449 and 450; SEQ ID NOs: 451 and 452; SEQ ID NOs: 453 and 454; SEQ ID NOs: 455 and 456; SEQ ID NOs: 457 and 458; or SEQ ID NOs: 459 and 460. Illustrative embodiments of the variable domains VH and VL sequences of the anti-HIV gp120 V3 glycan-guided antibody that can be used in the methods described herein are provided in Table B. (Page 46 / 81, 52 CN 122005785 A)
[0123] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody comprises VH and VL amino acid sequences that have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequences shown below, respectively, and contains one or more of the following amino acids at the indicated position (according to the Kabat position number): SEQ ID NO: 400 or 402, which contains one or more of the following amino acids: Ser-Ser-Val (SSV) or Thr- at positions 82a-82c. Gly-Val (TGV), Gln(Q) at position 39, Asn(N) at position 60, His(H) at position 68, Lys(K), His(H), or Thr(T) at position 105, Leu(L) at position 2, Ala(A) at position 32, and / or Ala(A) at position 95; and SEQ ID NO:401, 403 or 404, which contains one or more of the following amino acids: Gly (G) at position 67, Tyr (Y), Phe (F) or Thr (T) at position 67a, Arg (R) at position 67b, Pro (P) at position 67c and / or Lys (K) at position 103. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody comprises VH and VL amino acid sequences having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequences shown below, and containing one or more of the following amino acids at the indicated position (according to the Kabat position number): SEQ ID NO: 400 or 402, which contains Thr-Gly-Val (TGV) at positions 82a-82c, Asn(N) at position 60, His(H) at position 68, Lys(K), His(H), and / or Thr(T) at position 105; and SEQ ID NO: 401, 403, or 404, which contains one or more of the following amino acids: Gly (G) at position 67, Tyr (Y), Phe (F), or Thr (T) at position 67a, Arg (R) at position 67b, and Pro (P) at position 67c.
[0124] Fc mutations that increase serum half-life In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 V3 glycan-directed antibody contains amino acid modifications that promote an increase in the serum half-life of the anti-binding molecule. Mutations that increase antibody half-life have been described. In one embodiment, the Fc region or Fc domain of one or both of the CD3-targeting heavy chain and the HIV antigen-targeting heavy chain contains a methionine-to-tyrosine substitution at position 252 (EU number), a serine-to-threonine substitution at position 254 (EU number), and a threonine-to-glutamic acid substitution at position 256 (EU number). See, for example, U.S. Patent 7,658,921. This type of mutant, named the “YTE mutant,” exhibits a fourfold increase in half-life compared to the wild-type of the same antibody (Dall'Acqua et al., J Biol Chem, Vol. 281, pp. 23514–23524, 2006; Robbie et al., Antimicrobial Agents Chemotherap., Vol. 57, No. 12, pp. 6147–6153, 2013). In some embodiments, the Fc region or Fc domain of one or both of the CD3-targeting heavy chain and the HIV antigen-targeting heavy chain contains IgG constant binding.The IgG constant domain comprises one, two, three, or more amino acid substitutions at positions 251-257, 285-290, 308-314, 385-389, and 428-436 (EU numbers). Alternatively, M428L and N434S (“LS”) substitutions may increase the pharmacokinetic half-life of the multispecific antigen-binding molecule. In other embodiments, the Fc region or Fc domain of one or both of the CD3-targeting heavy chain and the HIV antigen-targeting heavy chain comprises M428L and N434S substitutions (EU numbers). In other embodiments, the Fc region or Fc domain of one or both of the CD3-targeting heavy chain and the HIV antigen-targeting heavy chain comprises T250Q and M428L (EU number) mutants. In other embodiments, the Fc region or Fc domain of one or both of the CD3-targeting heavy chain and the HIV antigen-targeting heavy chain comprises H433K and N434F (EU numbers) mutants.
[0125] Fc mutants that enhance effector activity In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 V3 glycan-directed antibody comprises post-translational and / or amino acid modifications that increase effector activity, such as having improved FcγIIIa binding and increased antibody-dependent cytotoxicity (ADCC). In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 V3 glycan-directed antibody comprises DE modifications (i.e., EU numbers S239D and I332E) in the Fc region. In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 V3 glycan-guided antibody includes DEL modification (i.e., EU designations S239D, I332E, and A330L). In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 V3 glycan-guided antibody includes DEA modification (i.e., EU designations S239D, I332E, and G236A). In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 V3 glycan-guided antibody includes DEAL modification (i.e., EU designations S239D, I332E, G236A, and A330L). See, for example, U.S. Patents 7,317,091; 7,662,925; 8,039,592; 8,093,357; 8,093,359; 8,383,109; 8,388,955; 8,735,545; 8,858,937; 8,937,158; 9,040,041; 9,353,187; 10,184,000; and 10,584,176. Further amino acid modifications that increase effector activity, such as those with improved FcγIIIa binding andIncreased antibody-dependent cytotoxicity (ADCC) includes, but is not limited to, (EU designations) F243L / R292P / Y300L / V305I / P396L; S298A / E333A / K334A; or L234Y / L235Q / G236W / S239M / H268D / D270E / S298A in the first Fc domain and D270E / K326D / A330M / K334E in the second Fc domain. Amino acid mutations that increase C1q binding and complement-dependent cytotoxicity (CDC) include, but are not limited to, (EU designations) S267E / H268F / S324T or K326W / E333S. A review of Fc region mutations that enhance effector activity is available, for example, in Wang et al., Protein Cell, 2018, Vol. 9, No. 1, pp. 63–73; and Saunders, Front Immunol., 2019, Vol. 10, p. 1296.
[0126] In other embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment has a modified glycosylation, which may be introduced, for example, post-translational or by genetic engineering. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment is non-fucosylated, for example, at a glycosylation site present in the antibody or its antigen-binding fragment. Most approved monoclonal antibodies have an IgG1 isotype, in which two N-linked bibranched complex-type oligosaccharides bind to the Fc region. The Fc region exerts effector function of ADCC through its interaction with leukocyte receptors of the FcγR family. Non-fucosylated monoclonal antibodies are monoclonal antibodies engineered such that the oligosaccharides in the Fc region of the antibody do not have any fucosylate units.
[0127] In some embodiments, depending on the circumstances, the Fc region or Fc domain of the anti-HIV gp120 V3 glycan-directed antibody may contain post-translational and / or amino acid modifications to increase serum half-life and enhance effector activity.
[0128] 4. Combination therapy with two or more anti-HIV antibodies In some embodiments, this disclosure provides a method for treating or preventing HIV infection in a human subject who is infected with HIV or at risk of HIV infection. The method includes administering to the human subject a therapeutically effective amount of an anti-HIV 120 V3 glycan-directed antibody or antigen-binding fragment, or a pharmaceutical composition thereof, as disclosed herein, and a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents. In one embodiment, a method is provided for treating an HIV-infected human subject who is infected or at risk of infection, the method comprising administering to the human subject a therapeutically effective amount of one or more antibodies disclosed herein, or pharmaceutically acceptable antibodies thereof.The salt, and a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents.
[0129] Antibody combination therapy In some embodiments, an anti-V3 glycan antibody or its antigen-binding fragment is co-administered with a second anti-HIV antibody. In some embodiments, an anti-V3 glycan antibody or its antigen-binding fragment is co-administered with a second anti-HIV antibody that binds to an epitope or region of gp120 selected from: (i) a second variable loop (V2) and / or an Env trimer apex; (ii) a CD4 binding site (CD4bs); (iii) a gp120 / gp41 interface; or (v) a gp120 silencing surface. The aforementioned epitopes or regions of gp120 that bind to broadly neutralizing antibodies are described, for example, McCoy, Retrovirology, 2018, Vol. 15, pp. 48 / 81, 54 CN 122005785 A, p. 70; Sok and Burton, Nat Immunol, 2018, Vol. 19, No. 11, pp. 1179-1188; Possas et al., Expert Opin Ther Pat, July 2018, Vol. 28, No. 7, pp. 551-560; and Stephenson and Barouch, Curr HIV / AIDS Rep, 2016, Vol. 13, pp. 31-37. All these references are incorporated herein by reference in their entirety for all purposes.
[0130] In some embodiments, the combination therapy requires co-administration of an anti-V3 glycan antibody or its antigen-binding fragment and another broadly neutralizing anti-HIV antibody or bNAb (i.e., a neutralizing antibody that neutralizes multiple HIV-1 viral strains). Various bNAbs are known in the art and can be used as combination therapeutic agents. Other exemplary bNAbs used include antibodies comprising VH and VL that bind to or compete with an epitope or region of gp120 selected from: (i) a second variable loop (V2) and / or the apex of the Env trimer; (ii) a CD4 binding site (CD4bs); (iii) a gp120 / gp41 interface; or (v) a gp120 silencing surface. Exemplary bNAbs for anti-HIV antibody combination therapy include antibodies containing VH and VL that bind to or compete with the following: 2F5, 4E10, M66.6, CAP206-CH12, 10E8, 10E8v4, 10E8-5R-100cF, DH511.11P, 7b2, and LN01 (all of which bind to gp41 MPER); PG9, PG16, and CH01-04 (all of which...All bind to V1V2-glycans), 2G12 (which binds to the outer domain glycan); b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01, VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103, 44-VRC13.01, 1NC9, 12A12, N6, N6LS (VRC-HIVMAB091-00-AB), N49-P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25 (all of which bind to the CD4 binding site).
[0131] In some embodiments, the combination therapy includes an antibody that binds to an epitope or region of gp120 in the second variable ring (V2) and / or the apex of the Env trimer, and competes for or includes the CDR and / or VH and VL regions of an antibody selected from the following: PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CH01, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E, and VRC38.01.
[0132] In some embodiments, the combination therapy includes an antibody that binds to the gp120 epitope or region in a CD4 binding site (CD4bs) and competes for or includes the CDR and / or VH and VL regions of an antibody selected from the following: b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01, VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103, 44- VRC13.01, 1NC9, 12A12, N6, N6LS (VRC-HIVMAB091-00-AB), N49-P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25.
[0133] In some embodiments, the combination therapy includes an antibody that binds to gp120 at the gp120 / gp41 interface.The epitope or region, and competes with or includes the CDR and / or VH and VL regions of antibodies selected from the following: PGT-151, CAP248-2B, 35O22, 8ANC195, ACS202, VRC34, and VRC34.01.
[0134] In some embodiments, the combination therapy includes an antibody that binds to an epitope or region of the gp120 silencing surface, and competes with or includes the second VH and VL regions of antibody VRC-PG05.
[0135] In some embodiments, the combination therapy includes an antibody that binds to an epitope or region of gp41 in the proximal membrane region (MPER) and competes for or includes a second VH and VL region from an antibody selected from: 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01. In some embodiments, the combination therapy includes an antibody that binds to an epitope or region of KLIC (“KLIC” disclosed as SEQ ID NO: 468) (an immutable site of the transmembrane protein gp41) and competes for or includes a second VH and VL region from a clone 3 human monoclonal antibody (Cl3hmAb) (Protheragen). See, for example, Vanini et al., AIDS, 1993, Vol. 7, pp. 49 / 81, 55 CN 122005785 A, No. 2, pp. 167-174.
[0136] In some embodiments, the combination therapy includes an antibody that binds to an epitope or region of the gp41 fusion peptide and competes for or includes a second VH and VL region from antibodies selected from VRC34 and ACS202.
[0137] In some embodiments, the combination therapy includes a multispecific antibody, such as a bispecific or trispecific antibody that binds to an HIV antigen. Examples of HIV bispecific and trispecific antibodies include: MGD014, B12BiTe, BiIA-SG, TMB-bispecific, SAR-441236, VRC-01 / PGDM-1400 / 10E8v4, 10E8.4 / iMab, and 10E8v4 / PGT121-VRC01.
[0138] Prior to administration, bNAb can be improved to possess enhanced drug-like properties, reduced immunogenicity, enhanced ADCC, and suitable pharmacokinetic properties. Such antibodies exhibit binding to HIV envelope glycoproteins expressed on the surface of the virus or infected cells and mediate direct viral neutralization as well as potent NK, monocyte, and PBMC killing of these cells. This property allows...Antibodies treat HIV infection by neutralizing the virus and also kill and eliminate potentially HIV-infected cells in an infected individual, potentially leading to sterilization of HIV.
[0139] In various embodiments, all antibodies administered in combination anti-HIV antibody therapy may have Fc and / or post-translational modifications that increase serum half-life and / or enhance effector activity, as described above.
[0140] In various embodiments, anti-HIV gp120 V3 glycan-directed antibodies or antigen-binding fragments, and optionally combined bNAbs, may be delivered in vivo, for example by administered mRNA or expressed in vivo by engineered B cells. Examples of in vivo delivered bNAbs include AAV8-VRC07; mRNA encoding the anti-HIV antibody VRC01; and engineered B cells encoding 3BNC117 (Hartweger et al., J. Exp. Med., 2019, p. 1301).
[0141] 5. Combination therapy with other anti-HIV therapeutic agents. In some embodiments, a method for treating or preventing HIV infection in a person who is infected or at risk of infection is provided, the method comprising administering to the person a therapeutically effective amount of an anti-HIV 120 V3 glycan-directed antibody or antigen-binding fragment, as disclosed herein, and a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents. In some embodiments, a method for treating HIV infection in a person who is infected or at risk of infection is provided, the method comprising administering to the person a therapeutically effective amount of an anti-HIV 120 V3 glycan-directed antibody or antigen-binding fragment, as disclosed herein, and a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents.
[0142] In one embodiment, pharmaceutical compositions are provided comprising an anti-HIV 120 V3 glycan-directed antibody or antigen-binding fragment, as disclosed herein, and one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent, or excipient.
[0143] In some embodiments, methods for treating HIV infection are provided, comprising administering to a patient in need a therapeutically effective amount of an anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment, as described herein, and a therapeutically effective amount of one or more additional therapeutic agents suitable for treating HIV infection.
[0144] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment is combined with one, two, three, four, or more additional therapeutic agents. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment is combined with one, two, three, four, or more additional therapeutic agents.The antibody or its antigen-binding fragment is combined with two additional therapeutic agents. In other embodiments, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment is combined with three additional therapeutic agents. In another embodiment, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment is combined with four additional therapeutic agents. The one, two, three, four or more additional therapeutic agents may be different therapeutic agents selected from the same class of therapeutic agents (e.g., one or more broadly neutralizing anti-HIV antibodies), and / or they may be selected from different classes of therapeutic agents. Specification 50 / 81 pages 56 CN 122005785 A
[0145] Administration of HIV combination therapy In some embodiments, as described herein, the anti-HIV gp120 V3 glycan-directed antibody or its antigen-binding fragment is co-administered with one or more additional therapeutic agents. Co-administration of the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment disclosed herein with one or more other therapeutic agents generally refers to the simultaneous or sequential administration of the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment disclosed herein with one or more other therapeutic agents, such that a therapeutically effective amount of the disclosed anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment and the one or more other therapeutic agents are present in the patient. When administered sequentially, the combination may be administered in two or more doses.
[0146] Co-administration includes simultaneous administration and administration of a unit dose of the anti-HIV gp120 V3 glycan-guided antibody or its antigen-binding fragment, as described herein, before or after administration of a unit dose of one or more other therapeutic agents. For example, as described herein, the anti-HIV 120 V3 glycan-guided antibody or its antigen-binding fragment may be administered within seconds, minutes, hours, or days after administration of the one or more other therapeutic agents. In some embodiments, a single dose of the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment disclosed herein is administered first, followed by a single dose of one or more other therapeutic agents administered over seconds, minutes, hours, or days. Alternatively, a single dose of one or more other therapeutic agents is administered first, followed by a single dose of the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment disclosed herein over seconds, minutes, hours, or days. In other embodiments, a single dose of the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment disclosed herein is administered first, followed by several hours (e.g., 1 hour–12 hours, 1 hour–24 hours, 1 hour–36 hours, 1 hour–48 hours, 1 hour–60 hours, 1 hour–72 hours).After a period of several hours (e.g., 1 hour to 12 hours, 1 hour to 24 hours, 1 hour to 36 hours, 1 hour to 48 hours, 1 hour to 60 hours, 1 hour to 72 hours), a unit dose of the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment disclosed herein is administered.
[0147] In some embodiments, the anti-HIV 120 V3 glycan-directed antibody or antigen-binding fragment disclosed herein is combined with one or more other therapeutic agents in a single dosage form for simultaneous administration to a patient, for example as a solid, liquid, or suspension dosage form for oral, intravenous, intramuscular, or subcutaneous administration.
[0148] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment is formulated as a liquid solution or suspension, which may optionally contain one or more other compounds that can be used to treat HIV. In some embodiments, the liquid solution or suspension may contain another active ingredient for treating HIV, such as an HIV protease inhibitor, a non-nucleoside or non-nucleotide inhibitor of HIV reverse transcriptase, a nucleoside or nucleotide inhibitor of HIV reverse transcriptase, an HIV integrase inhibitor, an HIV non-catalytic site (or allosteric) integrase inhibitor, a pharmacokinetic enhancer, and combinations thereof.
[0149] In some embodiments, such liquid solutions or suspensions are suitable for administration once daily, once weekly (i.e., QW), once every two weeks (i.e., every other week, or every two weeks or Q2W), once monthly (i.e., QM), or once every two months (i.e., every month, or every two months or Q2M) or at dosing intervals. In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment is administered once daily, once weekly (i.e., QW), once every two weeks (i.e., once every other week, or once every two weeks or Q2W), once monthly (i.e., QM), once every two months (i.e., once every month, or once every two months or Q2M), once every three months (i.e., Q3M), and once every four months (i.e., Q4M).
[0150] HIV combination therapy In the above embodiments, the additional therapeutic agent may be an anti-HIV agent. HIV protease inhibitors, HIV reverse transcriptase non-nucleoside or non-nucleotide inhibitors, HIV reverse transcriptase nucleoside or nucleotide inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, HIVTat or Rev inhibitors, immunomodulators (e.g., immunostimulants), immunotherapeutic agents, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modulators, gene editing compounds (such as CRISPR / Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALEN), cell therapies (such as chimeric antigen receptor T-cells, CAR-T and engineered T-cell receptors, TCR-T, autologous T-cell therapy), delayed reversal agents, compounds targeting the HIV capsid, immunotherapy, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitors, fatty acid synthase inhibitors, HIV vif gene modulators, Vif Dimerization antagonists, HIV-1 viral infection factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators (e.g., Nef inhibitors), Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain-containing protein 1 modulators, HIV ribonuclease H inhibitors, defensin modulators, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, dendritic ICAM-3 grasping non-integrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, complementary factor H regulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin-dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP-dependent RNA helicase DDX3X inhibitors, reverse transcriptase initiation complex inhibitors, G6PD and NADH oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P-glycoprotein regulators, TAT protein inhibitors, prolyl endopeptidase inhibitors, phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, TNFα ligand inhibitors, IFN antagonists, HIV vaccines, and combinations thereof.
[0151] In some embodiments, the additional therapeutic agent is selected from combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, delayed reversal agents, HIV capsid inhibitors, HIV Tat or Rev inhibitors, immunomodulators (e.g., immunostimulants), immunotherapeutic agents, immune-based therapies, PI3K inhibitors.HIV combination drugs, HIV antibodies and bispecific antibodies and "antibody-like" therapeutic proteins and combinations thereof.
[0152] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one, two, three, four or more additional anti-HIV therapeutic agents. Exemplary combination anti-HIV treatments include, but are not limited to, ATRIPLA® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD® (erteiravir, cobistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA® (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY® (tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA® (tenofovir alafenamide, emtricitabine, cobistat, and erteiravir). BIKTARVY (bicagvir + emtricitabine + tenofovir alafenamide), adefovir; adefovir dipivoxil; cobistat; emtricitabine; tenofovir; tenofovir alafenamide and erteiravir; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate; tenofovir alafenamide; tenofovir alafenamide hemifumarate; TRIUMEQ® (durutexvir, abacavir, and lamivudine); durutexvir, abacavir sulfate, and lamivudine; retigvir; polyethylene glycol-modified retigvir; retigvir and lamivudine; maraviro; tenofovir + emtricitabine + maraviro, entfuvir peptide; ALUVIA® (KALETRA®; lopinavir and ritonavir); COMBIVIR® (Zidovudine and Lamivudine; AZT+3TC); EPZICOM® (LIVEXA®; Abacavir Sulfate and Lamivudine; ABC+3TC); TRIZIVIR® (Abacavir Sulfate, Zidovudine and Lamivudine) Instructions for Use 52 / 81 pages 58 CN 122005785 A Lamivudine; ABC+AZT+3TC); Atazanavir and Cobicista; Atazanavir Sulfate and Cobicista; Atazanavir Sulfate and Ritonavir; Dermiravir; Dermiravir and Cobicista; Dulutegravir and Rilpivirine; Dulutegravir and Rilpivirine Hydrochloride; Dulutegravir, Abacavir and Lamivudine; Lamivudine, Nevirapine and Zidovudine; Rettagvir and Lamivudine; Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate; Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate; Dulutegravir + Lamivudine, Lamivudine + Abacavir + Zidovudine, Lamivudine + Abacavir, LamivudineTenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride, lopinavir + ritonavir, lopinavir + ritonavir + abacavir + lamivudine, lopinavir + ritonavir + zidovudine + lamivudine, tenofovir + lamivudine and tenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride, lopinavir, ritonavir, zidovudine and lamivudine; cabotevir + rilpivirine; elsulfavirine (VM-1500; VM-1500A); rilpivirine; rilpivirine hydrochloride; atazanavir sulfate and cobistat; atazanavir and cobistat; diravir and cobistat; Atazanavir; Atazanavir sulfate; Dulutevir; Ertirapvir; Ritonavir; Atazanavir sulfate and Ritonavir; Dermiravir; Lamivudine; α1-Protein inhibitor; Fosanavir; Fosanavir calcium Efaviraxyl; Efaviraxyl, Lamivudine and Emtricitabine; Etravirine; Nefenavirvir; Nefenavirvir mesylate; Interferon; Didanoxin; Stavudine; Indinavir; Indinavir sulfate; Tenofovir and Lamivudine; Zidovudine; Nevirapine; Saquinavir; Saquinavir mesylate; Aldehyde interleukin; Zacitabine; Tiranavir; Ampravir; Delavudine; Delavudine mesylate; Radha-108 (receptol); lamivudine and tenofovir disoproxil fumarate; efavirenz, lamivudine and tenofovir disoproxil fumarate; phosphine azide; lamivudine, nevirapine and zidovudine; abacavir; and abacavir sulfate.
[0153] Other HIV Medications
[04] Examples of other medications for treating HIV that can be combined with the agents of this disclosure include aspenigrin C, acetylmonazine, arapovir, BanLec, deferiphenone, Gamimune, metronidazole, naltrexone, α1-protease inhibitors, REP 9, RPI-MN, VSSP, H1 viral, SB-728-T, 1,5-dicaffeoylquinic acid, rHIV7-shl-TAR-CCR5RZ, AAV-eCD4-Ig gene therapy, MazF gene therapy, BlockAide, bevirima derivatives, ABX-464, AG-1105, APH-0812, lichenin analogues, BIT-225, CYT-107, CS-TATI-1, fluoro-β-D-arabinonucleotide (FANA)- Modified antisense oligonucleotides, FX-101, Griffonsin, HGTV-43, HPH-116, HS-10234, hydroxychloroquine, IMB-10035, IMO-3100, IND-02, JL-18008, LADAVRU, MK-1376, MK-2048, MK-4250, MK-8507, MK-8558, MK-8591 (Isravir), NOV-205, OB-002H, ODE-Bn-TFV, M1-TFV, PA-1050040 (PA-040), PC-707, PGN-007, QF-036, S-648414, SCY-635, SB-9200, SCB-719, TR-452, TEV-90110, TEV-90112, TEV-90111, TEV-90113, RN-18, DIACC-1010, Fasnall, Immuglo, 2-ClIPS peptide, HRF- 4467, platelet-reactive protein analogs, TBL-1004HI, VG-1177, XL-081, RFHSP-D, [18F]-MC-225, URMC-099-C, RES-529, and VIR-576.
[0154] HIV protease inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with an HIV protease inhibitor. Examples of HIV protease inhibitors include ampravir, atazanavir, brenavir, deriravir, forosanavir, forosanavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, tepranavir, AEBL-2, DG-17, GS-1156, TMB-657 (PPL-100), T-169, BL-008, MK-8122, TMB-607, GRL-02031, and TMC-310911.
[0155] HIV ribonuclease H inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with an HIV ribonuclease H inhibitor. Examples of combinable HIV ribonuclease H inhibitors include NSC-727447. Instructions for Use, Pages 53 / 81, 59, CN 122005785 A
[0156] HIV Nef Inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with an HIV Nef inhibitor. Examples of combinable HIV Nef inhibitors include FP-1.
[0157] HIV Reverse Transcriptase Inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with a non-nucleoside or non-nucleotide inhibitor. Examples of non-nucleoside or non-nucleotide inhibitors of HIV reverse transcriptase include dapirine, delavudine, delavudine mesylate, doravirine, efavirenz, ectrevirine, lentinan, nevirapine,Rilpivirine, ACC-007, ACC-008, AIC-292, F-18, KM-023, PC-1005, VM-1500A-LAI, PF-3450074, elsulfavirine (sustained-release oral, HIV infection), elsulfavirine (long-acting injectable nanosuspension, HIV infection), and elsulfavirine (VM-1500).
[0158] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with an HIV nucleoside or nucleotide inhibitor. Examples of nucleoside or nucleotide inhibitors of HIV reverse transcriptase include: adefovir, adefovir dipivoxil, azivudine, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir octadecyloxyethyl ester (AGX-1009), tenofovir disoproxil fumarate, VIDEX® and VIDEX EC® (didanovine, ddl), abacavir, abacavir sulfate, alovudine, aripalabine, censavudine, didanovine, elvucitabine, festinavir, fosalvudine tidoxil, CMX-157, dapoxetine, doravirine, ectavirine, OCR-5753, tenofovir disoproxil fumarate orotate, fozivudine, lamivudine, zisifenesin, stavudine, zalcitabine, zidovudine, rovafovir etalafenamide (GS-9131), GS-9148, MK-8504, MK-8591, MK-858, VM-2500, and KP-1461.
[0159] HIV integrase inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with an HIV integrase inhibitor. Examples of HIV integrase inhibitors include erteiravir, erteiravir (extended-release microcapsules), curcumin, curcumin derivatives, chicoric acid, chicoric acid derivatives, 3,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid derivatives, ginsenoside tricarboxylic acid, ginsenoside tricarboxylic acid derivatives, caffeic acid phenylethyl ester, caffeic acid phenylethyl ester derivatives, tyrosine phosphorylation inhibitors, tyrosine phosphorylation inhibitor derivatives, quercetin, quercetin derivatives, retegvir, pegylated retegvir, dulutegravir, JTK-351, bicagvir, AVX-15567, cabotevir (long-acting injectable), diketoquinoline-4-1 derivatives, integrase-LEDGF inhibitors, ledgins, M-522, M-532, MK-0536, NSC-310217, and NSC-371056.NSC-48240, NSC-642710, NSC-699171, NSC-699172, NSC-699173, NSC-699174, stilbene disulfonic acid, T-169, STP-0404, VM-3500, and cabotevir.
[0160] In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with an HIV noncatalytic site or allosteric integrase inhibitor (NCINI). Examples of HIV noncatalytic site or allosteric integrase inhibitors (NCINI) include CX-05045, CX-05168, and CX-14442.
[0161] HIV entry inhibitor In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with an HIV entry inhibitor. Examples of HIV entry (fusion) inhibitors include AAR-501, LBT-5001, sinivirol, CCR5 inhibitors, gp41 inhibitors, CD4 attachment inhibitors, gp120 inhibitors, gp160 inhibitors, and CXCR4 inhibitors.
[0162] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a CCR5 inhibitor. Examples of CCR5 inhibitors include apravirone, vevicvirone, maravir, maravir (long specification 54 / 81 pages 60 CN 122005785 A effective injectable nanoemulsion), sinivirone, lelimumab (PRO-140), adaptavir (RAP-101), nifevirone (TD-0232), anti-GP120 / CD4 or CCR5 bispecific antibody, B-07, MB-66, peptide C25P, TD-0680, seravino, and vMIP (Haimipu).
[0163] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a CXCR4 inhibitor. Examples of CXCR4 inhibitors include praxavir, ALT-1188, N15 peptide, and vMIP (Haimipu).
[0164] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a gp41 inhibitor. Examples of gp41 inhibitors include Ebolavir, emfuvirtide, Griffonsin (gp41 / gp120 / gp160 inhibitor), BMS-986197, modified biosimilar of emfuvirtide, emfuvirtide biosimilar, HIV-1 fusion inhibitor, (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, CPT-31, C13hmAb, PIE-12 trimer, and sifvirtide.
[0165] In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with a CD4 attachment inhibitor. Examples of CD4 attachment inhibitors include ipalzumab and CADA analogs. In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with a gp120 inhibitor. Examples of gp120 inhibitors include anti-HIV antimicrobial agents, Radha-108 (receptol) 3B3-PE38, BanLec, bentonite-based nanomedicines, fostemsavir tromethamine, IQP-0831, VVX-004, and BMS-663068.
[0166] In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with a gp160 inhibitor. Examples of combinable gp160 inhibitors include tetrandrine.
[0167] HIV maturation inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with an HIV maturation inhibitor. Examples of HIV maturation inhibitors include BMS-955176, GSK-3640254, and GSK-2838232.
[0168] Delay reversal agents In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with an HIV delay reversal agent. Examples of delayed reversal agents that can be combined with one or more multispecific antigen-binding molecules described herein include IL-15 receptor agonists (e.g., ALT-803; interleukin-15 / Fc fusion proteins (e.g., XmAb24306); recombinant interleukin-15 (e.g., AM0015, NIZ-985); PEGylated IL-15 (e.g., NKTR-255)); Toll-like receptor (TLR) agonists (including TLR7 agonists, such as GS-9620, and TLR8 agonists, such as GS-...). 9688), histone deacetylase (HDAC) inhibitors, proteasome inhibitors such as bortezomib, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, iomycin, IAP antagonists (apoptosis protein inhibitors, such as APG-1387, LBW-242), SMAC mimics (including TL32711, LCL161, GDC-0917, HGS1029, AT-406), Debio-1143, PMA, SAHA (vorinostat or succinyl succinate, oxytocin, and isohydroxamic acid), NIZ-985, IL-15 regulatorsAntibodies against IL-15 (including IL-15, IL-15 fusion proteins, and IL-15 receptor agonists such as ALT-803), JQ1, disulfiram, amphotericin B, and ubiquitin inhibitors such as lagozola analogs, APH-0812, and GSK-343. Examples of HDAC inhibitors include romidasine, vorinostat, and pabisostat. Examples of PKC activators include indolinamide, prostratin, phorbol B, and DAG-lactone.
[0169] In some embodiments, the Toll-like receptor (TLR) agonist described herein is combined with a Toll-like receptor (TLR) agonist, such as a TLR1 agonist (NCBI gene ID: 7096), a TLR2 agonist (NCBI gene ID: 7097), a TLR3 agonist (NCBI gene ID: 7098), a TLR4 agonist (NCBI gene ID: 7099), a TLR5 agonist (NCBI gene ID: 7100), a TLR6 agonist (NCBI gene ID: 10333), a TLR7 agonist (NCBI gene ID: 51284), a TLR8 agonist (NCBI gene ID: 51311), a TLR9 agonist (NCBI gene ID: 54106), and / or a TLR10 agonist. Agonist (NCBI Gene ID: 81793). Exemplary TLR7 agonists that can be co-administered or combined with one or more multispecific antigen-binding molecules described herein include, but are not limited to, AL-034, DSP-0509, GS-9620 (vesamimod), vesamimod analogs, LHC-165, TMX-101 (imiquimod), GSK-2245035, remiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7854, RG-7795, and compounds disclosed in the following patents: US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences). Sciences) and US20090047249 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014 / 056953 (Janssen), WO2014 / 076221 (Janssen), WO2014 / 128189 (Janssen), US20140350031 (Janssen), WO2014 / 023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics) and US20130251673 (Novira Therapeutics). Co-administerable TLR7 / TLR8 agonists are NKTR-262, telratolimod, and BDB-001. Exemplary TLR8 agonists that can be co-administered or combined with one or more multispecific antigen-binding molecules described herein include, but are not limited to, E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, Motomod, Requimod, GS-9688, VTX-1463, VTX-763, 3M-051, 3M-052, and compounds disclosed in the following patents: US20140045849 (Janssen), US20140073642 (Janssen), WO2014 / 056953 (Janssen), WO2014 / 076221 (Janssen), WO2014 / 128189 (Janssen), US20140350031 (Janssen), WO2014 / 023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (VentirxPharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics) and US20130251673 (Novira Therapeutics). Exemplary co-administerable TLR9 agonists include, but are not limited to, AST-008, cototimod, CMP-001, IMO-2055, IMO-2125, linimod, MGN-1601, BB-001, BB-006, IMO-3100, IMO-8400, IR-103, IMO-9200, atortimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, atortimod (MGN-1703), CYT-003, CYT-003-QbG10, tilsotolimod, and PUL-042. Examples of TLR3 agonists include: lintamod, polyICLC, RIBOXXON®, Apoxxim, RIBOXXIM®, IPH-33, MCT-465, MCT-475, and ND-1.1. Examples of TLR4 agonists include: G-100 and GSK-1795091.
[0170] Histone deacetylase (HDAC) inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with an inhibitor of histone deacetylase, such as histone deacetylase 1, histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; gene ID: 9734). Examples of HDAC inhibitors include, but are not limited to, ibexat, ACY-241, AR-42, BEBT-908, belistat, CKD-581, CS-055 (HBI-8000), CT-101, CUDC-907 (phenomenostat), entrinoid, gilvesat, motistat, perbistat, prespicon, quinolone (JNJ-26481585), remixat, linosat, romidesin, SHP-141, TMB-ADC, valproic acid (VAL-001), vorinostat, tinostamustine, remixat, and entrinoid.
[0171] Cyclin-dependent kinase (CDK) inhibitors or antagonists, in some embodiments, include the anti-HIV gp120 described herein.V3 glycan-guided antibody or antigen-binding fragment is combined with a cyclin-dependent kinase (CDK) inhibitor or antagonist, such as cyclin-dependent kinase 4 (CDK4; NCBI gene ID: 1019), cyclin-dependent kinase 6 (CDK6; NCBI gene ID: 1021), or cyclin-dependent kinase 9 (CDK9; NCBI gene ID: 1025). In some embodiments, the CDK4 / CDK6 / CDK9 inhibitor or antagonist is selected from VS2-370.
[0172] Interferon gene stimulator (STING) agonist In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with an interferon gene stimulator (STING). In some embodiments, the STING receptor agonist or activator is selected from ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, AdVCA0848, GSK-532, SYN-STING, MSA-1, SR-8291, 5,6-dimethylxanthone-4-acetic acid (DMXAA), cyclic GAMP (cGAMP), and cyclic diAMP.
[0173] In some embodiments, the RIG-I agonist combines the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein with DExD / H-box helicase 58 (DDX58; also known as RIG-I, RIG1, RIGI, RLR-1, SGMRT2; NCBI gene ID: 23586). In some embodiments, the reagents described herein are combined with RIG-I modulators such as RGT-100 or NOD2 modulators such as SB-9200 (also known as GS 9992; inarigivir) and IR-103. An illustrative RIG-I agonist is KIN1148, described in Hemann et al., J Immunol, May 1, 2016, Vol. 196, Supplement 1, p. 76.1. Other RIG-I agonists are described, for example, in Elion et al., Cancer Res., 2018, Vol. 78, No. 21, pp. 6183-6195; and Liu et al., J Virol., 2016, Vol. 90, No. 20, pp. 9406-9419. RIG-I agonists are commercially available, for example, from Invivogen (invivogen.com).
[0174] LAG-3 and TIM-3 inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with anti-TIM-3 (also known as hepatitis A virus cell receptor 2 antibody (HAVCR2; NCBI gene ID: 84868) such as TSR-022, LY-3321367, MBG-453, INCAGN-2390 are combined. In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with anti-LAG-3 (lymphocyte activation) (NCBI gene ID: 3902) antibodies such as renalalimumab (ONO-4482), LAG-525, MK-4280, REGN-3767, INCAGN2385.
[0175] Capsid inhibitor In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with a capsid inhibitor. Examples of capsid inhibitors that can be combined with the reagents of this disclosure include capsid polymerization inhibitors or capsid interference compounds, HIV nucleocapsid P7 (NCp7) inhibitors such as azodicarbonamide, HIV p24 capsid protein inhibitors, GS-6207, GS-CA1, AVI-621, AVI-101, AVI-201, AVI-301 and the AVI-CAN1-15 series, PF-3450074, and compounds described in International Patent Publication WO2019 / 087016.
[0176] Immunotherapy In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with an immunotherapy. Examples of immunotherapy-based therapies include Toll-like receptor (TLR) modulators such as TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13; programmed cell death protein 1 (PD-1) modulators; programmed death ligand 1 (PD-L1) inhibitors; IL-15 inhibitors (e.g., IL-15 receptor agonists, e.g., ALT-803); interleukin-15 / Fc fusion proteins (e.g., XmAb24306); recombinant interleukin-15 (e.g., ...). AM0015, NIZ-985); PEGylated IL-15 (e.g., NKTR-255); DermaVir; Interleukin-7; Hydroxychloroquine (hydroxychloroquine); Interleukin (aldeleukin, IL-2); Interferon α; Interferon α-2b; Interferon α-n3; PEGylated interferon α; Interferon γ; Hydroxyurea; Mycophenolate mofetil (MPA) and its ester derivatives Mycophenolate mofetil (MMF); Ribavirin; Polyethylene imide (PEI); Gepon; IL-12; WF-10; VGV-1; MOR-22; BMS-936559; CYT-107, NomFulon, pegylated interferon α-2a, pegylated interferon α-2b, RPI-MN, STING modulator, RIG-I modulator, NOD2 modulator, SB-9200, and IR-103.
[0177] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a TLR agonist. Examples of TLR agonists include, but are not limited to, vesamimod (GS-9620), letotimod, tilsotolimod, lintamod, DSP-0509, AL-034, G-100, cototimod, AST-008, mototimod, GSK-1795091, GSK-2245035, VTX-1463, GS-9688, LHC-165, BDB-001, RG-7854, and telratolimod.
[0178] Immune checkpoint receptor protein modulators, in various embodiments, combine the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and / or with one or more stimulators, activators, or agonists of one or more stimulating immune checkpoint proteins or receptors. Blocking or inhibiting inhibitory immune checkpoints can positively modulate T cell or NK cell activation and prevent immune escape by infected cells. Stimulating or activating immune checkpoints can enhance the efficacy of immune checkpoint inhibitors in the treatment of infections. In various embodiments, immune checkpoint proteins or receptors modulate T cell responses (e.g., reviewed in Xu et al., J Exp Clin Cancer Res., 2018, Vol. 37, p. 110). In various implementations, immune checkpoint proteins or receptors regulate NK cell responses (e.g., reviewed in Davis et al., Semin Immunol., 2017, Vol. 31, pp. 64–75, and Chiossone et al., Nat Rev Immunol., 2018, Vol. 18, No. 11, pp. 671–688).
[0179] Examples of immune checkpoint proteins or receptors that can be combined with the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein include, but are not limited to, CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); T cell activation inhibitor 1 containing the V-set domain (VTCN1, B7H4); V-setImmunomodulatory receptors (VSIR, B7H5, VISTA); Immunoglobulin superfamily member 11 (IGSF11, VSIG3); Natural killer cytotoxic receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-association 2 (HHLA2, B7H7); Inducible T cell costimulators (ICOS, CD278); Inducible T cell costimulatory ligands (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, ... TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated protein (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I peptide-associated sequence A (MICA); MHC class I peptide-associated sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death protein 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; fibronectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); Containing PVR-associated immunoglobulin domain (PVRIG, CD112R); T cell immune receptor with Ig and ITIM domains (TIGIT); Containing T cell immunoglobulin and mucin domains 4 (TIMD4; TIM4); Hepatitis A virus cell receptor 2 (HAVCR2, TIMD3, TIM3); Galactagogue 9 (LGALS9); Lymphocyte activation 3 (LAG3, CD223); Signal transduction lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); Lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6,CD352); SLAM family members 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); early retinoic acid transcript 1E (RAET1E; ULBP4); early retinoic acid transcript 1G (RAET1G; ULBP5); Early retinoic acid transcript 1L (RAET1L; ULBP6); Lymphocyte activation 3 (CD223); Cytokine immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail region 1 (KIR, CD158E1); Cytokine lectin-like receptor C1 (KLRC1, NKG2A, CD159A); Cytokine lectin-like receptor K1 (KLRK1, NKG2D, CD314); Cytokine lectin-like receptor C2 (KLRC2, CD159c, NKG2C); Cytokine lectin-like receptor C3 (KLRC3, NKG2E); Cytokine lectin-like receptor C4 (KLRC4, NKG2F); Cytokine immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail region 1 (KIR2DL1); cytotoxic cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); cytotoxic cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); cytotoxic cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); cytotoxic cell lectin-like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7).
[0180] In various embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one or more blockers or inhibitors of one or more T cell-inhibiting immune checkpoint proteins or receptors. Exemplary T-cell inhibitory immune checkpoint proteins or receptors include, but are not limited to, CD274 (CD274, PDL1, PD-L1); programmed cell death protein 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death protein 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); T-cell activation inhibitor 1 containing the V-set domain (VTCN1, B7H4); V-set immunomodulatory receptors (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated protein 1); and other T-cell-associated protein 1 (T-cell-associated protein 2).(BTLA); containing PVR-associated immunoglobulin domains (PVRIG, CD112R); T-cell immune receptors with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG3, CD223); hepatitis A virus cell receptor 2 (HAVCR2, TIMD3, TIM3); galactagogue 9 (LGALS9); cytotoxic cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); cytotoxic cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); cytotoxic cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); cytotoxic cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and cytotoxic cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In various implementations, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one or more agonists or activators of one or more T-cell-stimulated immune checkpoint proteins or receptors. Examples of T cell-stimulated immune checkpoint proteins or receptors include, but are not limited to, CD27, CD70; CD40, CD40LG; inducible T cell costimulators (ICOS, CD278); inducible T cell costimulatory ligands (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; fibronectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4); and poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). See, for example, Xu et al., J Exp Clin Cancer Res., 2018, Vol. 37, p. 110.
[0181] In various embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one or more blockers or inhibitors of one or more NK cell-inhibiting immune checkpoint proteins or receptors. Exemplary NK cell-inhibiting immune checkpoint proteins or receptors include, but are not limited to, cytotoxic cell immunoglobulin-like receptors, three Ig domains and a long cytoplasmic tail 1 (KIR, CD158E1); cytotoxic cell immunoglobulin-like receptors, two Ig domains and a long cytoplasmic tail 1 (KIR, CD158E1);Cytoplasmic tail region 1 (KIR2DL1); cytotoxic cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail region 2 (KIR2DL2); Specification 59 / 81 pages 65 CN 122005785 A Cytotoxic cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail region 3 (KIR2DL3); Cytotoxic cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail region 1 (KIR3DL1); Cytotoxic cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and Cytotoxic cell lectin-like receptor D1 (KLRD1, CD94). In various embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one or more agonists or activators of one or more NK cell-stimulated immune checkpoint proteins or receptors. Exemplary NK cell-stimulated immune checkpoint proteins or receptors include, but are not limited to, CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); cytotoxic cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). See, for example, Davis et al., Semin Immunol., 2017, Vol. 31, pp. 64-75; Fang et al., Semin Immunol., 2017, Vol. 31, pp. 37-54; and Chiossone et al., Nat Rev Immunol., 2018, Vol. 18, No. 11, pp. 671-688.
[0182] In some embodiments, the one or more immune checkpoint inhibitors include protein-based (e.g., antibody or fragment thereof, or antibody mimic) inhibitors of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4. In some implementations, the one or more immune checkpoint inhibitors include small organic molecule inhibitors of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4.
[0183] Examples of co-administerable CTLA4 inhibitors include, but are not limited to, ipilimumab, trimemumab BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, BPI-002, and multispecific inhibitors FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD‑1 / CTLA4), MGD‑019 (PD‑1 / CTLA4), KN‑046 (PD‑1 / CTLA4), MEDI‑5752 (CTLA4 / PD‑1), XmAb‑20717 (PD‑1 / CTLA4) and AK‑104 (CTLA4 / PD‑1).
[0184] Examples of co-administerable PD-L1 (CD274) or PD-1 (PDCD1) inhibitors include, but are not limited to, pembrolizumab, nivolumab, cimetizumab, pildizumab, AMP-224, MEDI0680 (AMP-514), spartazumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI- 754091, AGEN-2034, JS-001 (Toripalimab), JNJ-63723283, Genomeamarab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (Camrelizumab), Sym-021, ABBV-181 (Bug's maize), PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (Dotalimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155), KN-035, IBI-308 (Sintilimab) HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, GS-4224, GS-4416, INCB086550, MAX10181, and multispecific inhibitors FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-013 (PD-1 / LAG-3), FS-118 (LAG-3 / PD-L1), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), RO-7121661 (PD-1 / TIM-3).XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM3 / PDL1), and INBRX-105 (4-1BB / PDL1).
[0185] In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550, and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002.
[0186] In various embodiments, the antibody or antigen-binding fragment as described herein is combined with an anti-TIGIT antibody, such as BMS-986207, RG-6058, or AAGEN-1307.
[0187] TNF Receptor Superfamily (TNFRSF) Member Agonists or Activators Specification 60 / 81 Page 66 CN 122005785 A In various embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one or more agonists of the TNF receptor superfamily (TNFRSF) member, such as TNFRSF1A (NCBI gene ID: 7132), TNFRSF1B (NCBI gene ID: 7133), TNFRSF4 (OX40, CD134; NCBI gene ID: 7293), TNFRSF5 (CD40; NCBI gene ID: 958), TNFRSF6 (FAS, NCBI gene ID: 355), TNFRSF7 (CD27, NCBI gene ID: 939), TNFRSF8 (CD30, NCBI gene ID: 943), TNFRSF9 (4-1BB, CD137, NCBI gene ID: 3604). TNFRSF10A (CD261, DR4, TRAILR1, NCBI gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR2, NCBI gene ID: 8795), TNFRSF10C (CD263, TRAILR3, NCBI gene ID: 8794), TNFRSF10D (CD264, TRAILR4, NCBI gene ID: 8793), TNFRSF11A (CD265, RANK, NCBI gene ID: 8792), TNFRSF11B (NCBI gene ID: 4982), TNFRSF12A (CD266, NCB gene ID: 51330), TNFRSF13B (CD267, NCBI gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR2, NCBI gene ID: 8795), TNFRSF10C (CD263, TRAILR3, ...8794), TNFRSF10D (CD264, TRAILR4, NCBI gene ID: 8793), TNFRSF11A (CD265, RANK, NCBI gene ID: 8792), TNFRSF11B (CD267, NCBI gene ID: 8795), TNFRSF10B (CD266, NA agonist of one or more of the following: TNFRSF13C (CD268, NCBI gene ID: 115650), TNFRSF16 (NGFR, CD271, NCBI gene ID: 4804), TNFRSF17 (BCMA, CD269, NCBI gene ID: 608), TNFRSF18 (GITR, CD357, NCBI gene ID: 8784), TNFRSF19 (NCBI gene ID: 55504), TNFRSF21 (CD358, DR6, NCBI gene ID: 27242), and TNFRSF25 (DR3, NCBI gene ID: 8718).
[0188] Exemplary anti-TNFRSF4 (OX40) antibodies that can be co-administered include, but are not limited to, MEDI6469, MEDI6383, MEDI0562 (taflizizumab), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and antibodies described in the following patents: WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628.
[0189] Exemplary anti-TNFRSF5 (CD40) antibodies that can be co-administered include, but are not limited to, RG7876, SEA-CD40, APX-005M, and ABBV-428.
[0190] In some embodiments, the anti-TNFRSF7 (CD27) antibody varigramab (CDX-1127) is co-administered.
[0191] Exemplary anti-TNFRSF9 (4-1BB, CD137) antibodies that can be co-administered include, but are not limited to, urinumab, utorumab (PF-05082566), AAGEN2373, and ADG-106.
[0192] Exemplary anti-TNFRSF18 (GITR) antibodies that can be co-administered include, but are not limited to, MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and antibodies described in the following patents: WO2017096179, WO2017096276, WO2017096189, and WO2018089628. In some embodiments, an antibody or fragment thereof that co-targets TNFRSF4 (OX40) and TNFRSF18 (GITR) is co-administered. Such antibodies are described, for example, WO2017096179 and WO2018089628.
[0193] Interleukin receptor agonists, in some embodiments, include the anti-HIV gp120 described herein.V3 glycan-guided antibody or antigen-binding fragments combined with interleukin receptor agonists, such as IL-2 antagonists, IL-7 antagonists, IL-15 antagonists, IL-10 antagonists, and IL-12 antagonists; examples of IL-2 receptor antagonists include interleukins (aldeleukin, IL-2); PEGylated IL-2 (e.g., NKTR-214); modified variants of IL-2 (e.g., THOR-707), beempegaldesleukin, AIC-284, ALKS-4230, CUI-101, and Neo-2 / 15; IL-15 receptor antagonists such as ALT-803, NKTR-255 and hetIL-15, interleukin 15 / Fc fusion protein, AM-0015, NIZ-985, SO-C101, IL-15 Synthorin (PEGylated IL-15), and P-22339. And IL-15-PD-1 fusion protein N-809; examples of IL-7 include CYT-107.
[0194] Other interleukin receptor agonists that can be combined with the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein include interferon α; interferon α-2b; interferon α-n3; pegylated interferon α; interferon γ; Flt3 agonists such as CDX-301; gepon; nomfullon, pegylated interferon α-2a, pegylated interferon α-2b, RPI-MN. Specification 61 / 81 pages 67 CN 122005785 A
[0195] Bispecific and trispecific natural killer (NK) cell adaptors, in various embodiments, combine the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein with targets against NK cell activation receptors such as CD16A, C-type lectin receptors (CD94 / NKG2C, NKG2D, NKG2E / H and NKG2F), native cytotoxic receptors (NKp30, NKp44 and NKp46), cytotoxic cell C-type lectin-like receptors (NKp65, NKp80), Fc receptor FcγR (which mediates antibody-dependent cell cytotoxicity), SLAM family receptors (e.g. 2B4, SLAM6 and SLAM7), cytotoxic cell immunoglobulin-like receptors (KIR) (KIR-2DS and KIR-3DS), DNAM-1 and CD137 (4-1BB) Bispecific NK cell adaptor (BiKE) or trispecific NK cell adaptor (TriKE) (e.g., without Fc) or bispecific antibody (e.g., with Fc) binds. Exemplary anti-CD16 bispecific antibody, BiKE, or... can be co-administered.TriKEs include AFM26 (BCMA / CD16A) and AFM-13 (CD16 / CD30). Depending on the situation, anti-CD16 binding bispecific molecules may or may not have an Fc. BiKEs and TriKEs are described, for example, Felices et al., Methods Mol Biol., 2016, Vol. 1441, pp. 333-346; Fang et al., Semin Immunol., 2017, Vol. 31, pp. 37-54. Examples of trispecific NK cell adaptors (TRiKEs) include OXS-3550 and CD16-IL-15-B7H3 TriKe.
[0196] Phosphatidylinositol 3-kinase (PI3K) inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a PI3K inhibitor. Examples of PI3K inhibitors include ederaris, apeliximab, buparlisib, CAI orotic acid, cupanixine, duveliximab, gedatolisib, neratinib, panulisib, perifolliculin, pictilisib, pilaralisib, praquitinib mesylate, regoracitinib, regoracitinib sodium, sonoliximab, taceliliximab, AMG-319, AZD-8186, BAY-1082439, CLR-1401, CLR-457, CUDC-907, DS-7423, EN-3342, GSK-2126458, GSK-2269577, GSK-2636771, INCB-040093, LY-3023414, MLN-1117, PQR-309, RG-7666, RP- 6530, RV-1729, SAR-245409, SAR-260301, SF-1126, TGR-1202, UCB-5857, VS-5584, XL-765, and ZSTK-474.
[0197] α-4 / β-7 antagonists In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with an α-4 / β-7 antagonist. Examples of integrin α-4 / β-7 antagonists include PTG-100, TRK-170, alirubumab, itralizumab, methylcartastat, and vedozumab.
[0198] Pharmacokinetic enhancers In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a pharmacokinetic enhancer. Examples of pharmacokinetic enhancers include cobistat and ritonavir.
[0199] Other therapeutic agents Examples of other therapeutic agents include compounds disclosed in the following patent: WO 2004 / 096286 (Gilead)WO 2006 / 015261 (Gilead Sciences); WO 2006 / 110157 (Gilead Sciences); WO 2012 / 003497 (Gilead Sciences); WO 2012 / 003498 (Gilead Sciences); WO 2012 / 145728 (Gilead Sciences); WO 2013 / 006738 (Gilead Sciences); WO 2013 / 159064 (Gilead Sciences); WO 2014 / 100323 (Gilead Sciences), US 2013 / 0165489 (University of Pennsylvania), US 2014 / 0221378 (Japan Tobacco), US 2014 / 0221380 (Japan Tobacco); WO 2009 / 062285 (Boehringer Ingelheim); WO 2010 / 130034 (Boehringer Ingelheim); WO 2013 / 006792 (Pharma Resources), US 20140221356 (Gilead Sciences), US 20100143301 (Gilead Sciences and WO 2013 / 091096 (Boehringer Ingelheim).
[0200] HIV Combination Therapy Prescription 62 / 81 pages 68 CN 122005785 A In one specific embodiment, the anti-HIV 120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one, two, three, four or more additional therapeutic agents selected from ATRIPLA® (efavirenz, tenofovir disoproxil fumarate and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate and emtricitabine); STRIBILD® (Ertiravir, Cobistat, Tenofovir Disoproxil Fumarate, and Emtricitabine); TRUVADA® (Tenofovir Disoproxil Fumarate and Emtricitabine; TDF+FTC); DESCOVY® (Tenofovir Alammet and Emtricitabine); ODEFSEY® (Tenofovir Alammet, Emtricitabine, and Rilpivirine); GENVOYA® (Tenofovir Alammet, Emtricitabine, Cobistat, and Ertiravir); Adefovir; Adefovir Dipropionate; Cobistat; Emtricitabine; Tenofovir; Tenofovir Disoproxil Fumarate ...Flavoxetine; Tenofovir disoproxil fumarate; TRIUMEQ® (durutexvir, abacavir, and lamivudine); durutexvir, abacavir sulfate, and lamivudine; retegvir; retegvir and lamivudine; maraviro; enfuvirtide; ALUVIA® (KALETRA®; lopinavir and ritonavir); COMBIVIR® (zidovudine and lamivudine; AZT+ 3TC); EPZICOM® (LIVEXA®; abacavir sulfate and lamivudine; ABC+ 3TC); TRIZIVIR® (abacavir sulfate, zidovudine, and lamivudine; ABC+ AZT+ 3TC); rilpivirine; rilpivirine hydrochloride; atazanavir sulfate and cobistat; Atazanavir and cobicistat; drenellavir and cobicistat; atazanavir; atazanavir sulfate; dulutegravir; ertirapvir; ritonavir; atazanavir sulfate and ritonavir; drenellavir; lamivudine; α1-protease inhibitor; fosanavir; fosanavir calcium efavirenz; ectavirin; nelfinavir; nelfinavir mesylate; interferon; didanoxin; stavudine; indinavir; indinavir sulfate; tenofovir and lamivudine; zidovudine; nevirapine; saquinavir; saquinavir mesylate; adeleukin; zalcitabine; telanavir; ampravir; delavudine; delavudine mesylate; Radha- 108 (receptol); lamivudine and tenofovir disoproxil fumarate; efavirenz, lamivudine and tenofovir disoproxil fumarate; azidophosphine; lamivudine, nevirapine and zidovudine; abacavir; and abacavir sulfate.
[0201] Those skilled in the art will understand that the additional therapeutic agents listed above may include more than one of the categories listed above. Specific categories are not intended to limit the function of the compounds listed in those categories.
[0202] In one specific embodiment, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a nucleoside or nucleotide inhibitor of HIV reverse transcriptase and a non-nucleoside inhibitor of HIV reverse transcriptase. In another specific embodiment, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a nucleoside or nucleotide inhibitor of HIV reverse transcriptase and an HIV protease inhibitory compound. In another embodiment, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with a nucleoside or nucleotide inhibitor of HIV reverse transcriptase, a non-nucleoside inhibitor of HIV reverse transcriptase, and a pharmacokinetic enhancer. In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with at least one nucleoside inhibitor of HIV reverse transcriptase, an integrase inhibitor, and a pharmacokinetic enhancer. In another embodiment, the present invention...The described anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment is combined with two HIV reverse transcriptase nucleoside or nucleotide inhibitors.
[0203] In one specific embodiment, the described anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment is combined with abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir alafenamide, or tenofovir alafenamide.
[0204] In one specific embodiment, the described anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment is combined with tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, or tenofovir alafenamide.
[0205] In one specific embodiment, the anti-HIV gp120 V3 glycan-directed antibody or antigen fragment described herein (page 63 / 81, CN 122005785 A) is combined with a first additional therapeutic agent and a second additional therapeutic agent, the first additional therapeutic agent being selected from: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, and the second additional therapeutic agent being selected from emtricitabine and lamivudine.
[0206] In one specific embodiment, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a first additional therapeutic agent and a second additional therapeutic agent, the first additional therapeutic agent being selected from: tenofovir, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, wherein the second additional therapeutic agent is emtricitabine.
[0207] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one or more additional therapeutic agents at a therapeutically effective dose, the therapeutically effective dose being, for example, in the following ranges: 1 mg to 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 1000 mg, or 1500 mg of the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one or more additional therapeutic agents at a therapeutically effective dose, which is in, for example, the following ranges: about 0.1 mg / kg to about 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, etc.The dosages are 5 mg / kg, 8 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 35 mg / kg, 40 mg / kg, 45 mg / kg, or 50 mg / kg of anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with one or more additional therapeutic agents at a therapeutically effective dose, which is in, for example, the range of about 5 mg to about 10 mg, 20 mg, 25 mg, 50 mg, 100 mg, 125 mg, 150 mg, 250 mg, 300 mg, 500 mg, 1000 mg, or 1500 mg of anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment.
[0208] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with 5 mg–30 mg of tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide and 200 mg of emtricitabine. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with 5 mg–10 mg, 5 mg–15 mg, 5 mg–20 mg, 5 mg–25 mg, 25 mg–30 mg, 20 mg–30 mg, 15 mg–30 mg, or 10 mg–30 mg of tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide and 200 mg of emtricitabine. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with 10 mg of tenofovir alafenamide fumarate, tenofovir alafenamide hemisphericate, or tenofovir alafenamide and 200 mg of emtricitabine. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with 25 mg of tenofovir alafenamide fumarate, tenofovir alafenamide hemisphericate, or tenofovir alafenamide and 200 mg of emtricitabine. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with reagents provided herein at any dose of the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment (e.g., 1 mg to 500 mg of the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment, as described herein), as each combination of the same dose is specifically and individually listed.
[0209] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding tablet described herein is used.The fragment is combined with 200 mg–400 mg tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, or tenofovir disoproxil fumarate and 200 mg emtricitabine. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with 200 mg–250 mg, 200 mg–300 mg, 200 mg–350 mg, 250 mg–350 mg, 250 mg–400 mg, 350 mg–400 mg, 300 mg–400 mg, or 250 mg–400 mg tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, or tenofovir disoproxil fumarate and 200 mg emtricitabine. In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein (pages 64 / 81, CN 122005785 A) is combined with 300 mg of tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, or tenofovir disoproxil fumarate and 200 mg of emtricitabine. The anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment may be combined with the reagents provided herein at any dose (e.g., 1 mg to 500 mg of anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment), as each combination of the same dose is specifically and individually listed.
[0210] Long-acting HIV inhibitors In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein may be co-administered with a long-acting HIV inhibitor. Examples of drugs being developed as long-acting HIV inhibitors include, but are not limited to, cabotevir LA, rilpivirine LA, any integrase LA, VM-1500 LAI, maraviro (LAI), tenofovir implant, MK-8591 implant, and long-acting durutexvir.
[0211] In one embodiment, the kit comprises the anti-HIV 120 V3 glycan-directed antibody or antigen-binding fragment described herein, and one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents.
[0212] In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with an HIV vaccine. Examples of HIV vaccines include peptide vaccines, recombinant subunit protein vaccines, live vector vaccines, DNA vaccines, HIV MAG DNA vaccines, CD4-derived peptide vaccines, vaccine combinations, adenovirus vector vaccines (e.g., Ad5, Ad26, or Ad35), simian adenovirus (chimpanzee, gorilla, rhesus monkey, i.e., rhAd), adeno-associated virus vector vaccines, and chimpanzee adenovirus vaccines (e.g., ...).Vaccines based on various viruses, including ChAdOX1, ChAd68, ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan5, Pan6, Pan7, and Pan9; Coxsackievirus-based vaccines; Enterovirus-based vaccines; Gorilla adenovirus vaccines; Lentiviral vector-based vaccines; Two- or three-part arenavirus-based vaccines (e.g., LCMV, Pitender virus); Trimer-based HIV-1 vaccines; Measles virus-based vaccines; Flavivir virus-based vaccines; Tobacco mosaic virus-based vaccines; and Varicella-zoster virus-based vaccines. Vaccines based on viruses, including human parainfluenza virus 3 (PIV3) and poxviruses (modified Ankara vaccinia virus (MVA), orthopoxvirus-derived NYVAC, and fowlpoxvirus-derived ALVAC (canarypox virus) strains); fowlpox virus-based vaccines, rhabdovirus-based vaccines such as vesicular stomatitis virus (VSV) and Malaba virus; recombinant human CMV (rhCMV)-based vaccines, and alpha-virus-based vaccines such as Semliki forest virus, Venezuelan equine encephalitis virus, and Sindbis virus (see, for example, Lauer et al., Clin Vaccine Immunol., 2017, Vol. 24, No. 1, pp. e00298-16). LNP-formulated mRNA-based therapeutic vaccines; and LNP-formulated self-replicating RNA / self-amplifying RNA vaccines.
[0213] Examples of HIV vaccines include, but are not limited to, anti-CD40 Env-gp140 vaccine, Ad4-EnvC150, BG505 SOSIP.664 gp140 adjuvant vaccine, BG505 SOSIP.GT1.1 gp140 adjuvant vaccine, Chimigen HIV vaccine, ConM SOSIP.v7 gp140, rgp120 (AIDSVAX), ALVAC HIV (vCP1521) / AIDSVAX B / E (gp120) (RV144), monomeric gp120 HIV-1 subtype C vaccine, MPER-656 liposomal subunit vaccine, Remune, ITV-1, Contre Virus, Ad5-ENVA-48, DCVax-001 (CDX-2401), Vacc-4x, Vacc-C5, VAC-3S, multiclade DNA recombinant adenovirus-5 (rAd5), rAd5 gag-pol env A / B / C vaccines, Pennvax-G, Pennvax-GP, Pennvax-G / MVA-CMDR, HIV-TriMix-mRNA vaccine, HIV-LAMP-vax, Ad35, Ad35-GRIN, NAcGM3 / VSSP ISA-51, poly-ICLC adjuvantVaccines, TatImmune, GTU-multiHIV (FIT-06), ChAdV63.HIVconsv, gp140[delta]V2.TV1+MF-59, rVSVIN HIV-1 gag vaccine, SeV-EnvF, SeV-Gag vaccine, AT-20, DNK-4, ad35-Grin / ENV, TBC-M4, HIVAX, HIVAX-2, N123-VRC-34.01 induction of epitope-based HIV vaccines, NYVAC-HIV-PT1, NYVAC-HIV-PT4, DNA-HIV-PT123, rAAV1-PG9DP, GOVX-B11, GOVX-B21, GOVX-C55, TVI-HIV-1, Ad-4 (Ad4- env clade C+Ad4-mGag), Paxvax, EN41-UGR7C, EN41-FPA2, ENOB-HV-11, PreVaxTat, AE-H, MYM-V101, CombiHIVvac, ADDAX, MYM-V201, MVA-CMDR, MagaVax, DNA-Ad5 gag / pol / nef / nev (HVTN505), MVATG-17401, ETV-01, CDX-1401, DNA and Sev vector vaccines expressing SCaVII, rcAD26.MOS1.HIV-Env, Ad26.Mod.HIV vaccine, Ad26.Mod.HIV + MVA mosaic vaccine + gp140, AGS- 004, AVX-101, AVX-201, PEP-6409, SAV-001, ThV-01, TL-01, TUTI-16, VGX-3300, VIR-1111, IHV-001 and virus-like particle vaccines such as pseudovirus particle vaccines, CombiVICHvac, LFn-p24 B / C fusion vaccines, GTU-based DNA vaccines, HIV gag / pol / nef / env DNA vaccines, anti-TAT HIV vaccines, conjugated peptide vaccines, dendritic cell vaccines, gag-based DNA vaccines, GI-2010, gp41 HIV-1 vaccines, HIV vaccines (PIKA adjuvant), I i-key / MHC class II epitope hybrid peptide vaccines, ITV-2, ITV-3, ITV-4, LIPO-5, multiclade Env vaccines, MVA vaccines, Pennvax-GP, pp71-defective HCMV vector HIV GAG vaccine, recombinant peptide vaccine (HIV infection), NCI, rgp160 HIV vaccine, RNActive vaccineHIV vaccine, SCB-703, Tat Oyi vaccine, TBC-M4, therapeutic HIV vaccine, UBI HIV gp120, Vacc-4x+romidesin, variant gp120 peptide vaccine, rAd5 gag-pol env A / B / C vaccine; DNA .HTI and MVA .HTI, VRC-HIVDNA016-00-VP+VRC-HIVADV014-00-VP, INO-6145, JNJ-9220, gp145 C.6980; eOD-GT8 60mer-based vaccine, PD-201401, ENV (A, B, C, A / E) / gag (C) DNA vaccine, gp120 (A, B, C, A / E) protein vaccine, PDPHV-201401, Ad4-EnvCN54, EnvSeq-1 Env HIV-1 vaccine (GLA-SE adjuvant), HIV p24gag primer booster plasmid DNA vaccine, HIV-1 iglb12 neutralizing VRC-01 antibody-stimulated anti-CD4 vaccine, MVA-BNHIV-1 vaccine regimen, UBI HIV gp120, mRNA-based prophylactic vaccine, VPI-211, and TBL-1203HI.
[0214] Birth control (contraceptive) combination therapy In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with a birth control or contraceptive regimen. Therapeutic agents (contraceptives) used to control birth include cyproterone acetate, desogestrel, dinogest, drospirenone, estradiol valerate, ethinylestradiol, norethindrone, etoposide, levonorgestrel, linenoprogesterone acetate, medroxyprogesterone acetate, ethinylestradiol methyl ether, mifepristone, misoprostol, nomenoprogesterone acetate, noreprogesterone acetate, norethindrone, norgestrel, olmexifen, segestersone acetate, ulipristal acetate, and any combination thereof.
[0215] Gene therapy and cell therapy In some embodiments, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein is combined with a gene or cell therapy regimen. Gene therapy and cell therapy include, but are not limited to, gene modifications that silence genes; gene therapies that directly kill infected cells; infusion of immune cells engineered to replace a large portion of a patient's own immune system to enhance the immune response to infected cells, or to activate the patient's own immune system to kill infected cells, or to locate and kill infected cells; and gene therapies that modify cell activity to further alter the endogenous immune response to infection. Examples of cell therapies include those based on LB-1903, ENOB-HV-01, GOVX-B01, and SupT1 cells. Dendritic cellsExamples of cell therapies include AGS-004. CCR5 gene editing agents include SB-728T. CCR5 gene inhibitors include Cal-1. In some embodiments, CD4-positive T cells expressing C34-CCR5 / C34-CXCR4 are co-administered with an anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment. In some embodiments, an anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment is co-administered with AGT-103-transduced autologous T cell therapy or AAV-eCD4-Ig gene therapy.
[0216] Gene editing products In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a gene editing product such as an HIV-targeting gene editing product. In various implementations, the genome editing system may be an optional CRISPR / Cas9 complex, zinc finger nuclease complex, TALEN complex, homing endonuclease complex, and large-scale nuclease complex. Exemplary HIV targeting the CRISPR / Cas9 system includes, but is not limited to, EBT-101.
[0217] CAR-T cell therapy In some implementations, the anti-HIV gp120 V3 glycan-guided antibody or antigen-binding fragment described herein may be co-administered with a population of immune effector cells engineered to express a chimeric antigen receptor (CAR), wherein the CAR contains an HIV antigen-binding domain. The HIV antigen includes an HIV envelope protein or a portion thereof, gp120 or a portion thereof, a CD4 binding site on gp120, a CD4-induced binding site on gp120, an N-glycan on gp120, V2 of gp120, and a proximal membrane region on gp41. The immune effector cells are T cells or NK cells. In some embodiments, the T cells are CD4+ T cells, CD8+ T cells, or a combination thereof. The cells can be autologous or allogeneic. Examples of HIV CAR-T include convertible CAR-T, VC-CAR-T, anti-CD4 CAR-T cell therapy, and autologous hematopoietic stem cells genetically engineered to express CD4 CAR and C46 peptide.
[0218] TCR-T cell therapy In some embodiments, the anti-HIV gp120 V3 glycan-directed antibody or antigen-binding fragment described herein is combined with a TCR-T cell population. The TCR-T cells are engineered to target HIV-derived peptides present on the surface of virus-infected cells.
[0219] 6. The kit also provides a kit for performing the diagnostic and therapeutic methods as described herein. In some embodiments, the kit includes primers for amplifying and sequencing at least the gp120 V3 glycan region of an HIV species in a biological sample.In some embodiments, the kit includes a set or a group of nested primers for amplifying and sequencing at least the gp120 V3 glycan region of HIV species in a biological sample. In some embodiments, the kit includes a pair of primers or a set of nested primers for amplifying and sequencing the full-length gp120. In some embodiments, the kit includes sample preparation, nucleic acid quantification, amplification, and / or sequencing reagents, such as nucleic acid isolation reagents for isolating RNA and / or DNA, protein denaturing solvents, buffers, dNTPs, reverse transcriptase, polymerase, and / or detection tags. In some embodiments, the kit includes library preparation reagents, such as barcode reagents and / or target-specific primers. In some embodiments, the kit includes analysis guidelines and / or software, for example, to facilitate the implementation of the diagnostic methods described herein. In some embodiments, the kit includes instructions for sequencing the gp120 V3 glycan region of at least one HIV species in a biological sample and detecting or identifying HIV species expressing gp120 containing the following amino acid residues: glycosylated asparagine (N332 glycan) at position 332, aspartic acid (D325) at position 325, and one or more amino acid residues selected from: threonine (T63) at position 63, leucine (L179) at position 179, threonine (T320) at position 320, and histidine (H330) at position 330, wherein the amino acid positions refer to residues 1-511 of SEQ ID NO: 4 (i.e., NCBI reference sequence number NP_057856.1), as described herein.
[0220] In one embodiment, the kit includes one or more pharmaceutical packages comprising one or more containers (e.g., vials, ampoules, pre-loaded syringes) containing one or more components of the pharmaceutical compositions described herein, such as antibodies against the HIV gp120 V3 glycan region or antigen-binding fragments thereof, or one or more polynucleotides encoding such antibodies or antigen-binding fragments, as provided herein. In some cases, the kit includes the pharmaceutical compositions described herein. In some embodiments, the kit includes one or more containers comprising antibodies against the HIV gp120 V3 glycan region or antigen-binding fragments thereof in aqueous or lyophilized form, or one or more polynucleotides encoding such antibodies or antigen-binding fragments. Optionally associated with such containers may be a notification in the form prescribed by a government agency regulating the manufacture, use, or sale of the pharmaceutical or biological product, reflecting the agency's approval of the product. (67 / 81 pages 73 CN 122005785 A)Manufacturing, use, or sale for human application.
[0221] Examples The following examples are provided to illustrate, and not to limit, the invention protected by the claims.
[0222] Example 1 Identification of HIV-infected patients responding to therapy with anti-HIV gp120 V3 glycan-directed antibodies or antigen-binding fragments thereof This example demonstrates the identification of Env genotypes associated with susceptibility to viral neutralization of PGT121 and its derivative GS-9722 (epavivirumab) for pre-screening HIV-infected subjects for PGT121 / GS-9722 susceptibility.
[0223] The high level of sequence diversity in the HIV envelope gene makes pre-screening subjects in clinical trials of broadly neutralizing antibodies (bNAb) attractive for increasing the likelihood of high response rates. To identify Env genotypes predicting viral susceptibility to PGT121 and GS-9722, we examined neutralization data for PGT121 and GS-9722 and corresponding Env sequences for 206 clade B Envs.
[0224] GS-9722 is an engineered variant of PGT121 that retains the same neutralizing activity as PGT121, as evidenced by the highly statistically significant correlation of the neutralizing IC50 of PGT121 and GS-9722 in 397 HIV strains tested with PGT121 and GS-9722 (r² = 0.9698, P < 0.0001). Therefore, we combined GS-9722 neutralization data obtained from 140 clade B Env isolates from viremia subjects participating in a Gilead-sponsored clinical trial with publicly available PGT121 neutralization data (n = 66) obtained from the Los Alamos HIV sequence database to improve statistical power.
[0225] Full-length Env amino acid sequences were aligned using ClustalW and manually adjusted during visual inspection. To identify genotypes associated with susceptibility to neutralization of PGT121 / GS-9722, we compared the frequencies of amino acids and potential N-linked glycosylation sites (PNGS) at each residue in PGT121 / GS-9722-sensitive viruses with those in PGT121 / GS-9722-resistant viruses using Fisher's exact test. The N-linked glycosylation motif is N-X-S / T, where X is any residue except proline. Neutralization susceptibility to PGT121 / GS-9722 was defined as IC50 < 1 µg / mL. For residues statistically significantly associated with susceptibility to PGT121 / GS-9722, the positive predictive value (PPV; i.e., the probability that Env is susceptible to PGT121 / GS-9722 when the genotype is present) and susceptibility (i.e., the probability of the genotype occurring when Env is susceptible to PGT121 / GS-9722) were calculated as follows: Table 1A 2 × 2 table was used to calculate the PPV, NPV, susceptibility, and specificity of the PGT121 / GS-9722 susceptibility genotype determinants
[0226] PPV = Sensitivity = The Mann-Whitney test was also applied to identify susceptibility determinants independent of the 1 µg / mL cutoff value defined as “susceptibility” and “resistance”.
[0227] Table 2 lists the residues that are statistically associated with PGT121 / GS-9722 susceptibility and / or previously reported to be associated with PGT121 susceptibility, in descending order of PPV. Among the previously reported residues conferring PGT121 susceptibility, 307I, 295 PNGS, and 300 PNGS were not statistically associated with PGT121 / GS-9722 susceptibility in this clade B dataset. We identified a number of previously unreported residues that were significantly associated with susceptibility to PGT121 / GS-9722.
[0228] Table 2 Individual genotypes associated with susceptibility to neutralization of PGT121 / GS-9722 in clade B Env
[0229] 1 Viral genotype, indicating the presence of specific amino acid residues translated from the HIV envelope gene that confer neutralization susceptibility to PGT121 as reported in the literature (Julg et al., Sci Transl Med., 2017, Vol. 9, p. 408).
[0230] Since epitopes consist of more than one residue, combinations of genotype determinants that were statistically associated with susceptibility to PGT121 / GS-9722 were evaluated to see if combining individual genotype determinants could improve PPV by preferentially enriching true positives rather than false positives. Sensitivity was also considered, as genotypes with low sensitivity would require screening a larger number of subjects to enroll a sufficient number of subjects in clinical trials.
[0231] The combined genotypes providing the highest PPV and susceptibility are listed in Table 3 and shown in Figure 1. Several combined genotypes, including previously unreported genotypes associated with susceptibility to neutralization of PGT121 / GS-9722, provided higher PPVs than those achievable using only the previously described genotypes. The highest PPV obtained was 98.4% (for a virus containing amino acid N332 glycan / D325 / H330 / T63 / T320 / L179), which is a 57% increase over the positive predictive value of 62.6% without genotype selection.
[0232] Table 3 Individual genotypes and combined genotypes associated with susceptibility to neutralization of PGT121 / GS-9722 in clade B Env Specification 69 / 81 pages 75 CN 122005785 A
[0233] 1Viral genotype, indicating the presence of specific amino acid residues translated from the HIV envelope gene. 3. None, indicating that 206 subtype B viruses did not select specific amino acids in the HIV envelope gene. Genotypes consisting of residues previously reported in the literature as associated with susceptibility to PGT121 are listed in, for example, Julg et al., Sci Transl Med., 2017, Vol. 9, p. 408.
[0234] Using neutralization data and corresponding Env sequences of 66 clade A Envs and 258 clade C Envs, the combined PGT121 / GS-9722 genotypes of clade B in Table 3 were used to determine PPV, susceptibility, and prevalence for clades A (Table 4) and C (Table 5). The clade A and clade C datasets are publicly available data obtained from the Los Alamos HIV sequence database. The highest PPV obtained for clade A was 93.8% (for viruses containing amino acid N332 glycan / D325 / H330 / T320 / L179), which is 88% higher than the positive predictive value of 50% without genotype selection. The highest PPV obtained for clade C was 89.3% (for viruses containing amino acid N332 glycan / D325 / H330 / T320 / L179), which is 53% higher than the positive predictive value of 58.5% without genotype selection.
[0235] Table 4 Individual genotypes and combined genotypes associated with susceptibility to PGT121 neutralization in clade A Env
[0236] 1 Viral genotype, indicating the presence of a specific amino acid residue translated from the HIV envelope gene 2 None, indicating that 66 clade A viruses did not select a specific amino acid in the HIV envelope gene Table 5 Specification 70 / 81 pages 76 CN 122005785 A Individual genotypes and combined genotypes associated with susceptibility to PGT121 neutralization in clade C Env
[0237] 1 Viral genotype, indicating the presence of a specific amino acid residue translated from the HIV envelope gene 2 No, indicating that 258 clade C viruses did not select specific amino acids in the HIV envelope gene for clade A, clade B, and clade C virus sequences, the prevalence of individual amino acids (T63, L179, T320, D325, H330, N332, NotP333, and S / T334) used in the PGT121 / GS-9722 combinatorial genotype was determined (Table 6). The prevalence of all amino acids was higher than 60% in clade B and clade A except L179 (51.5%) and in clade C except T63 (10.1%).
[0238] Table 6 Prevalence of individual amino acids in clade A, clade B, and clade C viruses
[0239] 1Analysis of viruses from 66 clades A, 206 clades B, and 258 clades C based on the PGT121 / GS-9722 dataset shows that 10-1074 is a broadly neutralizing antibody that targets the V3 glycan region of HIV gp120 and is associated with PGT121 / GS-9722. See, for example, Mouquet et al., Proc Natl Acad Sci USA. November 20, 2012, Vol. 109, No. 47, pp. 3268-3277; and Walker et al., Nature, September 22, 2011, Vol. 477, No. 7365, pp. 466-470. Using neutralization data and the corresponding Env sequences of 315 clade B Envs (Table 7), the combined genotypes of PGT121 / GS-9722 in Table 3 were used to determine PPV, susceptibility, and prevalence from 10 to 1074. This dataset of 315 clade B Envs includes 143 clade B Envs isolated from viral blood subjects participating in Gilead-sponsored clinical trials, and 172 clade B Envs from publicly available data obtained from the Los Alamos HIV sequence database. The highest PPV obtained was 100% (for viruses containing amino acid N332 glycan / D325 / H330 / T63 / T320 / L179, as per manual page 77, CN 122005785 A), which is a 61% increase over the positive predictive value of 62.2% without genotype selection.
[0240] Table 7 Individual genotypes and combined genotypes associated with susceptibility to neutralization in clade B Env (10–1074)
[0241] 1 Viral genotype, indicating the presence of a specific amino acid residue translated from the HIV envelope gene 2 None, indicating that 315 clade B viruses did not select a specific amino acid in the HIV envelope gene Subsequently, the highest-scoring genotyping algorithm (Table 3) was applied to analyze pre-ART plasma samples from HIV-infected individuals from the Zurich Primary HIV Infection Cohort Study (ZPHI) to predict their susceptibility to GS-9722 treatment. A total of 92 individual plasma samples were analyzed in NGS assays of the HIV envelope gene (GenoSure HIV envelope RNA assay, Monogram Biosciences, South San Francisco, CA). If the derived viral sequence contained the amino acid specified by the algorithm without sequence variability (sequence variability at the specified position was zero), the subject was characterized as positive for a given genotype. Based on these criteria, the following groups were predicted to respond to GS-9722: 47 / 92, 37 / 92, 32 / 92, 27 / 92, 22 / 92, and 16 / 92 subjects.Sensitivity was predicted in GS-9722 in 59 out of 92 subjects (Figure 1), with corresponding positive predictive values of 80.7%, 83.5%, 86.1%, 91.6%, 93.7%, and 98.4% (Table 3). For subjects infected with clade B (59 out of 92), 35 / 59, 27 / 59, 22 / 59, 23 / 59, 18 / 59, and 12 / 59 subjects were predicted to be sensitive to GS-9722 (Figure 2), with corresponding positive predictive values of 80.7%, 83.5%, 86.1%, 91.6%, 93.7%, and 98.4% (Table 3).
[0242] For pre-ART plasma samples from all subjects (n=92) and a subset of subjects infected with clade B (n=59), 100% conservation (zero sequence variation at the specified position) of individual amino acids (T63, L179, T320, D325, H330, N332, NotP333, and S / T334) in the combinatorial genotypes used for GS-9722 sensitivity prediction was determined (Table 8).
[0243] Table 8 100% Conservation of Individual Amino Acids in ZPHI Subjects 72 / 81 pages 78 CN 122005785 A
[0244] 1 Analysis of Pre-ART Plasma Samples from 92 (All Subjects) and 59 (Clade B Subjects) ZPHI Individuals To confirm the genotype prediction for GS-9722 susceptibility, the viral population of pre-ART plasma samples from ZPHI individuals was cloned and evaluated in the GS-9722 neutralization assay (PhenoSense HIV Entry Assay, Monogram Biosciences, South San Francisco, CA). The virus was derived from 29 clade B samples with a positive predictive value of 80.7% or higher. When the IC50 was 1 µg / ml or lower, the derived virus was characterized as GS-9722 susceptible. Based on these criteria, viruses 25 / 29, 20 / 22, 16 / 18, 18 / 20, 14 / 16, and 10 / 11 were confirmed to be susceptible to GS-9722 (Figure 2), with corresponding positive predictive values of 80.7%, 83.5%, 86.1%, 91.6%, 93.7%, and 98.4%, respectively (Table 3).
[0245] To further confirm the genotypic prediction and phenotypic susceptibility to GS-9722, 20 individual viruses from four viral serogroups in pre-ART plasma samples from ZPHI were subcloned and evaluated in the GS-9722 neutralization assay (PhenoSense HIV entry assay, Monogram Biosciences, South San Francisco, CA). All individual viruses were susceptible to GS-9722, with IC50 values comparable to those of the serogroups (Figure 4).
[0246] It should be understood that the embodiments and implementations described herein are for illustrative purposes only, and those skilled in the art will make various modifications or alterations based on these embodiments and implementations, which will be included within the spirit and scope of this patent application and the appended claims. All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety for all purposes.
[0247] Preferred embodiments: 1. A method for treating or preventing HIV in a human subject in need of such treatment, the method comprising: a) identifying a human subject infected with HIV or a population of HIV expressing gp120 comprising the following amino acid residues: N332 glycan, D325, and one or more amino acid residues selected from the following amino acid residues: T63, L179, T320 and H330, wherein the amino acid positions refer to SEQ ID NO: 4; and b) administering to the subject an effective amount of an antibody or an antigen-binding fragment thereof, the antibody or the antigen-binding fragment thereof competing for or comprising the VH and VL regions, the VH and VL regions binding to epitopes of gp120 within a third variable ring (V3) and / or a high-mannose patch comprising N332 oligomannose glycan.
[0248] 2. The method according to Project 1, the method comprising identifying subjects infected with HIV or HIV populations expressing gp120 containing the following amino acid residues: (Instructions for Use, Page 73 / 81, 79 CN 122005785 A) i. N332 glycan, D325, and T63; ii. N332 glycan, D325, and L179; iii. N332 glycan, D325, and T320; iv. N332 glycan, D325, and H330; v. N332 glycan, D325, T63, and L179; vi. N332 glycan, D325, T63, and T320; vii. N332 glycan, D325, T63, and H330; viii. N332 glycan, D325, L179, and T320; ix. N332 glycan, D325, L179, and H330; x. N332 glycan, D325, T320, and H330; xi. N332 glycan, D325, T63, T320, and H330; xii. N332 glycan, D325, T63, L179, and T320; xiii. N332 glycan, D325, T63, L179, and H330; xiv. N332 glycan, D325, L179, T320, and H330; or xv. N332 glycan, D325, T63, L179, T320, and H330.
[0249] 3. The method according to item 1, the method comprising identifying infection with expression containing the following amino acid residues.Subjects in HIV or HIV populations with gp120: i. N332 glycan, D325, and T63; ii. N332 glycan, D325, and L179; iii. N332 glycan, D325, and T320; or iv. N332 glycan, D325, and H330.
[0250] 4. The method according to any one of items 1 to 2, the method comprising identifying a subject infected with HIV or an HIV population expressing gp120 comprising the following amino acid residues: i. N332 glycan, D325, T63 and L179; ii. N332 glycan, D325, T63 and T320; iii. N332 glycan, D325, T63 and H330; iv. N332 glycan, D325, L179 and T320; v. N332 glycan, D325, L179 and H330; or vi. N332 glycan, D325, T320 and H330.
[0251] 5. The method according to any one of items 1 to 5, the method comprising identifying a subject infected with HIV or an HIV population expressing gp120 comprising the following amino acid residues: i. N332 glycan, D325, L179, T320 and H330; ii. N332 glycan, D325, T63, T320 and H330; iii. N332 glycan, D325, T63, L179 and T320; or iv. N332 glycan, D325, T63, L179 and H330.
[0252] 6. The method according to any one of items 1 to 5, the method comprising identifying a subject infected with HIV or an HIV population expressing gp120 comprising the following amino acid residues: i. N332 glycan, D325, T63 and H330; ii. N332 glycan, D325, T320 and H330; iii. N332 glycan, D325, L179, T320 and H330; or iv. N332 glycan, D325, T63, L179, T320 and H330.
[0253] 7. The method according to any one of items 1 to 6, wherein the subject is infected with HIV or HIV population expressing gp120 which also contains one or more of the following amino acid residues: i. glycan 301; ii. K677; iii. not_W17; iv. not_R747; v. insertion_321.01; vi. E429; vii. Q442; viii. R335; ix. I165; x. S393; xi. I307; xii. 295 glycan; and / or xiii. N300.
[0254] 8. The method according to any one of items 1 to 7, wherein at least 90%, for example, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% of the HIV species in the HIV population contains the amino acid residues.
[0255] 9. The method according to any one of items 1 to 8, wherein the applied antibody or its antigen-binding fragment competes for or includes the VH and VL regions of an antibody selected from the group consisting of: GS-9722, GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, GS-2872, 10-1074, 10-1074-J, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03.
[0256] 10. The method according to any one of items 1 to 9, wherein the antibody or its antigen-binding fragment competes for or includes the VH and VL regions of an antibody selected from the group consisting of: GS-9722, GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-124, PGT-134, GS-2872, 10-1074, 10-1074-J, PGT-122, and PGT-123.
[0257] 11. The method according to any one of items 1 to 10, wherein the antibody comprises an Fc region containing the following amino acids at designated positions (EU index numbers): i. tyrosine at position 252, threonine at position 254, and glutamic acid (YTE) at position 256; or ii. leucine at position 428 and serine (LS) at position 434.
[0258] 12. The method according to any one of items 1 to 11, wherein the antibody comprises an Fc region containing the following amino acids at designated positions (EU index numbers): i. aspartic acid at position 239 and glutamic acid (DE) at position 332; Specification 75 / 81 pages 81CN 122005785 A ii. Aspartic acid at position 239, glutamic acid at position 332, and leucine at position 330 (DEL); iii. Aspartic acid at position 239, glutamic acid at position 332, and alanine at position 236 (DEA); or iv. Aspartic acid at position 239, glutamic acid at position 332, alanine at position 236, and leucine at position 330 (DEAL).
[0259] 13. The method according to any one of items 1 to 10, wherein the method comprises administering an antigen-binding fragment.
[0260] 14. The method according to item 13, wherein the antigen-binding fragment is selected from: scFv, Fab, Fab2, Fab', F(ab')2, Fv, and bivalent antibodies.
[0261] 15. The method according to any one of items 1 to 14, wherein the antibody is a multispecific antibody.
[0262] 16. The method of any one of items 1 to 15, wherein the human subject is acutely infected with HIV.
[0263] 17. The method of item 16, wherein the antibody is administered to a human subject with Fiebig stage IV or earlier HIV infection.
[0264] 18. The method of item 16, wherein the antibody is administered to a human subject who has not undergone seroconversion.
[0265] 19. The method of any one of items 1 to 15, wherein the human subject has recently been infected with HIV.
[0266] 20. The method of item 19, wherein the antibody is administered to a human subject with Fiebig stage V or Fiebig stage VI HIV infection.
[0267] 21. The method of any one of items 1 to 15, wherein the human subject is chronically infected with HIV.
[0268] 22. The method of any one of items 1 to 21, wherein the human subject is infected with HIV clade B virus.
[0269] 23. The method of claim 22, the method comprising identifying a subject infected with HIV or an HIV population expressing gp120 comprising the following amino acid residues: i. N332 glycan, D325, T63, and H330; ii. N332 glycan, D325, L179, T320, and H330; or iii. N332 glycan, D325, T63, L179, T320, and H330.
[0270] 24. The method of any one of claims 1 to 23, wherein the human subject is infected with HIV clade A virus.
[0271] 25. The method of any one of claims 1 to 24, wherein the human subject is infected with HIV clade C virus.
[0272] 26.The method according to any one of items 1 to 25, further comprising administering to the subject one or more additional therapeutic agents for treating HIV infection.
[0273] 27. The method according to any one of items 1 to 26, wherein the subject has not received antiretroviral therapy (ART) or has discontinued ART prior to administration of the antibody.
[0274] 28. The method according to any one of items 1 to 26, wherein ART is discontinued after one or more administrations of the antibody or its antigen-binding fragment.
[0275] 29. The method according to any one of items 1 to 26, further comprising administering to the subject one or more antiretroviral therapy (ART) agents.
[0276] 30. The method according to any one of items 1 to 29, the method further comprising administering to the subject a second antibody or antigen-binding fragment thereof, as specified in the specification page 76 / 81, CN 122005785 A, the second antibody or antigen-binding fragment thereof binding to an epitope or region of gp120, said epitope or region being selected from: i. a second variable loop (V2) and / or the apex of the Env trimer; ii. a CD4 binding site (CD4bs); iii. a gp120 / gp41 interface; or iv. a gp120 silencing surface.
[0277] 31. The method according to item 30, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 in the second variable loop (V2) and / or the apex of the Env trimer, and competes for or includes the VH and VL regions of an antibody selected from: PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CH01, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E, and VRC38.01.
[0278] 32. The method according to item 30, wherein the second antibody or its antigen-binding fragment binds to the epitope or region of gp120 in the CD4 binding site (CD4bs) and competes for or includes the VH and VL regions of an antibody selected from: b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01, VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103,44-VRC13.01, 1NC9, 12A12, N6, N6LS (VRC-HIVMAB091-00-AB), N49-P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25.
[0279] 33. The method according to item 30, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 at the gp120 / gp41 interface and competes for or includes the VH and VL regions of an antibody selected from: PGT-151, CAP248-2B, 35O22, 8ANC195, ACS202, VRC34 and VRC34.01.
[0280] 34. The method of claim 30, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of the gp120 silencing surface and competes for or includes the VH and VL regions of antibody VRC-PG05.
[0281] 35. The method of claim 30, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp41 in the membrane proximal region (MPER) and competes for or includes the VH and VL regions of an antibody selected from: 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01.
[0282] 36. The method of claim 30, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of the gp41 fusion peptide and competes for or includes the VH and VL regions of an antibody selected from the group consisting of VRC34 and ACS202.
[0283] 37. The method of any one of claims 1 to 36, further comprising administering a TLR agonist to the subject.
[0284] 38. The method of claim 37, wherein the TLR agonist is a TLR2 agonist, a TLR3 agonist, a TLR7 agonist, a TLR8 agonist, or a TLR9 agonist.
[0285] 39. The method of claim 38, wherein the TLR7 agonist is selected from the group consisting of vesamimod, imiquimod, and requimod.
[0286] 40. The method of any one of claims 1 to 39, comprising administering the antibody or its antigen-binding fragment multiple times at predetermined intervals, optionally together with a TLR agonist.
[0287] 41. The method according to any one of items 1 to 40, wherein the antibody or its specification is administered once or multiple times. (Pages 77 / 81, CN 122005785 A)Following the antigen-binding fragment, in the absence of antiretroviral therapy (ART), the subject has not exhibited symptoms of HIV or AIDS for at least 6 months, at least 1 year, at least 2 years, at least 3 years, or longer.
[0288] 42. The method according to any one of items 1 to 41, wherein after one or more administrations of the antibody, in the absence of antiretroviral therapy (ART), the subject has a viral load of less than 500, for example less than 400, less than 300, less than 200, less than 100, less than 50 copies / ml of blood for at least 6 months, at least 1 year, at least 2 years, at least 3 years, or longer.
[0289] 43. A method for identifying a human subject infected with HIV or a population of HIV sensitive to an antibody or antigen-binding fragment thereof, said antibody or antigen-binding fragment thereof competing for or containing said VH and VL regions, said VH and VL regions binding to epitopes of gp120 within a third variable ring (V3) and / or a high-mannose patch containing N332 oligomannose glucomannan, said method comprising identifying in a biological sample from said human subject an HIV expressing gp120 comprising the following amino acid residues: N332 glucomannan, D325, and one or more amino acid residues selected from the following amino acid residues: T63, L179, T320 and H330, wherein said amino acid positions refer to SEQ ID NO: 4.
[0290] 44. The method according to item 43, wherein the subject is infected with HIV or an HIV population expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, and T63; ii. N332 glycan, D325, and L179; iii. N332 glycan, D325, and T320; iv. N332 glycan, D325, and H330; v. N332 glycan, D325, T63, and L179; vi. N332 glycan, D325, T63, and T320; vii. N332 glycan, D325, T63, and H330; viii. N332 glycan, D325, L179, and T320; ix. N332 glycan, D325, L179, and H330; x. N332 polysaccharide, D325, T320 and H330; xi. N332 polysaccharide, D325, T63, T320 and H330; xii. N332 polysaccharide, D325, T63, L179 and T320; xiii. N332 polysaccharide, D325, T63, L179 and H330; xiv. N332 polysaccharide, D325, L179, T320 and H330; or xv. N332 polysaccharide, D325, T63, L179, T320 and H330.
[0291] 45.According to the method of any one of items 43 to 44, wherein the subject is infected with HIV or HIV population expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, and T63; ii. N332 glycan, D325, and L179; iii. N332 glycan, D325, and T320; or iv. N332 glycan, D325, and H330.
[0292] 46. The method according to any one of items 43 to 45, wherein the subject is infected with HIV or an HIV population expressing gp120 containing the following amino acid residues: i. N332 glycan, D325, T63 and L179; ii. N332 glycan, D325, T63 and T320; iii. N332 glycan, D325, T63 and H330; iv. N332 glycan, D325, L179 and T320; v. N332 glycan, D325, L179 and H330; or vi. N332 glycan, D325, T320 and H330.
[0293] 47. The method according to any one of items 43 to 46, the method comprising identifying a subject infected with HIV or an HIV population expressing gp120 comprising the following amino acid residues: i. N332 glycan, D325, L179, T320 and H330; ii. N332 glycan, D325, T63, T320 and H330; iii. N332 glycan, D325, T63, L179 and T320; or iv. N332 glycan, D325, T63, L179 and H330.
[0294] 48. The method according to any one of items 43 to 47, the method comprising identifying a subject infected with HIV or an HIV population expressing gp120 comprising the following amino acid residues: i. N332 glycan, D325, T63 and H330; ii. N332 glycan, D325, T320 and H330; iii. N332 glycan, D325, L179, T320 and H330; or iv. N332 glycan, D325, T63, L179, T320 and H330.
[0295] 49. The method according to any one of items 43 to 48, the method comprising identifying a subject infected with HIV or an HIV population expressing gp120 comprising the following amino acid residues: i. glycan 301; ii. K677; iii. not_W17; iv. not_R747; v. insertion_321.01; vi. E429; vii. Q442; viii. R335; ix. I165; x.S393; xi. I307; xii. 295 polysaccharide; and / or xiii. N300.
[0296] 50. The method according to any one of items 43 to 49, wherein at least 90%, for example, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the HIV species in the HIV population contains the amino acid residues.
[0297] 51. The method according to any one of items 43 to 50, wherein the antibody or its antigen-binding fragment competes for or includes the VH and VL regions of an antibody selected from the group consisting of: GS-9722, GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, 10-1074, 10- 1074-J, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, Instruction manual 79 / 81 pages 85 CN 122005785 A 354BG411, 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03.
[0298] 52. The method according to any one of items 43 to 51, wherein the antibody or its antigen-binding fragment competes for or includes the VH and VL regions of an antibody selected from the group consisting of: GS-9722, GS-9721, PGT-121, PGT-121.66, PGT-121.414, PGT-124, PGT-134, GS-2872, 10-1074, 10-1074-J, PGT-122, and PGT-123.
[0299] 53. The method according to any one of items 43 to 52, wherein the human subject is acutely infected with HIV.
[0300] 54. The method according to item 53, wherein the antibody is administered to a human subject with HIV infection at or earlier stage IV (Fiebig stage IV).
[0301] 55. The method according to item 53, wherein the antibody is administered to a human subject who has not undergone seroconversion.
[0302] 56.57. The method according to any one of items 43 to 52, wherein the human subject has recently been infected with HIV.
[0303] 58. The method according to item 56, wherein the antibody is administered to a human subject infected with HIV in Fiebig stage V or Fiebig stage VI.
[0304] 59. The method according to any one of items 43 to 52, wherein the human subject is chronically infected with HIV.
[0305] 506. The method according to any one of items 43 to 58, wherein the human subject is infected with HIV clade B virus.
[0306] 60. The method of claim 59, the method comprising identifying a subject infected with HIV or an HIV population expressing gp120 comprising the following amino acid residues: i. N332 glycan, D325, T63, and H330; ii. N332 glycan, D325, L179, T320, and H330; or iii. N332 glycan, D325, T63, L179, T320, and H330.
[0307] 61. The method of any one of claims 43 to 60, wherein the human subject is infected with HIV clade A virus.
[0308] 62. The method of any one of claims 43 to 61, wherein the human subject is infected with HIV clade C virus.
[0309] 63. The method according to any one of items 1 to 63, wherein the gp120 amino acid is identified in one or more gp120 polypeptide sequences expressed in HIV or HIV population isolated from the subject.
[0310] 64. The method according to any one of items 1 to 64, wherein the gp120 amino acid is identified in one or more gp120 polynucleotide sequences in HIV or HIV population isolated from the subject.
[0311] 65. The method according to item 64, the method comprising next-generation sequencing (NGS) of a polynucleotide sequence encoding gp120 from an HIV population.
[0312] 66. The method according to item 65, wherein the gp120 variant is detected at a frequency level of about 1% of the viral population.
[0313] 67. The method according to any one of items 1 to 66, wherein the gp120 amino acid is identified in one or more biological samples from the subject, wherein the one or more biological samples are obtained from blood, peripheral blood mononuclear cells (PBMCs), serum, plasma, semen, or lymph nodes.
[0314] 68. The method according to any one of items 1 to 67, the method comprising identifying an HIV RNA population in a serum or plasma sample. Specification 80 / 81 pages 86 CN 122005785 A
[0315] 69.The method according to any one of items 1 to 68, the method further comprising the step of obtaining one or more biological samples from the subject.
[0316] 70. The method according to item 69, wherein two or more biological samples are obtained from the subject.
[0317] 71. The method according to item 70, wherein the two or more biological samples are obtained from the same tissue or fluid at two or more different time points.
[0318] 72. The method according to item 70, wherein the two or more biological samples are obtained from different tissues or fluids or from different anatomical locations. Instruction manual, page 81 / 81, 87 CN 122005785 A, Figure 1; Instruction manual, Figure 1 / 3, page 88 CN 122005785 A, Figure 2; Instruction manual, Figure 2 / 3, page 89 CN 122005785 A, Figure 3; Figure 4; Instruction manual, Figure 3 / 3, page 90 CN 122005785 A, Abstract: Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to the HIV gl20 V3 glycan region.
Claims
1. Use of reagents and antibodies or antigen-binding fragments thereof in the preparation of a kit for performing a method of treating or preventing HIV-1 clade B in a human subject in need, wherein the reagents identify HIV-1 clade B species having the following viral genotypes gp120: N332 glycan, D325, and L179, wherein the amino acid positions are referenced to SEQ ID NO:
4. The method includes: a) Using the reagent, identify human subjects infected with HIV-1 clade B or HIV-1 clade B population with the viral genotype gp120 in biological samples from the human subjects. as well as b) Administering an effective amount of the antibody or its antigen-binding fragment, comprising the amino acid sequences of the VH and VL regions as shown below, to the human subject: i. SEQ ID NO: 400 and 401; ii. SEQ ID NO: 402 and 404; or iii. SEQ ID NO: 405 and 406.
2. The use according to claim 1, wherein the method comprises using the reagent to identify human subjects infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: gp120: i. N332 polysaccharide, D325, T63 and L179; ii. N332 polysaccharide, D325, L179, and T320; iii. N332 polysaccharide, D325, L179, and H330; iv. N332 polysaccharides, D325, T63, L179, and T320; v. N332 polysaccharide, D325, T63, L179 and H330; vi. N332 polysaccharides, D325, L179, T320, and H330; or vii. N332 polysaccharide, D325, T63, L179, T320 and H330.
3. The use according to claim 1, wherein the method comprises using the reagent to identify human subjects infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: gp120: i. N332 polysaccharide, D325, T63 and L179; ii. N332 polysaccharides, D325, L179, and T320; or iii. N332 polysaccharide, D325, L179 and H330.
4. The use according to claim 1, wherein the method comprises using the reagent to identify human subjects infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: gp120: i. N332 polysaccharides, D325, T63, L179, and T320; or ii. N332 polysaccharide, D325, T63, L179 and H330.
5. The use according to claim 1, wherein the method comprises using the reagent to identify human subjects infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: gp120: i. N332 polysaccharide, D325, L179, T320, and H330; or ii. N332 polysaccharide, D325, T63, L179, T320 and H330.
6. The use according to claim 1, wherein 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the HIV-1 clade B population contains the viral genotype.
7. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region, the Fc region containing the following amino acids at a specified position according to the EU index number: i. Tyrosine at position 252, threonine at position 254, and glutamic acid at position 256; or ii. Leucine at position 428 and serine at position 434.
8. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region containing the following amino acids at designated positions according to EU index numbers: aspartic acid at position 239 and glutamic acid at position 332.
9. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region containing the following amino acids at designated positions according to EU index numbers: aspartic acid at position 239, glutamic acid at position 332, and leucine at position 330.
10. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region containing the following amino acids at designated positions according to EU index numbers: aspartic acid at position 239, glutamic acid at position 332, and alanine at position 236.
11. The use according to any one of claims 1 to 6, wherein the antibody comprises an Fc region containing the following amino acids at designated positions according to EU index numbers: aspartic acid at position 239, glutamic acid at position 332, alanine at position 236, and leucine at position 330.
12. The use according to any one of claims 1 to 6, wherein the method comprises administering an antigen-binding fragment.
13. The use according to claim 12, wherein the antigen-binding fragment is selected from: scFv, Fab, Fab', F(ab')2 and Fv.
14. The use according to claim 12, wherein the antigen-binding fragment is a bivalent antibody.
15. The use according to any one of claims 1 to 6, wherein the antibody is a multispecific antibody.
16. The use according to any one of claims 1 to 6, wherein the human subject is acutely infected with HIV-1 clade B.
17. The use according to claim 16, wherein the antibody is administered to a human subject with Fiebig stage IV or earlier HIV-1 clade B infection.
18. The use according to claim 16, wherein the antibody is administered to a human subject who has not undergone seroconversion.
19. The use according to any one of claims 1 to 6, wherein the antibody is administered to a human subject infected with HIV-1 clade B in Fiebig stage V or Fiebig stage VI.
20. The use according to any one of claims 1 to 6, wherein the human subject is chronically infected with HIV-1 clade B.
21. The use according to any one of claims 1 to 6, the method further comprising administering to the human subject one or more additional therapeutic agents for treating HIV infection.
22. The use according to any one of claims 1 to 6, wherein the human subject has not received antiretroviral therapy or has discontinued antiretroviral therapy prior to administration of the antibody.
23. The use according to any one of claims 1 to 6, wherein antiretroviral therapy is discontinued after one or more administrations of the antibody or its antigen-binding fragment.
24. The use according to any one of claims 1 to 6, wherein the method further comprises administering one or more antiretroviral therapeutic agents to the human subject.
25. The use according to any one of claims 1 to 6, wherein the method further comprises administering to the human subject a second antibody or an antigen-binding fragment thereof, the second antibody or the antigen-binding fragment thereof binding to an epitope or region of gp120, said epitope or region being selected from: i. The vertices of the second variable ring and / or the Env trimer; ii. CD4 binding site; iii. GP120 / GP41 interface; or iv. gp120 Silent Face.
26. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 at the apex of the second variable ring and / or Env trimer, and comprises a VH region and a VL region of an antibody selected from the group consisting of: PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CH01, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E, and VRC38.
01.
27. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 in the CD4 binding site and comprises a VH region and a VL region from an antibody selected from: b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01 VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103, 44-VRC13.01, 1NC9, 12A12, N6, N6LS, N49-P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25.
28. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp120 at the gp120 / gp41 interface and comprises a VH region and a VL region of an antibody selected from the group consisting of: PGT-151, CAP248-2B, 35O22, 8ANC195, ACS202, VRC34, and VRC34.
01.
29. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of the gp120 silencing surface and comprises the VH and VL regions from antibody VRC-PG05.
30. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of gp41 in the proximal region of the membrane and comprises a VH region and a VL region of an antibody selected from the group consisting of: 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01.
31. The use according to claim 25, wherein the second antibody or its antigen-binding fragment binds to an epitope or region of the gp41 fusion peptide and comprises a VH region and a VL region of an antibody selected from the group consisting of VRC34 and ACS202.
32. The use according to any one of claims 1 to 6, wherein the method further comprises administering a TLR agonist to the human subject.
33. The use according to claim 32, wherein the TLR agonist is a TLR2 agonist, a TLR3 agonist, a TLR7 agonist, a TLR8 agonist, or a TLR9 agonist.
34. The use according to claim 33, wherein the TLR7 agonist is selected from: vesamimod, imiquimod, and requimod.
35. The use according to any one of claims 1 to 6, wherein the method comprises administering the antibody or its antigen-binding fragment multiple times at predetermined intervals.
36. The use according to claim 35, wherein the antibody or its antigen-binding fragment is administered together with a TLR agonist.
37. The use according to any one of claims 1 to 6, wherein, following one or more administrations of the antibody or its antigen-binding fragment, the subject does not exhibit symptoms of HIV or AIDS for 6 months, 1 year, 2 years, or 3 years in the absence of antiretroviral therapy.
38. The use according to any one of claims 1 to 6, wherein after one or more administrations of the antibody, in the absence of antiretroviral therapy, the subject has a viral load of less than 500, less than 400, less than 300, less than 200, less than 100, or less than 50 copies / ml of blood at 6 months, 1 year, 2 years, or 3 years.
39. The use according to any one of claims 1 to 6, wherein the viral genotype of said gp120 is identified in one or more gp120 polypeptide sequences expressed in HIV-1 clade B or HIV-1 clade B population isolated from said human subject.
40. The use according to any one of claims 1 to 6, wherein the viral genotype of said gp120 is identified in one or more gp120 polynucleotide sequences in HIV-1 clade B or HIV-1 clade B population isolated from said human subject.
41. The use according to claim 40, wherein the method comprises next-generation sequencing of a polynucleotide sequence encoding gp120 from HIV-1 clade B population.
42. Use of the reagent in the preparation of a kit for performing a method for identifying a human subject infected with HIV-1 clade B or HIV-1 clade B population sensitive to an antibody or antigen-binding fragment thereof, wherein the reagent identifies HIV-1 clade B species having the following viral genotypes gp120: N332 glycan, D325, and L179, wherein the amino acid positions are referenced to SEQ ID NO: 4, the method comprising using the reagent to identify HIV-1 clade B or HIV-1 clade B population having the viral genotype gp120 in a biological sample from the human subject, wherein the antibody or antigen-binding fragment thereof comprises the following VH and VL region amino acid sequences, respectively: i. SEQ ID NO: 400 and 401; ii. SEQ ID NO: 402 and 404; or iii. SEQ ID NO: 405 and 406.
43. The use according to claim 42, wherein the human subject is infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: gp120 i. N332 polysaccharide, D325, T63 and L179; ii. N332 polysaccharide, D325, L179, and T320; iii. N332 polysaccharide, D325, L179, and H330; iv. N332 polysaccharides, D325, T63, L179, and T320; v. N332 polysaccharide, D325, T63, L179 and H330; vi. N332 polysaccharides, D325, L179, T320, and H330; or vii. N332 polysaccharide, D325, T63, L179, T320 and H330.
44. The use according to claim 42, wherein the human subject is infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: gp120 i. N332 polysaccharide, D325, T63 and L179; ii. N332 polysaccharides, D325, L179, and T320; or iii. N332 polysaccharide, D325, L179 and H330.
45. The use according to claim 42, wherein the human subject is infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: gp120 i. N332 polysaccharides, D325, T63, L179, and T320; or ii. N332 polysaccharide, D325, T63, L179 and H330.
46. The use according to claim 42, wherein the human subject is infected with HIV-1 clade B or HIV-1 clade B population having the following viral genotypes: gp120 i. N332 polysaccharide, D325, L179, T320, and H330; or ii. N332 polysaccharide, D325, T63, L179, T320 and H330.
47. The use according to claim 42, wherein 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the HIV-1 clade B population contains the viral genotype.
48. The use according to any one of claims 42 to 47, wherein the human subject is acutely infected with HIV-1 clade B.
49. The use according to claim 48, wherein the antibody is administered to a human subject with Fiebig stage IV or earlier HIV-1 clade B infection.
50. The use according to claim 49, wherein the antibody is administered to a human subject who has not undergone seroconversion.
51. The use according to any one of claims 42 to 47, wherein the antibody is administered to a human subject infected with HIV-1 clade B in Fiebig stage V or Fiebig stage VI.
52. The use according to any one of claims 42 to 47, wherein the human subject is chronically infected with HIV-1 clade B.
53. The use according to any one of claims 42 to 47, wherein the viral genotype of said gp120 is identified in one or more gp120 polypeptide sequences expressed in HIV-1 clade B or HIV-1 clade B population isolated from said human subject.
54. The use according to any one of claims 42 to 47, wherein the viral genotype of said gp120 is identified in one or more gp120 polynucleotide sequences in HIV-1 clade B or HIV-1 clade B population isolated from said human subject.
55. The use according to claim 54, wherein the method comprises next-generation sequencing of a polynucleotide sequence encoding gp120 from HIV-1 clade B population.
56. The use according to any one of claims 1 to 6 or 42 to 47, wherein the gp120 amino acid is identified in one or more biological samples from the subject, wherein the one or more biological samples are obtained from blood, peripheral blood mononuclear cells, serum, plasma, semen or lymph nodes.
57. The use according to any one of claims 1 to 6 or 42 to 47, wherein the method comprises identifying an HIV-1 clade B RNA population in a serum or plasma sample.
58. The method further comprises the step of obtaining one or more biological samples from the subject, according to any one of claims 1 to 6 or 42 to 47.
59. The use according to claim 58, wherein two or more biological samples are obtained from the subject.
60. The use according to claim 59, wherein the two or more biological samples are obtained from the same tissue or fluid at two or more different time points.
61. The use according to claim 59, wherein the two or more biological samples are obtained from different tissues or fluids or from different anatomical locations.
